



US 20230242593A1

(19) **United States**
 (12) **Patent Application Publication** (10) **Pub. No.: US 2023/0242593 A1**
DOWD et al. (43) **Pub. Date: Aug. 3, 2023**

(54) **ZIKA VIRAL ANTIGEN CONSTRUCTS** application No. PCT/EP2017/079343 on Nov. 15, 2017.

(71) Applicants: **GLAXOSMITHKLINE BIOLOGICALS SA**, Rixensart (BE); **THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES**, Bethesda, MD (US) (60) Provisional application No. 62/568,559, filed on Oct. 5, 2017, provisional application No. 62/485,090, filed on Apr. 13, 2017, provisional application No. 62/423,398, filed on Nov. 17, 2016.

(72) Inventors: **KIMBERLY DOWD**, ROCKVILLE, MD (US); **BARNEY S. GRAHAM**, ROCKVILLE, MD (US); **SUNG-YOUL KO**, ROCKVILLE, MD (US); **WING-PUI KONG**, ROCKVILLE, MD (US); **JOHN MASCOLA**, ROCKVILLE, MD (US); **THEODORE PIERSON**, ROCKVILLE, MD (US); **MAYURI SHARMA**, CAMBRIDGE, MA (US); **DONG YU**, ROCKVILLE, MD (US)

Publication Classification

(51) **Int. Cl.**
C07K 14/005 (2006.01)
A61K 39/12 (2006.01)
C12N 7/00 (2006.01)

(52) **U.S. Cl.**
 CPC *C07K 14/005* (2013.01); *A61K 39/12* (2013.01); *C12N 7/00* (2013.01); *A61K 2039/53* (2013.01)

(73) Assignees: **GLAXOSMITHKLINE BIOLOGICALS SA**, Rixensart (BE); **THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES**, Bethesda, MD (US) (57) **ABSTRACT**

Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.

(21) Appl. No.: 17/946,383

(22) Filed: Sep. 16, 2022

Related U.S. Application Data

(63) Continuation of application No. 16/461,503, filed as **Specification includes a Sequence Listing.**




FIG. 1




FIG.2




FIG.3B

	←prM → ←Signal Sequence → ←Envelope (E) →	
Uganda	TKHLIKVENWIFRNPGFALVAVAIAWLLGSSTSQKVIYLVMIILLIAPAYSIRCIGVSNRD	300
Micronesia	TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMIILLIAPAYSIRCIGVSNRD	300
Natal	TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMIILLIAPAYSIRCIGVSNRD	300
Salvador	TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMIILLIAPAYSIRCIGVSNRD	300
KU365777	TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMIILLIAPAYSIRCIGVSNRD	300
KU365778	TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMIILLIAPAYSIRCIGVSNRD	300
KU365779	TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMIILLIAPAYSIRCIGVSNRD	300
KU365780	TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMIILLIAPAYSIRCIGVSNRD	300
French	TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMIILLIAPAYSIRCIGVSNRD	300
Sao	TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMIILLIAPAYSIRCIGVSNRD	300
	*****:*****.*.*****	
	(E)	
Uganda	FVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMAS	360
Micronesia	FVEGMSGGTWVDVLEHGGCVTVMAQDKPAVDIELVTTTTSNMAEVRSYCYEASISDMAS	360
Natal	FVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMAS	360
Salvador	FVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMAS	360
KU365777	FVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMAS	360
KU365778	FVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMAS	360
KU365779	FVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMAS	360
KU365780	FVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMAS	360
French	FVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMAS	360
Sao	FVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMAS	360
	*****:*****:*****	
	(E)	
Uganda	DSRCPTQGEAYLDKQSDTYVCKRTLVDRGWNGCGLFGKGLVTCAKFACSKKMTGKSI	420
Micronesia	DSRCPTQGEAYLDKQSDTYVCKRTLVDRGWNGCGLFGKGLVTCAKFACSKKMTGKSI	420
Natal	DSRCPTQGEAYLDKQSDTYVCKRTLVDRGWNGCGLFGKGLVTCAKFACSKKMTGKSI	420
Salvador	DSRCPTQGEAYLDKQSDTYVCKRTLVDRGWNGCGLFGKGLVTCAKFACSKKMTGKSI	420
KU365777	DSRCPTQGEAYLDKQSDTYVCKRTLVDRGWNGCGLFGKGLVTCAKFACSKKMTGKSI	420
KU365778	DSRCPTQGEAYLDKQSDTYVCKRTLVDRGWNGCGLFGKGLVTCAKFACSKKMTGKSI	420
KU365779	DSRCPTQGEAYLDKQSDTYVCKRTLVDRGWNGCGLFGKGLVTCAKFACSKKMTGKSI	420
KU365780	DSRCPTQGEAYLDKQSDTYVCKRTLVDRGWNGCGLFGKGLVTCAKFACSKKMTGKSI	420
French	DSRCPTQGEAYLDKQSDTYVCKRTLVDRGWNGCGLFGKGLVTCAKFACSKKMTGKSI	420
Sao	DSRCPTQGEAYLDKQSDTYVCKRTLVDRGWNGCGLFGKGLVTCAKFACSKKMTGKSI	420
	*****:*****:*****	
	(E)	
Uganda	QPENLEYRIMLSVHGSQHSGMI----GYETDEDRAKVEVTPNSPRAEATLGGFGSLGLDC	476
Micronesia	QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDC	480
Natal	QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDC	480
Salvador	QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDC	480
KU365777	QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDC	480
KU365778	QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDC	480
KU365779	QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDC	480
KU365780	QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDC	480
French	QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDC	480
Sao	QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDC	480
	***** * .*****.*****	

FIG.3C

	(E)	
Uganda	EPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA	536
Micronesia	EPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA	540
Natal	EPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA	540
Salvador	EPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA	540
KU365777	EPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA	540
KU365778	EPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA	540
KU365779	EPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA	540
KU365780	EPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA	540
French	EPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA	540
Sao	EPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA	540

	(E)	
Uganda	KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTA	596
Micronesia	KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTA	600
Natal	KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTA	600
Salvador	KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTA	600
KU365777	KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTA	600
KU365778	KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTA	600
KU365779	KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTA	600
KU365780	KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTA	600
French	KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTA	600
Sao	KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLRLKGVSYSLCTA	600

	(E)	
Uganda	AFTFTKIPAETLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGRGITANPVI TESTE	656
Micronesia	AFTFTKIPAETLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGRGITANPVI TESTE	660
Natal	AFTFTKIPAETLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGRGITANPVI TESTE	660
Salvador	AFTFTKIPAETLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGRGITANPVI TESTE	660
KU365777	AFTFTKIPAETLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGRGITANPVI TESTE	660
KU365778	AFTFTKIPAETLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGRGITANPVI TESTE	660
KU365779	AFTFTKIPAETLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGRGITANPVI TESTE	660
KU365780	AFTFTKIPAETLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGRGITANPVI TESTE	660
French	AFTFTKIPAETLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGRGITANPVI TESTE	660
Sao	AFTFTKIPAETLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGRGITANPVI TESTE	660

	(E)	
Uganda	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD	716
Micronesia	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD	720
Natal	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD	720
Salvador	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD	720
KU365777	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD	720
KU365778	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD	720
KU365779	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD	720
KU365780	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD	720
French	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD	720
Sao	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD	720

FIG.3D

	————— (E) —————	
Uganda	FGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLA	776
Micronesia	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLA	780
Natal	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA	780
Salvador	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA	780
KU365777	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA	780
KU365778	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA	780
KU365779	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA	780
KU365780	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA	780
French	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA	780
Sao	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA	780
	*****.:*****:***** **	

	————— (E) —————>	
Uganda	LGGVMIFLSTAVSAD	791
Micronesia	LGGVLIFLSTAVSAD	795
Natal	LGGVLIFLSTAVSAD	795
Salvador	LGGVLIFLSTAVSAD	795
KU365777	LGGVLIFLSTAVSAD	795
KU365778	LGGVLIFLSTAVSAD	795
KU365779	LGGVLIFLSTAVSAD	795
KU365780	LGGVLIFLSTAVSAD	795
French	LGGVLIFLSTAVSAD	795
Sao	LGGVLIFLSTAVSAD	795
	*****.*****	

FIG. 4A




FIG.4B

(E)

Natal FVEGMSGGTWVDVLEHGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMAS
 Salvador FVEGMSGGTWVDVLEHGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMAS
 KU365777 FVEGMSGGTWVDVLEHGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMAS
 KU365778 FVEGMSGGTWVDVLEHGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMAS
 KU365779 FVEGMSGGTWVDVLEHGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMAS
 KU365780 FVEGMSGGTWVDVLEHGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMAS
 Sao FVEGMSGGTWVDIVLEHGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMAS
 *****:*****

(E)

Natal DSRCPQTQGEAYLDKQSDTQYVCKRTLVDLRGWGNGCGLFGKGSVLTCAKFAKSKKMTGKSI
 Salvador DSRCPQTQGEAYLDKQSDTQYVCKRTLVDLRGWGNGCGLFGKGSVLTCAKFAKSKKMTGKSI
 KU365777 DSRCPQTQGEAYLDKQSDTQYVCKRTLVDLRGWGNGCGLFGKGSVLTCAKFAKSKKMTGKSI
 KU365778 DSRCPQTQGEAYLDKQSDTQYVCKRTLVDLRGWGNGCGLFGKGSVLTCAKFAKSKKMTGKSI
 KU365779 DSRCPQTQGEAYLDKQSDTQYVCKRTLVDLRGWGNGCGLFGKGSVLTCAKFAKSKKMTGKSI
 KU365780 DSRCPQTQGEAYLDKQSDTQYVCKRTLVDLRGWGNGCGLFGKGSVLTCAKFAKSKKMTGKSI
 Sao DSRCPQTQGEAYLDKQSDTQYVCKRTLVDLRGWGNGCGLFGKGSVLTCAKFAKSKKMTGKSI

(E)

Natal QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFSGSLGLDC
 Salvador QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFSGSLGLDC
 KU365777 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFSGSLGLDC
 KU365778 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFSGSLGLDC
 KU365779 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFSGSLGLDC
 KU365780 QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFSGSLGLDC
 Sao QPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFSGSLGLDC

(E)

Natal EPRTGLDFSDLYLTMNNKHVLVHKEWPHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA
 Salvador EPRTGLDFSDLYLTMNNKHVLVHKEWPHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA
 KU365777 EPRTGLDFSDLYLTMNNKHVLVHKEWPHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA
 KU365778 EPRTGLDFSDLYLTMNNKHVLVHKEWPHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA
 KU365779 EPRTGLDFSDLYLTMNNKHVLVHKEWPHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA
 KU365780 EPRTGLDFSDLYLTMNNKHVLVHKEWPHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA
 Sao EPRTGLDFSDLYLTMNNKHVLVHKEWPHDIPLPWHAGADTGTPHWNNKEALVEFKDAHA

(E)

Natal KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKLRKGVSYSLCTA
 Salvador KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKLRKGVSYSLCTA
 KU365777 KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKLRKGVSYSLCTA
 KU365778 KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKLRKGVSYSLCTA
 KU365779 KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKLRKGVSYSLCTA
 KU365780 KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKLRKGVSYSLCTA
 Sao KRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKLRKGVSYSLCTA

FIG.4C

(E)

Natal	AFTFTKIPAE TLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGR LITANPVITESTE
Salvador	AFTFTKIPAE TLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGR LITANPVITESTE
KU365777	AFTFTKIPAE TLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGR LITANPVITESTE
KU365778	AFTFTKIPAE TLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGR LITANPVITESTE
KU365779	AFTFTKIPAE TLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGR LITANPVITESTE
KU365780	AFTFTKIPAE TLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGR LITANPVITESTE
Sao	AFTFTKIPAE TLHGTVTVEVQYAGTDGPKVPAQMAVDMQTLTPVGR LITANPVITESTE

(E)

Natal	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD
Salvador	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD
KU365777	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD
KU365778	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD
KU365779	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD
KU365780	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD
Sao	NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWD

(E)

Natal	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA
Salvador	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA
KU365777	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA
KU365778	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA
KU365779	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA
KU365780	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA
Sao	FGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLA

(E)

Natal	LGGVLI FLSTAVSAD
Salvador	LGGVLI FLSTAVSAD
KU365777	LGGVLI FLSTAVSAD
KU365778	LGGVLI FLSTAVSAD
KU365779	LGGVLI FLSTAVSAD
KU365780	LGGVLI FLSTAVSAD
Sao	LGGVLI FLSTAVSAD

FIG. 5





FIG.6

(A) antigen insert #5283



(B) antigen insert #5288



FIG.7




FIG.8




FIG.9

Viral Load Day 3 Post Challenge




FIG.10

Neutralizing Antibody Titers




FIG.11

Viral Load





FIG.12

Fold Change of nAb Titer



ZIKA VIRAL ANTIGEN CONSTRUCTS

STATEMENT OF U.S. GOVERNMENT INTEREST

[0001] This invention was created in the performance of a Cooperative Research and Development Agreement with the National Institutes of Health, an Agency of the Department of Health and Human Services. The Government of the United States has certain rights in this invention.

SEQUENCE LISTING

[0002] This application contains a Sequence Listing which has been submitted electronically in .XML format and is hereby incorporated by reference in its entirety. Said .XML copy, created on Sep. 15, 2022, is named "2801-0317PUS2.xml" and is 153,900 bytes in size. The sequence listing contained in this .XML file is part of the specification and is hereby incorporated by reference herein in its entirety.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] The present application is a 37 C.F.R. § 1.53(b) continuation of U.S. Application No. 16/461,503 filed on May 16, 2019 which is the National Phase of PCT International Application No. PCT/EP2017/079343, filed on Nov. 15, 2017, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Nos. 62/568,559 filed on Oct. 5, 2017; 62/485,090 filed on Apr. 13, 2017; and 62/423,398 filed on Nov. 17, 2016, all of which are hereby expressly incorporated by reference into the present application.

FIELD OF THE INVENTION

[0004] This invention is in the field of treating and preventing viral infections. In particular, the present invention relates to nucleic acid-based vaccine constructs encoding Zika viral antigens and the use of Zika viral antigens for treating and preventing Zika infections.

BACKGROUND TO THE INVENTION

[0005] Zika virus was first identified in Uganda in 1947 in rhesus monkeys through a monitoring network of sylvatic yellow fever. It was subsequently identified in humans in 1952 in Uganda and the United Republic of Tanzania. Outbreaks of Zika virus disease have been recorded in Africa, the Americas, Asia and the Pacific. Zika virus belongs to the genus *flavivirus*. Its reservoir is unknown.

[0006] Zika virus is a plus-strand RNA virus belonging to the family Flaviviridae. Zika virus disease is caused by a virus transmitted primarily by *Aedes* mosquitoes. People with Zika virus disease can have symptoms that can include mild fever, skin rash, conjunctivitis, muscle and joint pain, malaise or headache. These symptoms normally last for 2-7 days.

[0007] The Zika virus is known to circulate in Africa, the Americas, Asia and the Pacific. Transmitted by *Aedes* mosquitoes, the virus has been known to cause either asymptomatic infection (in the majority of people infected) or a self-limiting illness with descending rash, conjunctivitis and low grade fever. However, during the ongoing Zika virus outbreak in the Americas an alarming increase in the number of babies born with microcephaly, as well as an increase in the incidence of Guillain-Barré syndrome has been reported.

In addition to microcephaly, other fetal malformations and neurological disorders have been described.

[0008] Dowd et al. (Science, Vol. 354 Issue 6309, pp. 237-40 (2016) recently reported that DNA vaccines expressing the pre-membrane and envelope proteins of Zika virus were immunogenic in mice and nonhuman primates when administered by electroporation or needle-free injection; and that protection against viremia after Zika virus challenge correlated with serum neutralizing activity.

[0009] Chahal et al. (Scientific Reports, 7:252, pp. 1-9 (2017)) describe an alphavirus RNA vector encoding Zika virus structural antigens. When formulated with a modified dendrimer nanomaterial and administered to mice intramuscularly, the vaccine was found to be immunogenic.

[0010] Richner et al. (Cell, 168, pp. 1-12, (2017) describe a modified mRNA vaccine encoding wild-type or mutant Zika structural proteins. When encapsulated in lipid nanoparticles and administered intramuscularly to mice, the mRNA vaccine elicited high neutralizing antibody titers and protection from viral challenge.

[0011] Given the concerning disease burden and the potential for rapid dissemination, there is an urgent need for the development of components for use in a Zika virus immunogenic or vaccine composition.

SUMMARY OF THE INVENTION

[0012] The present inventors provide constructs useful as components of immunogenic compositions for the induction of an immune response in a subject against Zika viral infection, methods for their use in treatment, and processes for their manufacture.

[0013] In some embodiments, a nucleic acid-based vaccine construct encoding a polypeptide comprising a full-length Zika virus pre-M-E antigen (prME), or an immunogenic fragment thereof is provided.

[0014] In some embodiments, a vector comprising the construct as described is provided.

[0015] In some embodiments, a self-replicating RNA molecule (also referred to herein as a self-amplifying mRNA, or SAM molecule) comprising the construct as described is provided.

[0016] In some embodiments, a composition comprising an immunologically effective amount of one or more of the constructs, vectors, or self-replicating RNA molecules as described above is provided.

[0017] In some embodiments, a composition as described above is provided wherein the composition comprises an RNA-based vaccine.

[0018] In some embodiments, a composition as described above is provided wherein the composition comprises one or more constructs, vectors, or self-replicating RNA molecules as described above complexed with a particle of a cationic oil-in-water emulsion.

[0019] In some embodiments, a composition as described above for use in inducing an immune response against a Zika virus infection in a subject in need thereof is provided.

[0020] In some embodiments, a method is provided for inducing an immune response against a Zika virus infection in a subject in need thereof, which comprises administering to said subject an immunologically effective amount of a composition comprising one or more of the constructs, vectors, or self-replicating RNA molecules as described above.

[0021] In some embodiments, a method as described above is provided wherein the composition comprises one

or more constructs, vectors, or self-replicating RNA molecules as described above complexed with a particle of a cationic oil-in-water emulsion.

[0022] In some embodiments, a process is provided for producing an RNA-based vaccine comprising a step of transcribing a vector or DNA molecule encoding a self-replicating RNA molecule described above to produce an RNA comprising a coding region for the antigen.

[0023] In some embodiments, a method of preparing a composition as described above is provided wherein the method comprises 1) preparing a cationic oil-in-water emulsion; 2) preparing one or more constructs, vectors, or self-replicating RNA molecules as described above; and 3) adding the one or more constructs, vectors, or self-replicating RNA molecules to the cationic oil-in-water emulsion so that the construct, vector, or self-replicating RNA molecule complexes with the emulsion.

[0024] In some embodiments, a composition produced by the process described above is provided.

[0025] In some embodiments, a use of the construct, vector, self-replicating RNA molecule, or composition described above for inducing an immune response against a Zika virus infection in a subject is provided.

[0026] In some embodiments, a use of the construct, vector, self-replicating RNA molecule, or composition described above in the manufacture of a medicament that induces an immune response against a Zika virus infection in a subject is provided.

[0027] In some embodiments, a construct, vector, self-replicating RNA molecule, or composition described above for use in therapy is provided.

[0028] In some embodiments, a construct, vector, self-replicating RNA molecule, or composition described above for use in a method of inducing an immune response to a Zika virus infection in a subject is provided.

DESCRIPTION OF DRAWINGS/FIGURES

[0029] FIG. 1: The organization of the Flavivirus genome, showing the polyprotein that is cleaved into structural and nonstructural proteins by a combination of viral and cellular proteases.

[0030] FIG. 2: Formation of Flavivirus virions and subviral particles. (1) In natural infections, *flavivirus* proteins are produced by the processing of a polyprotein translated from the viral genomic RNA and inserted co-translationally into the endoplasmic reticulum (ER) membrane. Horizontal arrows indicate polyprotein cleavages by signal peptidase and arrow heads indicate cleavage by the viral NS2B-3 protease. The open arrow indicates a signalase cleavage which is inefficient unless cytoplasmic capsid (C) cleavage has occurred. (2) The minimal requirement for production of subviral particles is the precursor membrane (prM) and envelope (E) proteins. (3) Flavivirus particles are formed by budding on the ER membrane driven by the prM and E proteins independent of the C protein or preformed nucleocapsids. Virus infection results predominantly in the formation of virions. (4) Nucleocapsid-free virus-like particles are efficiently produced by recombinant expression of the prM and E proteins and are a by-product of *flavivirus* infection. (5) Virions and virus-like particles follow the exocytic pathway for secretion from infected/transfected cells. ‘Cy’ denotes the cytoplasmic side of the ER membrane.

[0031] FIGS. 3A-D: CLUSTAL O(1.2.1) multiple sequence alignment of CprME proteins of Zika virus strains: Uganda (SEQ ID NO:10); Micronesia (SEQ ID NO:11); Natal (SEQ ID NO:2); Salvador (SEQ ID NO:8); Genbank Accession No. KU365777 (SEQ ID NO:13); Genbank Accession No. KU365778 (SEQ ID NO:14); Genbank Accession No. KU365779 (SEQ ID NO:15); Genbank Accession No. KU365780 (SEQ ID NO:16); French Polynesia (“French”) (SEQ ID NO:12); and Sao Paulo (“Sao”) (SEQ ID NO:9). An “*” (asterisk) indicates positions which have a single, fully conserved residue. A “:” (colon) indicates conservation between groups of strongly similar properties. A “.” (period) indicates conservation between groups of weakly similar properties. The above SEQ ID NOS include the entire sequences shown in FIGS. 3A-D for each strain except that SEQ ID NO: 2 does not include the capsid (C) portion of the Natal strain. However, the entire corresponding sequence for the Natal strain is shown in FIGS. 3A-3D.

TABLE 1

Zika virus strains, year, and Genbank reference		
STRAIN	YEAR	GENBANK NUMBER
Uganda		NC_012532
Micronesia	2007	EU545988.1
Natal (Brazil)	2016	KU527068
Salvador (Brazil)	2016	KU707826.1
Sao Paulo (Brazil)	2016	KU321639
French Polynesia	2013	KJ776791

[0032] FIGS. 4A-C: CLUSTAL O(1.2.1) multiple sequence alignment of CprME proteins from Brazilian strains of Zika virus: Natal (SEQ ID NO:2); Salvador (SEQ ID NO:8); Genbank Accession No. KU365777 (SEQ ID NO:13); Genbank Accession No. KU365778 (SEQ ID NO:14); Genbank Accession No. KU365779 (SEQ ID NO:15); Genbank Accession No. KU365780 (SEQ ID NO:16); and Sao Paulo (“Sao”) (SEQ ID NO:9). See Table 1 for Zika virus strains, year, and Genbank reference.

[0033] FIG. 5: A SAM-Zika construct. The self-amplifying mRNA (SAM) background consists of VEE TC-83 replicon encoding the viral nonstructural proteins 1-4 (nsP1-4), followed by the subgenomic promoter, and an insert encoding a Zika antigen. The empty vector is shown in SEQ ID NO:17; the insert starts immediately after nucleotide 7561.

[0034] FIG. 6: Design of antigen inserts for Zika-SAM constructs.

[0035] Antigen insert #5283, shown in (A), comprises a Japanese Encephalitis Virus (JEV) signal sequence followed by Zika prME, including the wild type prM start sequence (“AEVTR”). The full length amino acid sequence of antigen insert #5283 is shown in SEQ ID NO:19, including the JEV signal sequence (SEQ ID NO:5), followed by the Zika pr region (SEQ ID NO:20), M protein (SEQ ID NO:21) and E protein (SEQ ID NO:22). The DNA and RNA sequences encoding the antigen insert shown in (A) are presented in SEQ ID NOS:18 and 39, respectively.

[0036] Antigen insert #5288, shown in (B), is identical to the insert of (A), except that the last 98 amino acids of the Zika E protein are replaced with the last 98 amino acids from the C-terminus of the JEV E protein (Genbank Accession No. AFV52311.1; SEQ ID NO:7). Chang et al. (2003)

Viol. 306:170-180. The full length amino acid sequence of antigen insert #5288 is shown in SEQ ID NO:24, including the JEV signal sequence (SEQ ID NO:5), followed by the Zika pr region and M protein (SEQ ID NOS:25 and 26, respectively), and a hybrid Zika-JEV E protein (SEQ ID NO:27). The DNA and RNA sequences encoding the antigen insert shown in (B) are presented in SEQ ID NOS:23 and 40, respectively.

[0037] FIG. 7: Analysis of expression and secretion of E protein from Zika-SAM constructs.

[0038] Expression and secretion of E protein was detected by immunoblot in cell lysates for self-amplifying mRNA (SAM) constructs encoding antigen inserts #5283 (JEV signal + Zika prME) and #5288 (JEV signal + hybrid Zika-JEV prME). Expression and secretion of E protein was also detected for a positive control antigen construct (#8111) but not for a negative control construct (#4974) or mock transfection (“Mock”). See Example 5.

[0039] FIG. 8: Neutralizing Antibody Responses in Mice. Mice were found to have significant neutralizing Zika antibodies two weeks after a single vaccination with Zika-SAM construct #5283 (JEV signal + Zika prME), or with positive control Zika DNA construct #5283, as measured by reporter virus particle (RVP) neutralization assay. Neutralizing antibody titers were further increased two weeks after a second vaccination with the same Zika-SAM construct, or the positive control. Neutralizing Zika antibodies were below the limit of quantification before vaccination (Day 0), and after vaccination with negative control construct (#4974, 1.5 µg dose) or with #5288 (JEV signal + hybrid Zika-JEV prME, 1.5 µg dose). A dose-response effect was observed for SAM construct #5283, with 15 µg of RNA eliciting more neutralizing antibodies than 1.5 µg RNA.

[0040] FIG. 9: Protection of Mice from Zika Challenge: Mice vaccinated on days 0 and 21 were challenged with live Zika virus on day 49. Viral load was measured 3 days post-challenge. Vaccination with SAM construct #5283 (at 1.5 µg and 15 µg doses), as well as the positive control (DNA #5283) were protective against Zika viremia. Unvaccinated mice and mice vaccinated with SAM construct #5288 (1.5 µg dose) or negative control construct #4974 were not protected in the Zika challenge. Dotted line indicates the limit of quantification (LOQ) of the assay.

[0041] FIG. 10: Neutralizing Antibody Responses in Non-Human Primates (NHPs). Rhesus Macaques were immunized at weeks 0 and 4 with the Zika-SAM construct #5283 (75 µg/dose) or a codon-optimized SAM construct encoding the native Zika prME antigen (Co.prME SAM; 75 µg/dose). Control NHPs were administered placebo or immunized with Zika DNA construct #5283 (4 mg/dose). Zika neutralizing antibodies were significantly elevated four weeks after the first immunization of Zika SAM construct #5283 or Zika DNA #5283 as compared to placebo, with titers being further increased 4 weeks after the second immunization. Zika-SAM construct Co.prME SAM produced significantly less neutralizing antibodies compared to #5283 DNA after a single dose, but similar titers after two injections. Dotted line indicates the limit of quantification (LOQ) of the assay.

[0042] FIG. 11: Protection of NHPs from Zika Challenge: Rhesus Macaques vaccinated as described in FIG. 10 were then challenged with live Zika virus at week 8. Viral load was measured daily from days 3-7 post-challenge. Placebo animals exhibited elevated viremia as early as 3 days post-

challenge (A). Vaccination with Zika-SAM construct #5283 (B), Zika-SAM Co.prME (C), and DNA #5283 (D) were protective against Zika viremia, with Zika-SAM construct #5283 exhibiting a complete protection against Zika viremia. Dotted line indicates the limit of quantification (LOQ) of the assay.

[0043] FIG. 12: Post-Challenge Serology in NHPs. Neutralizing antibody titers were determined 8, 10 and 12 weeks after Zika virus challenge, and are expressed as fold-change from pre-challenge levels. Placebo animals showed a sharp rise in neutralizing antibodies after Zika challenge, suggesting Zika infection in these animals. Two animals in the SAM Co.prME group, and one animal in the DNA #5283 group, showed elevated neutralizing antibody titers post-challenge, indicating that protection was not sterilizing in these animals. In contrast, animals in the Zika SAM #5283 group did not exhibit elevated neutralizing antibodies after Zika challenge, indicating that sterilizing protection was achieved in all subjects. Dotted line in (B), (C) and (D) indicates a 4-fold change in neutralizing titers, which is considered non-sterilizing in the flavivirus field.

DETAILED DESCRIPTION OF THE INVENTION

Antigens; Variants; Fragments; and Constructs

[0044] The present inventors provide constructs useful as components of immunogenic compositions for the induction of an immune response in a subject against Zika viral infection constructs useful for the expression of antigens, methods for their use in treatment, and processes for their manufacture. By construct is intended a nucleic acid that encodes polypeptide sequences described herein, and may comprise DNA, RNA, or non-naturally occurring nucleic acid monomers. The nucleic acid components of constructs are described more fully in the Nucleic Acids section herein.

[0045] In some embodiments, the constructs disclosed herein encode wild-type polypeptide sequences of a Zika virus, or a variant, or a fragment thereof. The constructs may further encode a polypeptide sequence heterologous to the polypeptide sequences of a Zika virus. In some embodiments, the constructs encode wild-type polypeptide sequences of a Brazilian strain Zika virus, or a variant, or a fragment thereof. By “Brazilian strain Zika virus” is intended any strain of Zika virus denoted as “Brazilian” in Table 1. Unless indicated otherwise, descriptions of the wild-type prME antigen are made by reference to the Natal strain (Brazil), GenBank number KU527068.1, as depicted in the SEQ ID NO:1 (nucleic acid) and SEQ ID NO:2 (polypeptide), and as depicted in FIGS. 3A-D, and FIGS. 4A-C.

[0046] A “variant” of a polypeptide sequence includes amino acid sequences having one or more amino acid substitutions, insertions and/or deletions when compared to the reference sequence. The variant may comprise an amino acid sequence which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a full-length wild-type polypeptide, for example, to a polypeptide according to SEQ ID NO:2. Alternatively, or in addition, a fragment of a polypeptide may comprise an immunogenic fragment (i.e. an epitope-containing fragment) of the full-length polypeptide which may comprise a contiguous amino acid sequence of at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least

16, at least 17, at least 18, at least 19, or more amino acids which is identical to a contiguous amino acid sequence of the full-length polypeptide.

[0047] A fragment of a polypeptide may comprise N- and/or C-terminal deletions when compared to a full-length polypeptide, for example SEQ ID NO:2, wherein the fragment comprises a deletion of up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 amino acids from the N-terminus, the C-terminus, or both the N-terminus and C-terminus of the full-length sequence. It may be specified that the deletions are of consecutive amino acids.

[0048] As used herein, the term “antigen” refers to a molecule containing one or more epitopes (e.g., linear, conformational or both) that will stimulate a host’s immune system to make a humoral and/or cellular antigen-specific immunological response (i.e. an immune response which specifically recognizes an antigen polypeptide). An “epitope” is that portion of an antigen that determines its immunological specificity.

[0049] T- and B-cell epitopes can be identified empirically (e.g. using PEPSCAN™ or similar methods). See the following references: Geysen et al. (1984) *PNAS USA* 81:3998-4002; Carter (1994) *Methods Mol Biol* 36:207-23. They can be predicted (e.g. using the Jameson- Wolf antigenic index (see Jameson et al. (1988) *CABIOS* 4(1): 181-186), matrix-based approaches (see Raddrizzani & Hammer (2000) *Brief Bioinform* 1(2): 179-89), TEPITOPE™ (see De Lalla et al. (1999) *J. Immunol.* 163: 1725-29), neural networks (see Brusci et al. (1998) *Bioinformatics* 14(2): 121-30), OptiMer & EpiMer (see Meister et al. (1995) *Vaccine* 13(6):581-91; see Roberts et al. (1996) *AIDS Res Hum Retroviruses* 12(7):593-610), ADEPT™ (see Maksyutov & Zagrebelnaya (1993) *Comput Appl Biosci* 9(3):291-7), Tsites (see Feller & de la Cruz (1991) *Nature* 349(6311):720-1), hydrophilicity (see Hopp (1993) *Peptide Research* 6:183-190), antigenic index (see Welling et al. (1985) *FEBS Lett.* 188:215-218) or the methods disclosed in reference Davenport et al. (1995) *Immunogenetics* 42:392-297, etc.).

[0050] In some embodiments, the constructs herein encode a Zika virus prME antigen. By “Zika virus prME antigen” is intended the amino acid sequence, or a nucleotide sequence encoding the amino acid sequence, of a wild-type Zika virus structural protein prME, a variant, or a fragment thereof. FIG. 3 and FIG. 4 identify the amino acid sequence of several full-length wild-type Zika virus prME structural protein variants. The sequence identifier numbers for each are set forth in the Sequence Listing herein. See SEQ ID NOS:2 and 8-16.

[0051] Thus, where a Zika virus prME antigen is a variant of a wild-type prME polypeptide, the variant may comprise an amino acid sequence which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a full-length wild-type polypeptide, for example, to a polypeptide according to SEQ ID NOS:2 and 8-16. Alternatively, or in addition, a fragment of a polypeptide may comprise an immunogenic fragment (i.e. an epitope-containing fragment) of the full-length polypeptide which may comprise a contiguous amino acid sequence of at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or more amino acids which is identical to a contiguous amino acid sequence of the full-length polypeptide.

[0052] A fragment of a Zika virus prME polypeptide may comprise N- and/or C-terminal deletions when compared to a full-length polypeptide, for example SEQ ID NOS:2 and 8-16, wherein the fragment comprises a deletion of up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 amino acids from the N-terminus, the C-terminus, or both the N-terminus and C-terminus of the full-length sequence. It may be specified that the deletions are of consecutive amino acids. In some embodiments, the Zika virus prME polypeptide comprises a fragment selected from the group consisting of amino acids 1 to 692 of SEQ ID NO:2 and amino acids 21 to 692 of SEQ ID NO:2.

[0053] In some embodiments, an immunogenic fragment of a prME antigen comprises the full-length of the Zika virus M antigen. By “Zika virus M antigen” is intended the amino acid sequence, or a nucleotide sequence encoding the amino acid sequence, of SEQ ID NO:21. Where a Zika virus M antigen is a variant of a wild-type M polypeptide, the variant may comprise an amino acid sequence which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a full-length wild-type polypeptide, for example, to a polypeptide according to SEQ ID NO:21.

[0054] A fragment of a Zika virus M antigen may comprise N- and/or C-terminal deletions when compared to a full-length polypeptide, for example SEQ ID NO:21, wherein the fragment comprises a deletion of up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 amino acids from the N-terminus, the C-terminus, or both the N-terminus and C-terminus of the full-length sequence. It may be specified that the deletions are of consecutive amino acids.

[0055] In some embodiments, an immunogenic fragment of a prME antigen comprises the full-length of the Zika virus E antigen. By “Zika virus E antigen” is intended the amino acid sequence, or a nucleotide sequence encoding the amino acid sequence, of SEQ ID NO:22. Where a Zika virus E antigen is a variant of a wild-type E polypeptide, the variant may comprise an amino acid sequence which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a full-length wild-type polypeptide, for example, to a polypeptide according to SEQ ID NO:22. In some embodiments, a variant Zika virus E antigen may be a hybrid E antigen comprising an N-terminal fragment of a Zika E protein fused to a C-terminal fragment of a heterologous viral E protein. In some embodiments, the heterologous viral E protein is derived from a heterologous *flavivirus*, such as Japanese Encephalitis Virus (JEV).

[0056] A fragment of a Zika virus E antigen may comprise N- and/or C-terminal deletions when compared to a full-length polypeptide, for example SEQ ID NO:22, wherein the fragment comprises a deletion of up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 amino acids from the N-terminus, the C-terminus, or both the N-terminus and C-terminus of the full-length sequence. It may be specified that the deletions are of consecutive amino acids.

[0057] In some embodiments, a variant Zika virus prME antigen comprises a hybrid Zika-JEV E protein. A hybrid Zika-JEV E antigen may comprise an N-terminal fragment of a Zika E protein comprising at least amino acids (1 + x) to (422 ± y) of SEQ ID NO:22, where x is a whole number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; and y is a whole number selected

from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. In one embodiment, the N terminal fragment of a Zika E protein comprises amino acids 1 to 422 of SEQ ID NO:22.

[0058] A hybrid E antigen may comprise a C-terminal fragment of a JEV E protein comprising at least amino acids $(205 \pm x)$ to $(302 \pm y)$ of SEQ ID NO:7, where x is a whole number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; and y is a whole number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. In one embodiment, the C-terminal fragment of a JEV E protein comprises amino acids 205 to 302 of SEQ ID NO:7.

[0059] In one embodiment, a hybrid E antigen comprises the amino acid sequence of SEQ ID NO:27, or a fragment or variant thereof. A variant may comprise an amino acid sequence which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the polypeptide according to SEQ ID NO:27. Alternatively, or in addition, a fragment of a polypeptide may comprise an immunogenic fragment (i.e. an epitope-containing fragment) of the full-length polypeptide, such as a contiguous amino acid sequence of at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500 or more amino acids which is identical to a contiguous amino acid sequence of SEQ ID NO:27.

[0060] As noted elsewhere herein, the Zika virus RNA is translated as a polyprotein comprising a prM signal sequence. The prM signal sequence is located N-terminal to the prM antigen sequence. Cleavage occurs in the ER lumen by a cellular signal peptidase and generates the N terminus of prM. Where the polyprotein comprises a wild-type amino acid sequence, the polyprotein comprises a native prM signal sequence, SEQ ID NO:3. By “native prM signal sequence” is intended the amino acid sequence, or a nucleotide sequence encoding the amino acid sequence, of a signal sequence of a wild-type viral prME, SEQ ID NO:3. FIGS. 3A-B and FIG. 4A identify the amino acid sequence of several full-length native prM signal sequence variants from various Zika virus strains.

[0061] In some embodiments, the constructs encode a native prM signal sequence. Where the prM signal sequence is a variant of a native prM signal sequence, the variant may comprise an amino acid sequence which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the full-length polypeptide according to SEQ ID NO:3. Alternatively, or in addition, a fragment of a polypeptide may comprise a functional fragment (i.e., containing the sequence recognized and cleaved by the protease) of the full-length polypeptide which may comprise a contiguous amino acid sequence of at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17 amino acids of SEQ ID NO:3 which is identical to a contiguous amino acid sequence of full-length polypeptide.

[0062] In some embodiments, the construct encodes a heterologous, non-Zika signal sequence. In some embodiments, the construct encodes a Japanese Encephalitis Virus (JEV) signal sequence, a variant, or a fragment thereof, in place of the Zika prM signal sequence. By “JEV signal sequence” is intended the amino acid sequence as set forth in FIG. 6: MGKRSAGSIMWLASLAWIACAGA (SEQ ID NO:5). A variant may comprise an amino acid sequence

which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a full-length wild-type polypeptide, for example, to a polypeptide according to SEQ ID NO:5. Alternatively, or in addition, a fragment of a polypeptide may comprise a functional fragment (i.e., containing the sequence recognized and cleaved by the protease) of the full-length polypeptide which may comprise a contiguous amino acid sequence of at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22 at least 23 amino acids, which is identical to a contiguous amino acid sequence of the full-length polypeptide.

[0063] In some embodiments, the construct encodes a polypeptide comprising from the N-terminal portion to the C-terminal portion: a JEV signal sequence and a Zika prME antigen, variant, or immunogenic fragment thereof. In some embodiments, the construct encodes a polypeptide comprising from the N-terminal portion to the C-terminal portion: a JEV signal sequence, a Zika prM antigen, and a hybrid E antigen comprising an N-terminal fragment of a Zika E protein fused to a C-terminal fragment of a JEV E protein.

[0064] In some embodiments, a construct encodes each component of the polypeptide, if present, juxtaposed immediately next to the adjacent component, i.e., without any intervening amino acids. In some embodiments, a linker group of 1, 2, 3, 4, or 5 amino acids is present between one or more of the components.

[0065] In some embodiments, the construct encodes a polypeptide having a sequence selected from the group consisting of SEQ ID NO:19 and SEQ ID NO:24. In some embodiments, the construct encodes a polypeptide which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from the group consisting of SEQ ID NO:19 and SEQ ID NO:24. In some embodiments, the construct encodes a polypeptide which comprises a fragment of a full-length sequence selected from the group consisting of SEQ ID NO:19 and SEQ ID NO:24, wherein the fragment comprises a contiguous stretch of the amino acid sequence of the full-length sequence up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids shorter than the full-length sequence.

[0066] In some embodiments, the construct comprises a DNA sequence selected from the group consisting of SEQ ID NO:18 and SEQ ID NO:23. In some embodiments, the construct comprises a DNA sequence which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from the group consisting of SEQ ID NO:18 and SEQ ID NO:23. In some embodiments, the construct comprises a DNA sequence which comprises a fragment of a full-length sequence selected from the group consisting of SEQ ID NO:18 and SEQ ID NO:23 wherein the fragment comprises a contiguous stretch of the DNA sequence of the full-length sequence up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 nucleic acids shorter than the full-length sequence.

[0067] In some embodiments, the construct comprises an RNA sequence selected from the group consisting of SEQ ID NO:39 and SEQ ID NO:40. In some embodiments, the construct comprises an RNA sequence which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least

98%, or at least 99% identical to a sequence selected from the group consisting of SEQ ID NO:39 and SEQ ID NO:40. In some embodiments, the construct comprises an RNA sequence which comprises a fragment of a full-length sequence selected from the group consisting of SEQ ID NO:39 and SEQ ID NO:40 wherein the fragment comprises a contiguous stretch of the RNA sequence of the full-length sequence up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 nucleic acids shorter than the full-length sequence.

[0068] In some embodiments, the construct comprises a fragment of a full-length RNA sequence selected from the group consisting of SEQ ID NO:39 and SEQ ID NO:40, wherein the fragment comprises a deletion of up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 nucleic acids from the 5' end, the 3' end, or both the 5' and 3' ends of the full-length sequence.

Polypeptides

[0069] In some embodiments, a polypeptide herein is in a non-naturally occurring form (e.g. a recombinant or modified form).

[0070] For example, polypeptides (e.g. antigens) disclosed herein can be prepared by chemical synthesis (in whole or in part), by digesting longer polypeptides using proteases, by translation from RNA, by purification from cell culture (e.g. from recombinant expression), from the organism itself, etc. An exemplary method for production of peptides <40 amino acids long involves in vitro chemical synthesis, see the following references: Bodanszky (1993) Principles of Peptide Synthesis (ISBN: 0387564314); and Fields et al. (1997) Meth Enzymol 289: Solid-Phase Peptide Synthesis. ISBN: 0121821900. Solid-phase peptide synthesis techniques, such as methods based on tBoc or Fmoc chemistry, are known in the art, see the following reference: Chan & White (2000) Fmoc Solid Phase Peptide Synthesis. ISBN: 0199637245. Enzymatic synthesis may also be used in part or in full, see the following reference: Kullmann (1987) Enzymatic Peptide Synthesis. ISBN: 0849368413. As an alternative to chemical synthesis, biological synthesis may be used e.g. the polypeptides may be produced by translation. This may be carried out in vitro or in vivo. Biological methods are in general restricted to the production of polypeptides based on L-amino acids, but manipulation of translation machinery (e.g. of aminoacyl tRNA molecules) can be used to allow the introduction of D-amino acids (or of other non-natural amino acids, such as iodotyrosine or methylphenylalanine, azidohomoalanine, etc.), see the following reference: Kullmann (1987) Enzymatic Peptide Synthesis. ISBN: 0849368413. Where D-amino acids are included, however, it is preferred to use chemical synthesis. Polypeptides of the disclosure may have covalent modifications at the C-terminus and/or N-terminus. They can also take various forms (e.g. native, fusions, glycosylated, non-glycosylated, lipidated, non-lipidated, phosphorylated, non-phosphorylated, myristoylated, non-myristoylated, monomeric, multimeric, particulate, denatured, etc.). The polypeptides can be naturally or non-naturally glycosylated (i.e. the polypeptide may have a glycosylation pattern that differs from the glycosylation pattern found in the corresponding naturally occurring polypeptide).

[0071] Non-naturally occurring forms of polypeptides herein may comprise one or more heterologous amino acid sequences (e.g. another antigen sequence, another signal

sequence, a detectable tag, or the like) in addition to a Zika virus prME antigen sequence or a chimeric Zika virus prME sequence. For example, a polypeptide herein may be a fusion protein. Alternatively, or in addition, the amino acid sequence or chemical structure of the polypeptide may be modified (e.g. with one or more non-natural amino acids, by covalent modification, and/or or by having a different glycosylation pattern, for example, by the removal or addition of one or more glycosyl groups) compared to a naturally-occurring polypeptide sequence.

[0072] Polypeptides (e.g. antigens) disclosed herein are preferably provided in purified or substantially purified form i.e. substantially free from other polypeptides (e.g. free from naturally-occurring polypeptides), particularly from other Zika virus or host cell polypeptides; for example, at least about 50% pure (by weight), at least about 60% pure (by weight), at least about 70% pure (by weight), at least about 80% pure (by weight), or at least about 90% pure, etc. Alternatively, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, or less than about 5% of a composition is made up of other expressed polypeptides.

Nucleic Acids

[0073] The present inventors disclose herein nucleic acid molecules comprising a sequence which encodes a Zika virus prME antigen. Nucleic acids as disclosed herein can take various forms (e.g. single-stranded, double-stranded, vectors etc.). Nucleic acids may be circular or branched, but will generally be linear.

[0074] The nucleic acids used herein are preferably provided in purified or substantially purified form i.e. substantially free from other nucleic acids (e.g. free from naturally-occurring nucleic acids), particularly from other Zika virus or host cell nucleic acids, generally being at least about 50% pure (by weight), at least about 60% pure (by weight), at least about 70% pure (by weight), at least about 80% pure (by weight), and usually at least about 90% pure (by weight).

[0075] Nucleic acids may be prepared in many ways e.g. by chemical synthesis (e.g. phosphoramidite synthesis of DNA) in whole or in part, by digesting longer nucleic acids using nucleases (e.g. restriction enzymes), by joining shorter nucleic acids or nucleotides (e.g. using ligases or polymerases), from genomic or cDNA libraries, etc.

[0076] The term "nucleic acid" in general means a polymeric form of nucleotides of any length, which contain deoxyribonucleotides, ribonucleotides, and/or their analogs. It includes DNA, RNA, DNA/RNA hybrids. It also includes DNA or RNA analogs, such as those containing modified backbones (e.g. peptide nucleic acids (PNAs) or phosphorothioates) or modified bases. Thus the nucleic acid of the disclosure includes mRNA, DNA, cDNA, recombinant nucleic acids, branched nucleic acids, plasmids, vectors, etc. Where the nucleic acid takes the form of RNA, it may or may not have a 5' cap.

[0077] The nucleic acids herein comprise a sequence which encodes at least one Zika virus prME antigen. Typically, the nucleic acids of the invention will be in recombinant form, i.e. a form which does not occur in nature. For example, the nucleic acid may comprise one or more heterologous nucleic acid sequences (e.g. a sequence encoding another antigen and/or a control sequence such as a promo-

ter or an internal ribosome entry site) in addition to the sequence encoding at least one Zika virus prME antigen. The nucleic acid may be part of a vector i.e. part of a nucleic acid construct designed for transduction/transfection of one or more cell types. Vectors may be, for example, “expression vectors” which are designed for expression of a nucleotide sequence in a host cell, or “viral vectors” which are designed to result in the production of a recombinant virus or virus-like particle.

[0078] Alternatively, or in addition, the sequence or chemical structure of the nucleic acid may be modified compared to a naturally-occurring sequence which encodes a Zika virus prME antigen. The sequence of the nucleic acid molecule may be modified, e.g. to increase the efficacy of expression or replication of the nucleic acid, or to provide additional stability or resistance to degradation.

[0079] The nucleic acid encoding the polypeptides described above may be codon optimized. By “codon optimized” is intended modification with respect to codon usage that may increase translation efficacy and/or half-life of the nucleic acid. A poly A tail (e.g., of about 30 adenosine residues or more) may be attached to the 3' end of the RNA to increase its half-life. The 5' end of the RNA may be capped with a modified ribonucleotide with the structure m7G (5') ppp (5') N (cap 0 structure) or a derivative thereof, which can be incorporated during RNA synthesis or can be enzymatically engineered after RNA transcription (e.g., by using Vaccinia Virus Capping Enzyme (VCE) consisting of mRNA triphosphatase, guanylyl-transferase and guanine-7-methyltransferase, which catalyzes the construction of N7-monomethylated cap 0 structures). Cap 0 structure plays an important role in maintaining the stability and translational efficacy of the RNA molecule. The 5' cap of the RNA molecule may be further modified by a 2'-O-Methyltransferase which results in the generation of a cap 1 structure (m7Gppp [m2 '-O] N), which may further increase translation efficacy.

[0080] The nucleic acids may comprise one or more nucleotide analogs or modified nucleotides. As used herein, “nucleotide analog” or “modified nucleotide” refers to a nucleotide that contains one or more chemical modifications (e.g., substitutions in or on the nitrogenous base of the nucleoside (e.g., cytosine (C), thymine (T) or uracil (U)), adenine (A) or guanine (G)). A nucleotide analog can contain further chemical modifications in or on the sugar moiety of the nucleoside (e.g., ribose, deoxyribose, modified ribose, modified deoxyribose, six-membered sugar analog, or open-chain sugar analog), or the phosphate. The preparation of nucleotides and modified nucleotides and nucleosides are well-known in the art, see the following references: US Pat. Nos. 4373071, 4458066, 4500707, 4668777, 4973679, 5047524, 5132418, 5153319, 5262530, 5700642. Many modified nucleosides and modified nucleotides are commercially available.

[0081] Modified nucleobases which can be incorporated into modified nucleosides and nucleotides and be present in the RNA molecules include: m5C (5-methylcytidine), m5U (5-methyluridine), m6A (N6-methyladenosine), s2U (2-thiouridine), Um (2'-O-methyluridine), mA (1-methyladenosine); m2A (2-methyladenosine); Am (2-1-0-methyladenosine); ms2m6A (2-methylthio-N6-methyladenosine); i6A (N6-isopentenyladenosine); ms2i6A (2-methylthio-N6-isopentenyladenosine); io6A (N6-(cis-hydroxyisopentenyl)adenosine); ms2io6A (2-methylthio-N6-(cis-hydroxy-

sopentenyl) adenosine); g6A (N6-glycinylylcarbamoyladenosine); t6A (N6-threonyl carbamoyladenosine); ms2t6A (2-methylthio-N6-threonyl carbamoyladenosine); m6t6A (N6-methyl-N6-threonylcarbamoyladenosine); hn6A (N6-hydroxynorvalylcarbamoyl adenosine); ms2hn6A (2-methylthio-N6-hydroxynorvalyl carbamoyladenosine); Ar(p) (2'-O-riboseyladenosine (phosphate)); I (inosine); mil (1-methylinosine); m'lm (1,2'-0-dimethylinosine); m3C (3-methylcytidine); Cm (2T-0-methylcytidine); s2C (2-thiocytidine); ac4C (N4-acetylcytidine); 5FC (5-fonnylcytidine); m5Cm (5,2-O-dimethylcytidine); ac4Cm (N4acetyl2TOMethylcytidine); k2C (lysidine); m1G (1-methylguanosine); m2G (N2-methylguanosine); m7G (7-methylguanosine); Gm (2'-0-methylguanosine); m22G (N2,N2-dimethylguanosine); m2Gm (N2,2'-0-dimethylguanosine); m22Gm (N2,N2,2'-0-trimethylguanosine); Gr(p) (2'-0-riboseylguanosine (phosphate)); yW (wybutosine); o2yW (peroxywybutosine); OHyW (hydroxywybutosine); oHyW* (undermodified hydroxywybutosine); imG (wyosine); mimG (methylguanosine); Q (queuosine); oQ (epoxyqueuosine); galQ (galtactosyl-queuosine); manQ (mamosyl-queuosine); preQo (7-cyano-7-deazaguanosine); preQi (7-aminomethyl-7-deazaguanosine); G* (archaeosine); D (dihydrouridine); m5Um (5,2'-0-dimethyluridine); s4U (4-thiouridine); m5s2U (5-methyl-2-thiouridine); s2Um (2-thio-2'-0-methyluridine); acp3U (3-(3-amino-3-carboxypropyl)uridine); ho5U (5-hydroxyuridine); mo5U (5-methoxyuridine); cmo5U (uridine 5-oxyacetic acid); mcmo5U (uridine 5-oxyacetic acid methyl ester); chm5U (5-(carboxyhydroxymethyl)uridine); mchm5U (5-(carboxyhydroxymethyl)uridine methyl ester); mcm5U (5-methoxycarbonyl methyluridine); mcm5Um (S-methoxycarbonylmethyl-2-O-methyluridine); mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine); nm5s2U (5-aminomethyl-2-thiouridine); mnm5U (5-methylaminomethyluridine); mnm5s2U (5-methylaminomethyl-2-thiouridine); mnm5se2U (5-methylaminomethyl-2-selenouridine); ncm5U (5-carbamoylmethyl uridine); ncm5Um (5-carbamoylmethyl-2'-0-methyluridine); cmmm5U (5-carboxymethylaminomethyluridine); cnmm5Um (5-carboxymethyl aminomethyl-2-L-Omethyl uridine); cmmm5s2U (5-carboxymethylaminomethyl-2-thiouridine); m62A (N6,N6-dimethyladenosine); Tm (2'-O-methylinosine); m4C (N4-methylcytidine); m4Cm (N4,2-0-dimethylcytidine); hm5C (5-hydroxymethylcytidine); m3U (3-methyluridine); cm5U (5-carboxymethyluridine); m6Am (N6,T-0-dimethyladenosine); rn62Am (N6,N6,0-2-trimethyladenosine); m2'7G (N2,7-dimethylguanosine); m2'2'7G (N2,N2,7-trimethylguanosine); m3Um (3,2T-0-dimethyluridine); m5D (5-methyldihydrouridine); f5Cm (5-formyl-2'-0-methylcytidine); m1Gm (1,2'-0-dimethylguanosine); m'Am (1,2-O-dimethyl adenosine) irinomethyluridine); tm5s2U (S-taurinomethyl-2-thiouridine)); iniG-14 (4-demethyl guanosine); imG2 (isoguanosine); ac6A (N6-acetyladenosine), hypoxanthine, inosine, 8-oxo-adenine, 7-substituted derivatives thereof, dihydrouracil, pseudouracil, 2-thiouracil, 4-thiouracil, 5-aminouracil, 5-(Ci-Ce)-alkyluracil, 5-methyluracil, 5-(C2-C6)-alkenyluracil, 5-(C2-Ce)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(Ci-C6)-alkylcytosine, 5-methylcytosine, 5-(C2-C6)-alkenylcytosine, 5-(C2-C6)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine, 5-bromocytosine, N2-dimethylguanine, 7-deazaguanine, 8-azaguanine, 7-deaza-7-substituted guanine, 7-deaza-7-(C2-C6)alkynylguanine, 7-deaza-8-substituted

guanine, 8-hydroxyguanine, 6-thioguanine, 8-oxoguanine, 2-aminopurine, 2-amino-6-chloropurine, 2,4-diaminopurine, 2,6-diaminopurine, 8-azapurine, substituted 7-deazapurine, 7-deaza-7-substituted purine, 7-deaza-8-substituted purine, hydrogen (abasic residue), m5C, m5U, m6A, s2U, W, or 2'-O-methyl-U. Many of these modified nucleobases and their corresponding ribonucleosides are available from commercial suppliers.

Nucleic Acid-based Vaccines

[0082] The present inventors disclose compositions comprising a nucleic acid sequence which encodes a polypeptide comprising a Zika virus antigen, variant or fragment thereof. Such compositions may be a nucleic acid-based vaccine. A further composition comprising a nucleic acid sequence which encodes one or more additional (e.g., a second, third, fourth, fifth or sixth) Zika virus antigens may also be provided as a nucleic acid-based vaccine. In some embodiments, a composition comprises a nucleic acid sequence encoding a Zika virus prME antigen from a first Zika virus strain and an additional nucleic acid sequence encoding an additional Zika virus prME antigen from one or more other strains of Zika virus. In some embodiments, a composition comprises a nucleic acid sequence encoding a Zika virus prME antigen and one or more additional (e.g., a second, third, fourth, fifth or sixth) Zika virus antigen. Alternatively, one or more additional non-Zika virus antigens may be encoded.

[0083] The nucleic acid may, for example, be RNA (i.e. an RNA-based vaccine) or DNA (i.e. a DNA-based vaccine, such as a plasmid DNA vaccine). In certain embodiments, the nucleic acid-based vaccine is an RNA-based vaccine. In certain embodiments, the RNA-based vaccine comprises a self-replicating RNA molecule, also referred to herein as a self-amplifying mRNA (SAM) molecule. The self-replicating RNA molecule may be an alphavirus-derived RNA replicon.

[0084] Self-replicating RNA molecules are well known in the art and can be produced by using replication elements derived from, e.g., alphaviruses, and substituting the structural viral proteins with a nucleotide sequence encoding a protein of interest. A self-replicating RNA molecule is typically a +-strand molecule which can be directly translated after delivery to a cell, and this translation provides a RNA-dependent RNA polymerase which then produces both antisense and sense transcripts from the delivered RNA. Thus, the delivered RNA leads to the production of multiple daughter RNAs. These daughter RNAs, as well as collinear subgenomic transcripts, may be translated themselves to provide in situ expression of an encoded antigen (i.e. a Zika virus prM-F antigen), or may be transcribed to provide further transcripts with the same sense as the delivered RNA which are translated to provide in situ expression of the antigen. The overall result of this sequence of transcriptions is a huge amplification in the number of the introduced replicon RNAs and so the encoded antigen becomes a major polypeptide product of the cells.

[0085] One suitable system for achieving self-replication in this manner is to use an alphavirus-based replicon. These replicons are +-stranded (positive sense-stranded) RNAs which lead to translation of a replicase (or replicase-transcriptase) after delivery to a cell. The replicase is translated as a polyprotein which auto-cleaves to provide a replication

complex which creates genomic-strand copies of the +-strand delivered RNA. These negative (-)-stranded transcripts can themselves be transcribed to give further copies of the +-stranded parent RNA and also to give a subgenomic transcript which encodes the antigen. Translation of the subgenomic transcript thus leads to in situ expression of the antigen by the infected cell. Suitable alphavirus replicons can use a replicase from a Sindbis virus, a Semliki forest virus, an eastern equine encephalitis virus, a Venezuelan equine encephalitis virus, etc. Mutant or wild-type virus sequences can be used e.g. the attenuated TC83 mutant of VEEV has been used in replicons, see the following reference: WO2005/113782, the context of which is incorporated by reference.

[0086] In certain embodiments, the self-replicating RNA molecule described herein encodes (i) a RNA-dependent RNA polymerase which can transcribe RNA from the self-replicating RNA molecule and (ii) a Zika virus prME antigen. The polymerase can be an alphavirus replicase e.g. comprising one or more of alphavirus proteins nsPI, nsP2, nsP3 and nsP4.

[0087] Whereas natural alphavirus genomes encode structural virion proteins in addition to the non-structural replicase polyprotein, in certain embodiments, the self-replicating RNA molecules do not encode alphavirus structural proteins. Thus, the self-replicating RNA can lead to the production of genomic RNA copies of itself in a cell, but not to the production of RNA-containing virions. The inability to produce these virions means that, unlike a wild-type alphavirus, the self-replicating RNA molecule cannot perpetuate itself in infectious form. The alphavirus structural proteins which are necessary for perpetuation in wild-type viruses are absent from self-replicating RNAs of the present disclosure and their place is taken by gene(s) encoding the immunogen of interest, such that the subgenomic transcript encodes the immunogen rather than the structural alphavirus virion proteins.

[0088] Thus, a self-replicating RNA molecule useful with the invention may have two open reading frames. The first (5') open reading frame encodes a replicase; the second (3') open reading frame encodes an antigen. In some embodiments, the RNA may have additional (e.g. downstream) open reading frames e.g. to encode further antigens or to encode accessory polypeptides.

[0089] In certain embodiments, the self-replicating RNA molecule disclosed herein has a 5' cap (e.g. a 7-methylguanosine). This cap can enhance in vivo translation of the RNA. In some embodiments, the 5' sequence of the self-replicating RNA molecule must be selected to ensure compatibility with the encoded replicase.

[0090] A self-replicating RNA molecule may have a 3' poly-A tail. It may also include a poly-A polymerase recognition sequence (e.g. AAUAAA) near its 3' end.

[0091] Self-replicating RNA molecules can have various lengths but they are typically 5000-25000 nucleotides long. Self-replicating RNA molecules will typically be single-stranded. Single-stranded RNAs can generally initiate an adjuvant effect by binding to TLR7, TLR8, RNA helicases and/or PKR. RNA delivered in double-stranded form (dsRNA) can bind to TLR3, and this receptor can also be triggered by dsRNA which is formed either during replication of a single-stranded RNA or within the secondary structure of a single-stranded RNA.

[0092] The self-replicating RNA can conveniently be prepared by in vitro transcription (IVT). IVT can use a (cDNA) template created and propagated in plasmid form in bacteria, or created synthetically (for example by gene synthesis and/or polymerase chain-reaction (PCR) engineering methods). For instance, a DNA-dependent RNA polymerase (such as the bacteriophage T7, T3 or SP6 RNA polymerases) can be used to transcribe the self-replicating RNA from a DNA template. Appropriate capping and poly-A addition reactions can be used as required (although the replicon's poly-A is usually encoded within the DNA template). These RNA polymerases can have stringent requirements for the transcribed 5' nucleotide(s) and in some embodiments these requirements must be matched with the requirements of the encoded replicase, to ensure that the IVT-transcribed RNA can function efficiently as a substrate for its self-encoded replicase.

[0093] A self-replicating RNA can include (in addition to any 5' cap structure) one or more nucleotides having a modified nucleobase. A RNA used with the invention ideally includes only phosphodiester linkages between nucleosides, but in some embodiments, it can contain phosphoramidate, phosphorothioate, and/or methylphosphonate linkages.

[0094] The self-replicating RNA molecule may encode a single heterologous polypeptide antigen (i.e. a Zika virus prME antigen) or, optionally, two or more heterologous polypeptide antigens linked together in a way that each of the sequences retains its identity (e.g., linked in series) when expressed as an amino acid sequence. The heterologous polypeptides generated from the self-replicating RNA may then be produced as a fusion polypeptide or engineered in such a manner to result in separate polypeptide or peptide sequences.

[0095] The self-replicating RNA molecules described herein may be engineered to express multiple nucleotide sequences, from two or more open reading frames, thereby allowing co-expression of proteins, such as one, two or more Zika virus antigens (e.g. one, two or more Zika virus prME antigens) together with cytokines or other immunomodulators, which can enhance the generation of an immune response. Such a self-replicating RNA molecule might be particularly useful, for example, in the production of various gene products (e.g., proteins) at the same time, for example, as a bivalent or multivalent vaccine.

[0096] If desired, the self-replicating RNA molecules can be screened or analyzed to confirm their therapeutic and prophylactic properties using various in vitro or in vivo testing methods that are known to those of skill in the art. For example, vaccines comprising self-replicating RNA molecule can be tested for their effect on induction of proliferation or effector function of the particular lymphocyte type of interest, e.g., B cells, T cells, T cell lines, and T cell clones. For example, spleen cells from immunized mice can be isolated and the capacity of cytotoxic T lymphocytes to lyse autologous target cells that contain a self-replicating RNA molecule that encodes a Zika virus prME antigen. In addition, T helper cell differentiation can be analyzed by measuring proliferation or production of TH1 (IL-2 and IFN- γ) and/or TH2 (IL-4 and IL-5) cytokines by ELISA or directly in CD4+ T cells by cytoplasmic cytokine staining and flow cytometry.

[0097] Self-replicating RNA molecules that encode a Zika virus prME antigen can also be tested for ability to induce humoral immune responses, as evidenced, for example, by

induction of B cell production of antibodies specific for a Zika virus prME antigen of interest. These assays can be conducted using, for example, peripheral B lymphocytes from immunized individuals. Such assay methods are known to those of skill in the art. Other assays that can be used to characterize the self-replicating RNA molecules can involve detecting expression of the encoded Zika virus prME antigen by the target cells. For example, FACS can be used to detect antigen expression on the cell surface or intracellularly. Another advantage of FACS selection is that one can sort for different levels of expression; sometimes-lower expression may be desired. Other suitable method for identifying cells which express a particular antigen involve panning using monoclonal antibodies on a plate or capture using magnetic beads coated with monoclonal antibodies.

[0098] In some embodiments, the self-replicating RNA molecules comprise a sequence selected from the group consisting of SEQ ID NO:36 and SEQ ID NO:37. In some embodiments, the self-replicating RNA molecules comprise a sequence which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from the group consisting of SEQ ID NO:36 and SEQ ID NO:37. In some embodiments, the self-replicating RNA molecule comprises a fragment of a full-length sequence selected from the group consisting of SEQ ID NO:36 and SEQ ID NO:37 wherein the fragment comprises a contiguous stretch of the nucleic acid sequence of the full-length sequence up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 nucleic acids shorter than full-length sequence.

[0099] In some embodiments, a DNA sequence encoding a self-replicating RNA molecule is provided, said DNA sequence selected from the group consisting of SEQ ID NO:33 and SEQ ID NO:34. In some embodiments, DNA sequence encoding a self-replicating RNA molecule comprises a sequence which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from the group consisting of SEQ ID NO:33 and SEQ ID NO:34. In some embodiments, the DNA sequence encoding a self-replicating RNA molecule comprises a fragment of a full-length sequence selected from the group consisting of SEQ ID NO:33 and SEQ ID NO:34 wherein the fragment comprises a contiguous stretch of the nucleic acid sequence of the full-length sequence up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 nucleic acids shorter than full-length sequence.

[0100] The nucleic acid-based vaccine may comprise a viral or a non-viral delivery system. The delivery system (also referred to herein as a delivery vehicle) may have adjuvant effects which enhance the immunogenicity of the encoded Zika virus prME antigen. For example, the nucleic acid molecule may be encapsulated in liposomes, non-toxic biodegradable polymeric microparticles or viral replicon particles (VRPs), or complexed with particles of a cationic oil-in-water emulsion. In some embodiments, the nucleic acid-based vaccine comprises a cationic nano-emulsion (CNE) delivery system or a lipid nanoparticle (LNP) delivery system. In some embodiments, the nucleic acid-based vaccine comprises a non-viral delivery system, i.e., the nucleic acid-based vaccine is substantially free of viral capsid. Alternatively, the nucleic acid-based vaccine may comprise viral replicon particles. In other embodiments, the nucleic acid-based vaccine may comprise a naked nucleic

acid, such as naked RNA (e.g. mRNA), but delivery via CNEs or LNPs is preferred.

[0101] In certain embodiments, the nucleic acid-based vaccine comprises a cationic nano-emulsion (CNE) delivery system. CNE delivery systems and methods for their preparation are described in the following reference: WO2012/006380. In a CNE delivery system, the nucleic acid molecule (e.g. RNA) which encodes the antigen is complexed with a particle of a cationic oil-in-water emulsion. Cationic oil-in-water emulsions can be used to deliver negatively charged molecules, such as an RNA molecule to cells. The emulsion particles comprise an oil core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. Further details of useful CNEs can be found in the following references: WO2012/006380; WO2013/006834; and WO2013/006837 (the contents of each of which are incorporated herein in their entirety).

[0102] Thus, in a nucleic acid-based vaccine of the invention, an RNA molecule encoding a Zika virus prME antigen may be complexed with a particle of a cationic oil-in-water emulsion. The particles typically comprise an oil core (e.g. a plant oil or squalene) that is in liquid phase at 25° C., a cationic lipid (e.g. phospholipid) and, optionally, a surfactant (e.g. sorbitan trioleate, polysorbate 80); polyethylene glycol can also be included. In some embodiments, the CNE comprises squalene and a cationic lipid, such as 1,2-dioleoyloxy-3-(trimethylammonio)propane (DOTAP). In some preferred embodiments, the delivery system is a non-viral delivery system, such as CNE, and the nucleic acid-based vaccine comprises a self-replicating RNA (mRNA). This may be particularly effective in eliciting humoral and cellular immune responses. Advantages also include the absence of a limiting anti-vector immune response and a lack of risk of genomic integration.

[0103] In some embodiments, an RNA molecule encoding a Zika virus prME antigen may be complexed with a sub-micron cationic oil-in-water emulsion. In some embodiments, the cationic oil-in-water emulsion is characterized by an average particle size of from about 80 nm to 180 nm in diameter (or alternatively from about 80 to about 150 nm; from about 80 to 130 nm; or from about 100 nm). In some embodiments, the concentration of DOTAP in said emulsion, before RNA complexation, is at least about 2.5 mM, or from about 2.5 mM to about 8 mM. In a particular embodiment, the concentration of DOTAP in said emulsion is about 4 mg/ml (5.73 mM). The oil can be squalene or squalane.

[0104] In some embodiments, an RNA molecule encoding a Zika virus prME antigen is complexed to a cationic oil-in-water emulsion comprising DOTAP, squalene, sorbitan trioleate and polysorbate 80 in citrate buffer. Cationic oil-in-water emulsions suitable for delivery of an RNA molecule encoding a Zika virus prME antigen may contain about 2 mg/ml to 7 mg/ml DOTAP; about 3 mg/ml to 6 mg/ml Span 85; about 3 mg/ml to 6 mg/ml TWEEN™ 80; and about 30 mg/ml to 50 mg/ml squalene. In certain embodiments, the cationic oil-in-water emulsion, before complexing with RNA, contains about 4.3% w/v squalene, 0.5% TWEEN™ 80, 0.5% SPAN85, and 4 mg/mL DOTAP.

[0105] Also provided is a method of preparing a composition comprising an RNA molecule encoding a Zika virus prME antigen complexed to a cationic oil-in-water emulsion, the method comprising: (i) providing an oil-in-water

emulsion as described herein; (ii) providing an aqueous solution comprising the RNA molecule; and (iii) combining the aqueous solution of (ii) and the oil-in-water emulsion of (i), thereby preparing the composition. If desired, the aqueous solution comprising the RNA molecule may be a buffer. The buffer may comprise one or more salt, buffer, saccharide, or polymer. In a preferred embodiment, the buffer comprises 560 mM sucrose, 20 mM NaCl, and 10 mM citrate, which can be mixed with a cationic oil in water emulsion described herein to produce a final aqueous phase that comprises 280 mM sucrose, 10 mM NaCl and 10 mM citrate.

[0106] LNP delivery systems and non-toxic biodegradable polymeric microparticles, and methods for their preparation are described in the following references: WO2012/006376 (LNP and microparticle delivery systems); Geall et al. (2012) PNAS USA. Sep 4; 109(36): 14604-9 (LNP delivery system); and WO2012/006359 (microparticle delivery systems). LNPs are non-virion liposome particles in which a nucleic acid molecule (e.g. RNA) can be encapsulated. The particles can include some external RNA (e.g. on the surface of the particles), but at least half of the RNA (and ideally all of it) is encapsulated. Liposomal particles can, for example, be formed of a mixture of zwitterionic, cationic and anionic lipids which can be saturated or unsaturated, for example; DSPC (zwitterionic, saturated), DlinDMA (cationic, unsaturated), and/or DMG (anionic, saturated). Preferred LNPs for use with the invention include an amphiphilic lipid which can form liposomes, optionally in combination with at least one cationic lipid (such as DOTAP, DSDMA, DODMA, DlinDMA, DLenDMA, etc.). A mixture of DSPC, DlinDMA, PEG-DMG and cholesterol is particularly effective. Other useful LNPs are described in the following references: WO2012/006376; WO2012/030901; WO2012/031046; WO2012/031043; WO2012/006378; WO2011/076807; WO2013/033563; WO2013/006825; WO2014/136086; WO2015/095340; WO2015/095346; WO2016/037053. In some embodiments, the LNPs are RV01 liposomes, see the following references: WO2012/006376 and Geall et al. (2012) PNAS USA. Sep 4; 109(36): 14604-9.

Pharmaceutical Compositions; Immunogenic Compositions

[0107] The disclosure provides compositions comprising a nucleic acid comprising a sequence which encodes a Zika virus polypeptide, for example a Zika virus prME antigen. The composition may be a pharmaceutical composition, e.g., an immunogenic composition or a vaccine composition. Accordingly, the composition may also comprise a pharmaceutically acceptable carrier. In some embodiments, the Zika virus is a Brazilian strain Zika virus.

[0108] A “pharmaceutically acceptable carrier” includes any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, sucrose, trehalose, lactose, and lipid aggregates (such as oil droplets or liposomes). Such carriers are well known to those of ordinary skill in the art. The compositions may also contain a pharmaceutically acceptable diluent, such as water, saline, glycerol, etc. Additionally,

auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. Sterile pyrogen-free, phosphate-buffered physiologic saline is a typical carrier.

[0109] Pharmaceutical compositions may include the constructs, nucleic acid sequences, and/or polypeptide sequences described elsewhere herein in plain water (e.g. “w.f.i.”) or in a buffer e.g. a phosphate buffer, a Tris buffer, a borate buffer, a succinate buffer, a histidine buffer, or a citrate buffer. Buffer salts will typically be included in the 5-20 mM range. Pharmaceutical compositions may have a pH between 5.0 and 9.5 e.g. between 6.0 and 8.0. Compositions may include sodium salts (e.g. sodium chloride) to give tonicity. A concentration of 10 ± 2 mg/mL NaCl is typical, e.g. about 9 mg/mL. Compositions may include metal ion chelators. These can prolong RNA stability by removing ions which can accelerate phosphodiester hydrolysis. Thus a composition may include one or more of EDTA, EGTA, BAPTA, pentetic acid, etc. Such chelators are typically present at between 10-500 μ M e.g. 0.1 mM. A citrate salt, such as sodium citrate, can also act as a chelator, while advantageously also providing buffering activity. Pharmaceutical compositions may have an osmolality of between 200 mOsm/kg and 400 mOsm/kg, e.g. between 240-360 mOsm/kg, or between 290-310 mOsm/kg. Pharmaceutical compositions may include one or more preservatives, such as thiomersal or 2-phenoxyethanol. Mercury-free compositions are preferred, and preservative-free vaccines can be prepared. Pharmaceutical compositions may be aseptic or sterile. Pharmaceutical compositions may be non-pyrogenic e.g. containing <1 EU (endotoxin unit, a standard measure) per dose, and preferably <0.1 EU per dose. Pharmaceutical compositions may be gluten free. Pharmaceutical compositions may be prepared in unit dose form. In some embodiments, a unit dose may have a volume of between 0.1-1.0 mL e.g. about 0.5 mL.

[0110] In some embodiments, the compositions disclosed herein are immunogenic composition that, when administered to a subject, induce a humoral and/or cellular antigen-specific immune response (i.e. an immune response which specifically recognizes a naturally occurring Zika virus polypeptide). For example, an immunogenic composition may induce a memory T and/or B cell population relative to an untreated subject following Zika virus infection, particularly in those embodiments where the composition comprises a nucleic acid comprising a sequence which encodes a Zika virus prME antigen or comprises a Zika virus antigen. In some embodiments, the subject is a vertebrate, such as a mammal e.g. a human or a veterinary mammal.

[0111] The compositions of the invention can be formulated as vaccine compositions. The vaccine will comprise an immunologically effective amount of antigen. By “an immunologically effective amount” is intended that the administration of that amount to a subject, either in a single dose or as part of a series, is effective for inducing a measurable immune response against Zika virus in the subject. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. human, non-human primate, etc.), the capacity of the individual’s immune system to synthesize antibodies, the degree of protection desired, the formulation of the composition or vaccine, the treating doctor’s assessment of the medical situation, the

severity of the disease, the potency of the compound administered, the mode of administration, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Vaccines as disclosed herein may either be prophylactic (i.e. to prevent infection) or therapeutic (i.e. to treat infection), but will typically be prophylactic. In some embodiments, the vaccine compositions disclosed herein may induce an effective immune response against a Zika virus infection, i.e., a response sufficient for treatment or prevention of a Zika virus infection.

[0112] In some embodiments, the composition further comprises an additional antigen. In some embodiments, the composition is administered to a subject in combination with a further composition which comprises an additional antigen.

[0113] A composition of the present disclosure may also comprise, or be administered in conjunction with, one or more adjuvants (e.g. vaccine adjuvants), in particular where the composition comprises an immunologically effective amount of a nucleic acid encoding a Zika virus prME antigen or a Zika virus prME antigen. By adjuvant is intended that is capable of increasing an immune response against an antigen compared to administration of said antigen alone. In some aspects, adjuvant compositions as disclosed herein further comprise one or more immunostimulants, for example, a saponin such as QS21.

[0114] Adjuvants which may be used in compositions of the invention include, but are not limited to: (A) Mineral-containing compositions, for example aluminum and calcium salts, such as aluminum phosphates. (B) Oil emulsions, for example squalene-in-water emulsions, such as MF59 or AS03. Complete Freund’s adjuvant (CFA) and incomplete Freund’s adjuvant (IF A) may also be used. (C) Saponin formulations. (D) Virosomes and virus-like particles (VLPs). (E) Bacterial or microbial derivatives such as non-toxic derivatives of enterobacterial lipopolysaccharide (LPS), Lipid A derivatives, immunostimulatory oligonucleotides and ADP-ribosylating toxins and detoxified derivatives thereof. (F) Human immunomodulators, for example cytokines, such as interleukins, interferons, macrophage colony stimulating factor, and tumor necrosis factor. (G) Bioadhesives and mucoadhesives, such as esterified hyaluronic acid microspheres, cross-linked derivatives of poly(acrylic acid), polyvinyl alcohol, polyvinyl pyrrolidone, polysaccharides and carboxymethylcellulose. (H) Microparticles, for example particles of ~ 100 nm to ~ 150 μ m in diameter, more preferably ~ 200 nm to ~ 30 μ m in diameter, and most preferably ~ 500 nm to ~ 10 μ m in diameter) formed from materials that are biodegradable and non-toxic (e.g. a poly(α -hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone, etc.), with poly(lactide-co-glycolide) are preferred, optionally treated to have a negatively-charged surface (e.g. with SDS) or a positively-charged surface (e.g. with a cationic detergent, such as CTAB). (I) Liposomes. (J) Polyoxyethylene ether and polyoxyethylene ester formulations. (K) Polyphosphazene (PCPP). (L) Muramyl peptides. (M) Imidazoquinolone compounds, for example Imiquimod and its homologues.

[0115] Combinations of one or more of the adjuvants identified above may also be used with the invention.

Methods of Use/Uses

[0116] In some embodiments are provided methods for inducing an immune response against a Zika virus infection in a subject in need thereof comprising a step of administering an immunologically effective amount of a construct or composition as disclosed herein. In some embodiments are provided the use of the constructs or compositions disclosed herein for inducing an immune response to a Zika virus prME antigen in a subject in need thereof. In some embodiments are provided the use of the constructs or compositions disclosed herein for inducing an immune response against a Zika virus infection in a subject. In some embodiments are provided use of the construct or composition as disclosed herein in the manufacture of a medicament that induces an immune response to a Zika virus infection in a subject. By “subject” is intended a vertebrate, such as a mammal e.g. a human or a veterinary mammal. In some embodiments, the subject is human. By “immune response” is intended a humoral and/or cellular antigen-specific immunological response (i.e. an immune response which specifically recognizes an antigen polypeptide) that can be demonstrated to neutralize Zika virus in vitro or control/reduce/eliminate Zika virus infection in vivo.

[0117] In some embodiments, the immune response is characterized by immunological memory against the Zika virus and/or an effective Zika virus-responsive memory T cell population.

[0118] In some embodiments the composition comprises an RNA molecule encoding a polypeptide selected from the group consisting of SEQ ID NO:19 and SEQ ID NO:24. In some embodiments, the composition comprises an RNA molecule encoding a polypeptide which is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from the group consisting of SEQ ID NO:19 and SEQ ID NO:24. In some embodiments, the composition comprises an RNA molecule encoding a polypeptide which comprises a fragment of a full-length sequence selected from the group consisting of SEQ ID NO:19 and SEQ ID NO:24, wherein the fragment comprises a contiguous stretch of the amino acid sequence of the full-length sequence up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids shorter than full-length sequence.

[0119] In some embodiments is provided a construct, a vector, a self-replicating RNA and/or molecule as described herein for use in therapy or medicine. In some embodiments, the compositions disclosed herein are for use in therapy or medicine. In preferred embodiment, the therapy is a vaccine therapy. Preferably the therapy is vaccine to prevent Zika virus infection.

[0120] In some embodiments is provided a construct, a vector, a self-replicating RNA and/or molecule as described herein for use in preventing or treating Zika virus infection in a subject in need thereof.

[0121] In some embodiments, the compositions disclosed herein are for use in preventing or treating Zika virus infection in a subject in need thereof.

[0122] In some embodiments, the compositions disclosed herein are for use in inducing an immune response against a Zika virus infection in a subject in need thereof.

[0123] In some embodiments is provided a construct, a vector, a self-replicating RNA molecule, and/or a composition as described herein for use in a method of inducing an

immune response to a Zika virus infection in a subject in need thereof.

[0124] In some embodiments, methods are provided for preventing or shortening Zika virus infection and/or reducing or preventing the clinical symptoms upon Zika virus infection in a subject in need thereof, which comprises administering to said subject an immunologically effective amount of an immunogenic composition as provided herein.

[0125] In some embodiments is provided use of a construct or composition disclosed herein in the manufacture of an immunogenic composition for preventing or shortening Zika virus infection in a subject and/or reducing or prevent the clinical symptoms upon Zika virus infection in a subject.

[0126] In some embodiments, methods are provided for preventing or reducing transmission of a Zika virus infection from one subject to another. In specific embodiments, methods are provided for preventing or reducing transmission of a Zika virus infection to a fetus across the placental barrier. In some embodiments, a composition as described herein is administered to a woman in an amount effective to prevent transmission of a Zika virus infection across the placental barrier.

[0127] In some embodiments is provided use of a construct or composition disclosed herein in the manufacture of an immunogenic composition for preventing or reducing transmission of a Zika virus infection to a fetus across the placental barrier.

[0128] In some embodiments is provided a construct, a vector, a self-replicating RNA molecule, and/or a composition as described herein for use in a method of preventing or reducing transmission of a Zika virus infection to a fetus across the placental barrier.

[0129] In some embodiments, the subject is a human subject. In specific embodiments, the human subject has been exposed, or is at risk of being exposed, to a Zika virus infection.

Routes of Administration/Dosages

[0130] Compositions disclosed herein will generally be administered directly to a subject. Direct delivery may be accomplished by parenteral injection {e.g. subcutaneously, intraperitoneally, intravenously, intramuscularly, intradermally, or to the interstitial space of a tissue}. Alternative delivery routes include rectal, oral (e.g. tablet, spray), buccal, sublingual, vaginal, topical, transdermal or transcutaneous, intranasal, ocular, aural, pulmonary or other mucosal administration. Intradermal and intramuscular administration are two preferred routes. Injection may be via a needle (e.g. a hypodermic needle), but needle-free injection may alternatively be used. A typical human intramuscular dose volume is 0.5 ml.

[0131] A dose of a nucleic acid (e.g. a nucleic acid-based vaccine, such as a Zika SAM vaccine) may have about 50 µg to about 100 µg nucleic acid. In one embodiment, a Zika SAM vaccine dose contains 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 µg RNA. In other embodiments, a dose of a Zika SAM vaccine may have <10 µg nucleic acid; e.g. from 1-10 µg, such as about 1 µg, 2.5 µg, 5 µg, 7.5 µg or 10 µg, but expression can be seen at much lower levels; e.g. using <1 µg/dose, <100 ng/dose, <10 ng/dose, <1 ng/dose, etc. Similarly, a dose of a protein antigen may have <10 µg

protein; e.g. from 1-10 μg , such as about 1 μg , 2.5 μg , 5 μg , 7.5 μg or 10 μg .

[0132] In preferred embodiments, a Zika SAM vaccine or vaccine composition is administered to a subject at an effective dose, meaning a dose sufficient to achieve a desired immune response, such as induction of neutralizing antibodies to Zika virus and/or protection against Zika virus infection.

[0133] In some embodiments, a Zika SAM vaccine described herein has an effective dose that is less than or equal to 50%, 40%, 30%, 20% or 10% of the effective dose of a DNA vaccine or vaccine composition encoding the same antigen. In some embodiments, a Zika SAM vaccine described herein has an effective dose that is one third or less of the effective dose of a DNA vaccine or vaccine composition encoding the same antigen.

Processes of Manufacture/Formulation

[0134] Processes for the manufacture of self-replicating RNA are provided herein. In some embodiments, the process of manufacturing a self-replicating RNA comprises a step of in vitro transcription (IVT) as described elsewhere herein. In some embodiments, the process of manufacturing a self-replicating RNA comprises a step of IVT to produce a RNA, and further comprises a step of combining the RNA with a non-viral delivery system as described elsewhere herein. In some embodiments, the process of manufacturing a self-replicating RNA comprises a step of IVT to produce a RNA, and further comprises a step of combining the RNA with a CNE delivery system as described elsewhere herein.

Sequence Identity

[0135] Identity or homology with respect to an amino acid sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the reference amino acid sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Identity or homology with respect to a nucleic acid sequence is defined herein as the percentage of nucleotides in the candidate sequence that are identical with the reference nucleic acid sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.

[0136] Sequence identity can be determined by standard methods that are commonly used to compare the similarity in position of the amino acids of two polypeptides. Using a computer program such as BLAST, two polypeptides are aligned for optimal matching of their respective amino acids (either along the full length of one or both sequences or along a pre-determined portion of one or both sequences). The programs provide a default opening penalty and a default gap penalty, and a scoring matrix such as PAM 250 [a standard scoring matrix; see Dayhoff et al., in Atlas of Protein Sequence and Structure, vol. 5, supp. 3 (1978)] can be used in conjunction with the computer program. For example, the percent identity can then be calculated as: the total number of identical matches multiplied by 100 and then divided by the sum of the length of the longer sequence within the matched span and the number of gaps introduced into the shorter sequences in order to align the two sequences. The same methods used to compare polypeptides

can also be used to calculate the percent identity of two polynucleotide sequences.

[0137] Where the present disclosure refers to a sequence by reference to a UniProt or Genbank accession code, the sequence referred to is the current version at the filing date of the present application.

General

[0138] Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. The term “plurality” refers to two or more. Additionally, numerical limitations given with respect to concentrations or levels of a substance, such as solution component concentrations or ratios thereof, and reaction conditions such as temperatures, pressures and cycle times are intended to be approximate. The term “about” used herein is intended to mean the amount $\pm 10\%$.

[0139] The term “comprises” means “includes.” Thus, unless the context requires otherwise, the word “comprises,” and variations such as “comprise” and “comprising” will be understood to imply the inclusion of a stated compound or composition (e.g., nucleic acid, polypeptide, antigen) or step, or group of compounds or steps, but not to the exclusion of any other compounds, composition, steps, or groups thereof. Embodiments described as comprising certain components are intended to include embodiments consisting of the indicated components.

[0140] The abbreviation, “e.g.” is derived from the Latin *exempli gratia*, and is used herein to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.”

[0141] The invention will be further described by reference to the following, non-limiting, figures and examples.

EXAMPLES

Example 1. Project Summary

[0142] The present inventors initiated work on a Zika vaccine using the SAM platform - synthetic, self-amplifying mRNA (SAM) derived from the alphavirus genome, expressing antigens of interest. The SAM constructs are evaluated for robust antigen production and antigenicity and further tested for their immunogenicity and efficacy using in vivo models.

Methods

[0143] The SAM vector VEE TC-83 was used as the background construct for cloning in the Examples. See SEQ ID NO:17.

Example 2. Selection of Antigen

[0144] The Flavivirus genome consists of capped single-stranded RNA of positive polarity of approximately 11.3 kb in length (FIG. 1). The 5' proximal quarter of the genome encodes the structural proteins capsid (C), pre-membrane (prM), and envelope (E). The nonstructural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 are involved

in viral RNA replication. The coding region is flanked by 5' and 3' untranslated regions (5' and 3' UTRs) of approximately 100 and 600 nucleotides in length, respectively. Translation of the viral genome yields a single polypeptide that is processed into the individual proteins by a combination of cellular proteases and a viral protease consisting of a catalytic subunit, NS3, and its cofactor, NS2B.

[0145] The structural proteins prM and E are cotranslationally inserted into the endoplasmic reticulum (ER) membrane and processed by signal peptidases, producing proteins that encapsidate C together with the viral RNA, by budding into the ER lumen (FIG. 2). At a later step in viral maturation, prM on these particles is cleaved into mature M protein by a cellular furin protease prior to release from the cell. This prM cleavage is required for infectivity of the released virions. In addition to infectious virions, *flavivirus*-infected cells release sub-viral particles (SVPs) (FIG. 2). These particles are smaller than virions, but contain the antigenically important E protein and the prM/M protein, which is essential for correct folding and incorporation of the E protein into SVPs and viral particles. However, unlike virions, SVPs do not contain either the C protein or the viral genome, and are thus non-infectious. SVPs can be produced in a variety of systems by co-expression of the prM and E proteins, and SVPs share properties with wild-type viruses, such as fusogenic activity and induction of a neutralizing immune response and have repeatedly been shown to stimulate protective immune responses against a number of *flavivirus* diseases. The present inventors selected structural proteins of Zika virus, namely- prM and E, for further experimentation.

Example 3. Strain Selection

[0146] The amino acid sequences of the C-prME proteins from Zika virus strains (available from NCBI/Genbank) from Zika outbreaks around the world from 2007 onwards were aligned to look for similarities and differences (FIG. 3). These included the original African lineage strain from Uganda, Micronesia (2007), French Polynesia (2013), and the Brazilian strains from 2016 (FIG. 3). In addition, seven strains of Zika virus from various regions in Brazil, were also compared for amino acid differences in the C-prME region (FIG. 4). A high conservation was observed across the strains from different outbreaks, with the Brazilian strains almost identical in the CprME region. The Natal, Bahia strain (KU527068) was chosen as the representative strain. KU527068 was one of the first strains to be isolated from the brain of a fetus showing microcephaly.

Example 4. Design of Constructs

[0147] The design of Zika-SAM constructs of FIG. 6 includes cloning the sequence encoding the Zika virus (Natal, Brazil strain) structural pre-membrane (prM) and envelope (E) proteins under the subgenomic promoter in a SAM vector. A series of modifications to the SAM-prME constructs were made (Table 1, FIG. 6). These include:

[0148] i. Substitution of the native prM signal peptide with the JEV signal peptide (FIGS. 6A-B, antigen inserts #5283 and #5288).

[0149] ii. Substitution of the native C-terminus of Zika E protein with the C-terminus of JEV E protein (FIG. 6B, antigen insert #5288).

[0150] iii. Truncation of the wild-type Zika prM start sequence to impair expression and secretion of the prME antigen (antigen insert #4974). Antigen insert #4974 was used as a negative control. The amino acid sequence of antigen insert #4974 is shown in SEQ ID NO:29, including the JEV signal sequence (SEQ ID NO:5), followed by a truncated Zika pr region (SEQ ID NO:30), Zika M protein (SEQ ID NO:31) and Zika E protein (SEQ ID NO:32). The DNA and RNA sequences encoding antigen insert #4974 are presented in SEQ ID NOs:28 and 41, respectively.

[0151] iv. A non-Zika antigen construct, #8111, was designed and used as a positive control.

Evaluation/Study Design

[0152] The constructs are evaluated in mammalian cells following electroporation of Zika-SAM RNA into BHK cells using the following methods:

[0153] a. SAM RNA replication- potency of the SAM-Zika constructs is tested by using antibodies against dsRNA and FACS.

[0154] b. Antigen expression is determined by immunoblots and immunofluorescence assays, to investigate cleaved prM and E protein in cell lysates and cell supernatant.

[0155] c. The production of SVPs is tested in mammalian cells by using established procedures for SVP isolation from cell supernatant.

[0156] Following identification of the most efficient candidate constructs formulation into LNP/CNE based-delivery systems is carried out and testing for antigenicity and immunogenicity is carried out in vivo.

Example 5. Expression and Secretion of Zika-SAM Constructs

[0157] The ability of cells to express and secrete Zika E protein and hybrid Zika-JEV E protein from the Zika-SAM constructs described above was evaluated according to the following methods.

[0158] On Day 0, BHK cells were plated at 8×10^6 in T225 flasks in Growth Media. For trypsinization, media was removed and cells were washed with 5 mls of PBS. The PBS wash was removed, and 5 mls of pre-warmed trypsin was added and spread thoroughly across the plate. Trypsin was removed and plates were kept at 37 deg C for 1-2 mins. Cells were then resuspended in 10 mls of growth media (5% FBS). Cells were counted and plated at required concentration into a new flask. The cells were then incubated at 37° C., 5% CO₂ for about 20 hours.

[0159] On Day 1, plates were prepared by adding 2 ml DMEM + 1% FBS + P/S (outgrowth media) to each well of a 6-well plate (one well per electroporation). Plates were kept warm in a 37° C. incubator. The electroporator was prepared to deliver 120 V, 25 ms pulse, 0.0 pulse interval, 1 pulse for a 2 mm cuvette. Cuvettes were labeled and kept on ice. Cells in growth phase were harvested as normal into BHK media (growth) and counted using a hemocytometer. Cells were trypsinized following the same trypsinization protocol as above. Standards and negative control electroporations were also prepared.

[0160] Cells were centrifuged at 1500 rpm (462x g) for 5 mins. Media was aspirated, and cells were washed once with 20 ml cold Opti-MEM media. Cells were again centrifuged at 1500 rpm (462x g) for 5 mins. Media was aspirated,

and the cells were resuspended in Opti-MEM media to 0.25 ml per electroporation.

[0161] For each sample, 4000 ng of RNA was mixed with 250 μ l cells, and the mixture was pipetted gently 4-5 times. The cells and RNA mixture were transferred to 2 mm cuvettes and subjected to one pulse of electroporation using the parameters described above. Cells were allowed to rest at room temperature for 10 mins. Cells from one cuvette were added to one well of a pre-warmed 6-well plate, and the plate was tipped front and back and then side to side at a 45° angle to distribute cells evenly.

[0162] On Day 2 (30 h post-electroporation), the supernatant was collected. An aliquot of 75 μ l was removed for Western blot, 25 μ l 4X NuPAGE buffer was added to the aliquot (no reducing agent), and the aliquot was stored at -20° C. The rest of the supernatant was stored at -80° C.

[0163] Cells were washed once with ice cold PBS, and then scraped into 200 μ l of RIPA buffer containing protease inhibitor cocktail (1 tablet in 10 ml) while keeping the plate on ice. The buffer containing cells was collected in microcentrifuge tubes, and subjected to two rounds of freeze thawing on dry ice. Samples were vortexed briefly, and pelleted at 8000 rpm for 5 min. Pellets were discarded and the supernatants were retained. 25 μ l 4X NuPAGE buffer was added to a 75 μ l aliquot of the lysates for Western blotting. Aliquots were stored at -20° C. The rest of the lysates were stored at -80° C.

Immunoblotting

[0164] 15 μ l of the cell culture supernatants and 15 μ l of the cell lysates were run on a 4-12% SDS PAGE gel (Bio-Rad) in 1X MOPS running buffer. The separated samples were transferred onto nitrocellulose membranes. Membranes were blocked for 2-3 hours in PBS-Tween 20 +5% milk. The *flavivirus* 4G2 primary antibody was added at 1:120 dilution in PBS-T-Milk and membranes were incubated overnight at 4° C. Membranes were then washed 3 times for 10 minutes each in PBS-T. Anti-mouse secondary (Odyssey® anti-Mouse 800CW-green (LI-COR, Inc., Lincoln, NE) at 1:5000) in LI-COR blocking buffer was then added, and the membranes were incubated for 1 hour. Membranes were washed three times for 2 minutes each, and then scanned on LI-COR Odyssey® imager (LI-COR, Inc., Lincoln, NE) at 800 channel, medium intensity.

Results

[0165] Zika E protein expression and secretion was detectable by immunoblot in lysates from cells electroporated with Zika-SAM constructs #5283 (JEV signal + wild type Zika prME), #5288 (JEV signal + hybrid Zika-JEV prME) and #8111 (positive control antigen). (FIG. 7). Expression and secretion of Zika E protein were not detected in the N-terminally truncated construct (#4974) or Mock controls.

Example 6: Cationic Oil-in-Water Emulsions

[0166] Cationic nanoemulsions (CNEs) were prepared essentially according to the methods described in Brito et al., Molecular Therapy, Vol. 22, No. 12, pp. 2118-29 (2014) and International Patent Publication WO2013006834.

[0167] Briefly, squalene (Sigma, St. Louis, MO) was heated to 37° C., and DOTAP (Lipoid, Ludwigshafen Ger-

many) was dissolved directly in squalene in the presence of sorbitan trioleate (SPAN 85; Sigma, St. Louis, MO). The resulting oil phase was then combined with the aqueous phase (TWEEN™; Sigma, St. Louis, MO, in citrate buffer) and immediately homogenized for 2 min using an T25 homogenizer (IKA, Wilmington, NC) at 24K RPM to produce a primary emulsion. The primary emulsions were passed three to five times through a M-110S Microfluidizer or a M-110P Microfluidizer (Microfluidics, Newton, MA) with an ice bath cooling coil at a homogenization pressure of approximately 15K-20K PSI. The batch samples were removed from the unit and stored at 4° C. The CNE formulation used in the present examples contains 4 mg/ml DOTAP; 4.7 mg/ml Span 85; 4.7 mg/ml TWEEN™; and 39 mg/ml squalene.

Example 7. Preparation of RNA-CNE Complexes

1. RNA Synthesis

[0168] Zika SAM constructs contain a bacteriophage T7 promoter located upstream of the alphavirus cDNA to facilitate the synthesis of the replicon RNA in vitro. SAM-Zika RNA for constructs #5283 (encoding JEV signal + Zika prME) and #5288 (encoding JEV signal + hybrid Zika-JEV prME), as well as negative control construct #4974, were synthesized using standard molecular biology techniques. Briefly, plasmid DNA encoding Zika-SAM constructs were linearized by endonuclease digestion a unique site located at the 3' end of the replicon sequence. The linearized DNA was then transcribed into RNA by in vitro synthesis using a T7 RNA polymerase in the presence of the template DNA and nucleoside triphosphates (ATP, CTP, GTP and UTP). Following transcription, DNA template was digested with DNase, and the RNA transcripts were purified by LiCl precipitation and reconstituted in nuclease-free water. RNA was then capped using the Vaccinia Capping System (New England BioLabs, Ipswich, MA) and purified by LiCl precipitation. RNA concentration in each reaction was determined by spectrophotometry. Prior to RNA complexation, RNA was diluted to a concentration of 300 μ g/ml in citrate buffer (10 mM citrate pH 6.2, 20 mM NaCl, 560 mM sucrose).

2. RNA Complexation

[0169] Zika SAM RNA was complexed with cationic nanoemulsion (CNE) particles essentially as described in Brito et al., Molecular Therapy, Vol. 22, No. 12, pp. 2118-29 (2014). Briefly, Zika SAM RNA (300 μ g/ml in citrate buffer) was added to an equal volume of the CNE produced in Example 6, mixed, and allowed to complex on ice for 30 minutes to 2 hours. The final concentration of CNE-complexed RNA was 150 μ g/ml.

[0170] The ratio of RNA to cationic lipid can be expressed as an N/P ratio, defined as the amount (moles) of protonatable nitrogen (N) atoms in the cationic lipid divided by the amount (moles) of phosphates (P) on the RNA. DOTAP for example has one nitrogen that can be protonated per molecule. The RNA concentration was used to calculate the amount of phosphate in solution using an estimate of 3 nmols of phosphate per microgram of RNA. The CNE formulations described above have an N/P ratio of 6.3:1.

Example 8. In Vivo Immunogenicity and Protection of Zika SAM CNE Formulations

[0171] Immunogenicity and protection of Zika SAM CNE formulations were examined in mice and non-human primates (NHP).

I. Mouse Study

[0172] Female BALB/c mice (6-12 weeks old; The Jackson Laboratory), were housed and bred in the animal facility of the Vaccine Research Center, NIAID, NIH, Bethesda, MD. All animal experiments were reviewed and approved by the Animal Care and Use Committee of the VRC, NIAID, NIH. All animals were housed and cared for in accordance with local, state, federal, and institutional policies in an American Association for Accreditation of Laboratory Animal Care-accredited facility at the NIH.

[0173] Mice were immunized twice according to the study design shown in Table 2. Briefly, groups of 10 mice each were administered CNE formulations containing the Zika SAM RNA constructs #5288 or #5283, or the negative control RNA construct #4974. Another group of mice received 50 μ g of a DNA vaccine encoding construct #5283 by intramuscular electroporation, as a positive control. See Dowd et al., Science, Vol. 354 Issue 6309, pp. 237-40 (2016). All mice were challenged by intraperitoneal (i.p.) injection of live Zika virus on day 49.

TABLE 2

Mouse study design						
Group	n	Delivery	Construct	Immunization Day 0	Immunization Day 21	Challenge Day 49
1	10	CNE56 / RNA	4974	1.5 μ g	1.5 μ g	100 PFU, IP
2	10	CNE56 / RNA	5288	1.5 μ g	1.5 μ g	100 PFU, IP
3	10	CNE56 / RNA	5283	15 μ g	15 μ g	100 PFU, IP
4	10	CNE56 / RNA	5283	1.5 μ g	1.5 μ g	100 PFU, IP
5	10	Electroporation/ DNA	5283	50 μ g	50 μ g	100 PFU, IP

[0174] Blood sera were collected on day 0, as well as 2 weeks after the first immunization, 2 weeks after the second immunization, and three days after the Zika virus challenge.

[0175] Zika neutralizing antibody titers were measured by reporter virus particle (RVP) neutralization assay according to methods described in Dowd, KA et al. Cell Rep. 16(6):1485-9 (2016). Results are shown in FIG. 8. Two weeks after the first immunization with Zika SAM construct #5283, or the positive control DNA construct, there were significant levels of Zika neutralizing antibodies detected in the sera of immunized mice. Zika neutralizing antibody levels were even higher two weeks after the second immunization with the SAM construct #5283 or the positive control DNA construct.

[0176] A dose-dependent effect was observed, with the 15 μ g dose of Zika SAM construct #5283 producing higher levels of neutralizing antibodies than the 1.5 μ g dose. Notably, the 15 μ g dose of Zika SAM construct #5283 produced a neutralizing antibody response that was comparable to the 50 μ g dose of the DNA format of the same vaccine construct (DNA #5283). These results indicate that Zika SAM construct #5283 is capable of

inducing a significant neutralizing antibody response to Zika virus.

[0177] On day 49 of the study, mice were challenged with intraperitoneal injections of live Zika virus (strain PRVABC57) at a dose of 100 plaque forming units (PFU). Serum samples were taken three days after challenge, and viral loads were determined by real time quantitative PCR (qPCR) of the Zika virus capsid gene.

[0178] As shown in FIG. 9, mice vaccinated with Zika SAM construct #5283 (1.5 or 15 μ g doses) or the positive control construct (DNA #5283) showed little or no detectable Zika virus in the serum. In contrast, significant Zika viral load was detected in unvaccinated animals, as well as in animals vaccinated with Zika SAM construct 5288 or negative control construct #4974. These results indicate that Zika SAM construct #5283 is capable of generating a protective immune response against Zika virus infection.

II. Non-Human Primate (NHP) Study

[0179] Immunogenicity of Zika SAM constructs was evaluated in non-human primates (NHPs). Rhesus macaques were immunized twice according to the study design shown in Table 3. Briefly, SAM-Zika RNA-CNE formulations were prepared as described in Example 7. Groups of 8 NHPs each were administered either placebo (phosphate buffered saline) or a CNE formulation containing a

codon-optimized SAM construct, Co.prME, encoding the native Zika prME antigen (Group 2, 75 μ g \times 2; as described in PCT/IB2017/053242, filed Jun. 1, 2017); or Zika SAM construct #5283 (Group 3; 75 μ g \times 2). Another group of NHPs (Group 4; n=8) received two immunizations (4 mg each) of a DNA vaccine encoding construct #5283 intramuscularly by a needle-free injection device (PharmaJet), as a positive control. See Dowd et al., Science, Vol. 354 Issue 6309, pp. 237-40 (2016). All animals were challenged by intraperitoneal (i.p.) injection of live Zika virus (1000 PFU) 8 weeks after the first immunization.

TABLE 3

Group	Vaccine	Group size	Week 0 Vaccination	Week 4 Boost	Week 8 Challenge
1	Placebo	8	PBS	PBS	1000 PFU ZIKV
2	Co.prME SAM	8	75 μ g	75 μ g	1000 PFU ZIKV
3	SAM #5283	8	75 μ g	75 μ g	1000 PFU ZIKV
4	DNA #5283	8	4 mg	4 mg	1000 PFU ZIKV

[0180] Blood sera were collected on day 0, as well as 4 and 8 weeks after the first immunization; at each of days 3-7 after the Zika virus challenge; and at weeks 8, 10 and 12 after Zika virus challenge. Zika neutralizing antibody titers were measured by reporter virus particle (RVP) neutralization assay according to methods described in Dowd, KA et al. Cell Rep. 16(6):1485-9 (2016).

[0181] The immunogenicity results shown in FIG. 10 demonstrate that Zika neutralizing antibodies were significantly elevated four weeks after the first immunization of Zika SAM construct #5283 as compared to placebo, with titers being further increased 4 weeks after the second immunization. Zika DNA #5283 elicited similar neutralizing antibody titers at 4 and 8 weeks. Zika-SAM construct Co.prME SAM produced significantly less neutralizing antibodies compared to DNA #5283 after a single dose, but similar titers after two injections.

[0182] In week 8 of the study, NHPs were challenged with intraperitoneal injections of live Zika virus (strain PRVABC57) at a dose of 1000 plaque forming units

(PFU). Viral loads after challenge were determined by real time quantitative PCR (qPCR) of the Zika virus capsid gene.

[0183] As shown in FIG. 11, placebo animals exhibited elevated viremia as early as 3 days post-challenge (A). Vaccination with Zika-SAM construct #5283 (B), as well as positive controls Zika-SAM Co.prME (C) and DNA #5283 (D), were protective against Zika viremia, with Zika-SAM construct #5283 exhibiting a complete protection against Zika viremia.

[0184] Consistent with the viremia results, placebo animals showed a sharp rise in neutralizing antibodies after Zika challenge, further confirming Zika infection in these animals (FIG. 12). Two animals in the SAM Co.prME group, and one animal in the DNA #5283 group, also showed elevated neutralizing antibody titers post-challenge, indicating that protection was not sterilizing in these animals. In contrast, animals in the Zika SAM #5283 group did not exhibit elevated neutralizing antibodies after Zika challenge, indicating that sterilizing protection was achieved in all subjects.

SEQUENCE LISTING

Sequence total quantity: 41

SEQ ID NO: 1 moltype = DNA length = 2079
FEATURE Location/Qualifiers
source 1..2079
 mol_type = genomic DNA
 organism = Zika virus

SEQ ID NO: 1
atgcgaggcg cagatactag tgtcggaatt gttgacctcc tgcgtgaccac agctatggca 60
gcgagggtca ctagacgtgg gagtgcatac tatatgtact tggacagaaa cgatgctggg 120
gaggccatat cttttccaac cacattgggg atgaataagt gttatataca gatcatggat 180
cttgacacaca tgtgtgatgc caccatgagc tatgaatgcc ctatgctgga tgaggggggtg 240
gaaccagatg acgtcgatgt ttggtgcaac acgacgtcaa cttgggtgtg gtacggaacc 300
tgccatcaca aaaagggtga agcaccggaga tctaggagag ctgtgacgct cccctcccat 360
tccactagga agctgcaaac gcggtcgcaa acctgggttg aatcaagaga atacacaaag 420
cacttgatta gagtcgaaaa ttggatattc aggaaccctg gcttgcgctt agcagcagct 480
gccatcgctt ggcttttggg aagctcaacg agccaaaaag tcatatactt ggtcatgata 540
ctgctgattg ccccggcata cagcatcagg tgcataaggag tcagcaatag ggactttgtg 600
gaaggtatgt caggtgggac ttgggttgat gttgtcttgg aacatggagg ttgtgtcacc 660
gtaatggcac aggacaaacc gactgtcgac atagagctgg ttacaacaac agtcagcaac 720
atggcggagg taagatccta ctgctatgag gcatcaatat cagacatggc ttcggacagc 780
cgctgcccaa cacagggtga agcctacctt gacaagcaat cagacactca atatgtctgc 840
aaaagaactg tagtggacag aggtgggga aatggatgtg gacttttggg caaagggagc 900
ctggtgacat gcgctaagtt tgcattgctc aagaaaatga ccgggaaaag catccagcca 960
gagaatctgg agtaccggat aatgctgtca gttcatggct cccagcacag tgggatgate 1020
gttaatgaca caggacatga aactgatgag aatagagcga aggttgagat aacgcccatt 1080
tcaccaagag ccgaagccac cctggggggt ttggaagcc taggacttga ttgtgaaccg 1140
aggacagggc ttgacttttc agatttgtat tacttgacta tgaatacaaa gcactgggtg 1200
gtccacaagg agtggttcca cgacattcca ttaccttggc acgctggggc agacaccgga 1260
actccacact gaaacaacaa agaagcactg gttaggttca aggacgcaca tgccaaaagg 1320
caaaactgtc tggttctagg gagtcaagaa ggagcagttc acacggccct tgctggagct 1380
ctggaggctg agatggatgg tgcaaaagga aggtgtcctc ctggccactt gaaatgtcgc 1440
ctgaaaatgg ataaacttag attgaagggc gtgtcatact ccttgtgtac cgcagcgttc 1500
acattcaaca agatcccggc tgaacaactg cacgggacag tcacagtgga ggtacagtac 1560
gcagggacag atggaccctg caaggttcca gctcagatgg cgggtggacat gcaaaactctg 1620
acccagttg ggaggttgat aaccgctaac ccgtaatac ctgaaagcac tgagaactct 1680
aagatgatgc tggaaactga tccaccattt ggggactctt acattgtcat aggagtcggg 1740
gagaagaaga agatcccggc ctggcacagg agtggcagca ccattggaaa agcatttgaa 1800
gccactgtga gaggtgccaa gagaatggca gctctgggag acacagcctg ggactttgga 1860
tcagttggag gcgctctcaa ctattgggc aagggcatcc atcaaatttt tggagcagct 1920
ttcaaatcat tgtttggagg aatgtcctgg ttctcacaaa tctctattgg aacgttgctg 1980
atgtggttgg gtcctgaacac aaagaatgga tctatttccc ttatgtgctt ggccctaggg 2040
ggagtgttga tcttcttacc cacagccgtc tetgctgat 2079

SEQ ID NO: 2 moltype = AA length = 693

-continued

FEATURE	Location/Qualifiers	
source	1..693	
	mol_type = protein	
	organism = Zika virus	
SEQ ID NO: 2		
MRGADTSVGI	VGLLLTTAMA	AEVTRRGSAY YMYLDRNDAG EAISFPPTLG MNKCYIQIMD 60
LGHMCDATMS	YECPLMDEGV	EPDDVDCWCN TTSTWVYGT CHHKKGEARR SRAVTLPSH 120
STRKLQTRSQ	TWLESREYTK	HLIRVENWIF RNPGFALAAA AIAWLLGSST SQKVIYLVMI 180
LLIAPAYSIR	CIGVSNRDFV	EGMSGGTWVD VVLEHGGCVT VMAQDKPTVD IELVTTVSN 240
MAEVRSYCYE	ASISDMASDS	RCPTQGEAYL DKQSDTQYVC KRTLVDRWGW NGCGLFGKGS 300
LVTCAKFACS	KKMTGKSIQP	ENLEYRIMLS VHGSQHSGMI VNDTGHETDE NRAKVEITPN 360
SPRAEATLGG	FGSLGLDCEP	RTGLDFSDLY YLTMNNKHWL VHKEWFHDIP LPWHAGADTG 420
TFHWNNKEAL	VEPKDAHAKR	QTVVVLGSQE GAVHTALAGA LEAEMDGAKG RLSSGHLKCR 480
LKMDKRLRKG	VSYSLCTAAF	TFTKIPAETL HGTVTVEVQY AGTDGPKCKVP AQMAVDMQTL 540
TPVGRLITAN	PVITESTENS	KMMELEDDPPF GDSYIVIGVG EKKITHHWHR SGSTIGKAFE 600
ATVRGAKRMA	VLGDTAWDFG	SVGGALNSLG KGIHQIFGAA FKSIFGGMSW FSQILIGTLL 660
MWLGLNTRNG	SISLMCLALG	GVLIFLSTAV SAD 693
SEQ ID NO: 3	moltype = AA length = 18	
FEATURE	Location/Qualifiers	
source	1..18	
	mol_type = protein	
	organism = Zika virus	
SEQ ID NO: 3		
GADTSVGIVG	LLLLTTAMA	18
SEQ ID NO: 4	moltype = DNA length = 72	
FEATURE	Location/Qualifiers	
source	1..72	
	mol_type = genomic DNA	
	organism = Japanese encephalitis virus	
SEQ ID NO: 4		
atgggcaagc	ggctccgccg	ctctatcatg tggctggcct ctctggccgt ggtcatcgca 60
tgccgaggag	ca	72
SEQ ID NO: 5	moltype = AA length = 24	
FEATURE	Location/Qualifiers	
source	1..24	
	mol_type = protein	
	organism = Japanese encephalitis virus	
SEQ ID NO: 5		
MGKRSAGSIM	WLASLAVVIA	CAGA 24
SEQ ID NO: 6	moltype = DNA length = 1008	
FEATURE	Location/Qualifiers	
source	1..1008	
	mol_type = genomic DNA	
	organism = Japanese encephalitis virus	
SEQ ID NO: 6		
gaagcggtct	atgtcatgac	cgtgggttcg aagtcattct tagtccatag ggaatggttc 60
catgaccttt	cccttccctg	gacgtccccc tcaagcacgg catggagaaa cagagaactc 120
ctcatggaat	ttgaagagcc	acatgccaca aaacaatctg ttgtagctct tgggtcacag 180
gagggaggcc	tccatcaagc	gltggcagga gccatcgttg tggagtactc gagctcagtg 240
aagttgacat	caggtcacct	gaaatgcagg ctaaaaatgg acaaactggc tctgaagggc 300
acgacttatg	gcatgtgtac	agagaaatc tegtccgca aaaaatccagc ggacacagge 360
catggaacag	ttgtcattga	gctcacatac tctggaagtg atggctccctg taaaatccg 420
attgtctcag	tccgagcctt	aaacgacatg acccctgtgg ggaggctggt aacagtaaac 480
cccttcgtcg	cgacatctag	ctccaactca aaggtgctgg ttgagatgga acctcccctc 540
ggagactcct	atatcgtggg	tggaagaggg gacaagcaga ttaacctca ctggcaciaa 600
gctggaagca	cgctgggtaa	agccttctca acaactttga aaggggctca gagactagca 660
gcgctaggcg	acacagcctg	ggatttcggc tccattggag gggatttcaa ctccataggg 720
aaagctgttc	accaagtatt	tggcggtgca ttcagaacgc tctttggggg aatgtcttgg 780
atcacacaag	gactaatggg	ggccttactt ctttggatgg gtgtcaacgc acgagaccgg 840
tcaatcgccc	tgcttttctt	ggccacggga ggtgtgctcg tgtttttagc gaccaatgtg 900
catgctgaca	ctggctgtgc	cattgacatc acaagaaaag agatgaggtg tggaaagtggc 960
atcttcgtgc	ataacgacgt	agaggcttgg gtagataggt acaaatat 1008
SEQ ID NO: 7	moltype = AA length = 336	
FEATURE	Location/Qualifiers	
source	1..336	

-continued

```

mol_type = protein
organism = Japanese encephalitis virus

SEQ ID NO: 7
EAFYVMTVGS KSFVLVHREWF HDLSLPWTSP SSTAWRNREL LMEFEEAHAT QQSVVALGSQ 60
EGGLHQALAG AIVVEYSSSV KLTSGLKCR LKMDKLALKG TTYGMCTEKF SFAKNPADTG 120
HGTVVIELTY SGSDGPKIP IVSVASLNDM TPVGRVLTVN PFMVATSSNS KVLVEMEPFF 180
GDSYIVVGRG DKQINHWHK AGSTLGKAFS TTLKGAQRLA ALGDTAWDFG SIGGVFNSIG 240
KAVHQVFGGA FRTLFGGMSW ITQGLMGALL LWMGVNARDR SIALAFLATG GVLVFLATNV 300
HADTGCALDI TRKEMRCGSG IFVHNDVEAV VDRYKY 336

SEQ ID NO: 8      moltype = AA length = 795
FEATURE          Location/Qualifiers
source           1..795
                 mol_type = protein
                 organism = Zika virus

SEQ ID NO: 8
MKNPKKSGG FRIVNMLKRG VARVSPFGGL KRLPAGLLG HGPIRMVLAI LAFLRFTAIAK 60
PSLGLINRWG SVGKKEAMEI IKKFKDLAA MLRIINARKE KRRRGADTSV GIVGLLLTTA 120
MAAEVTRRGS AYYMYLDRND AGEAISFPTT LGMNKCYIQI MDLGHMCDAT MSYECPLDE 180
GVEPDDVDCW CNTTSTWVVY GTCHHKKGEA RRSRAVTL PSHSTRKLQTR SQTWLESREY 240
TKHLIRVENW IFRNPGFALA AAAIAWLLGS STSQKVIYLV MILLIAPAYS IRCIGVSNRD 300
FVEGMSGGTW VDVVLEHGGC VTVMAQDKPT VDIELVTTTV SNMAEVRSYC YEASISDMAS 360
DSRCPTQGEA YLDKQSDTY VCKRTLVD RG WNGCGLEFGK GSLVTCAKFA CSKMTGKSI 420
QPENLEYRIM LSVHGSQHS MIVNDTGHE T DENRAKVEIT PNSPRAEATL GPGSLGLDC 480
EPRTGLDFSD LYYLTMNNKH WLVKKEWFHD IPLPWHAGAD TGTPHWNNKE ALVEFKDAHA 540
KRQTVVVLGS QEGAVHTALA GALEAEMDGA KGRLLSGHLK CRLKMDKRLR KGVSYSLCTA 600
AFTFTKIPAE TLHGTVTVEV QYAGTDGPK VPAQMAVDMQ TLTVPVGLIT ANPVITESTE 660
NSKMMLELDP PFGDSYIVIG VGEKKITHHW HRSGSTIGKA FEATVRGAKR MAVLGD TAWD 720
FGSVGGALNS LGKGIHQIFG AAFKSLF GGM SWFSQILIGT LLMWLGLNTK NGSISLMCLA 780
LGGVLI FLST AVSAD 795

SEQ ID NO: 9      moltype = AA length = 795
FEATURE          Location/Qualifiers
source           1..795
                 mol_type = protein
                 organism = Zika virus

SEQ ID NO: 9
MKNPKKSGG FRIVNMLKRG VARVSPFGGL KRLPAGLLG HGPIRMVLAI LAFLRFTAIAK 60
PSLGLINRWG SVGKKEAMEI IKKFKDLAA MLRIINARKE KRRRGADTSV GIVGLLLTTA 120
MAAEVTRRGS AYYMYLDRND AGEAISFPTT LGMNKCYIQI MDLGHMCDAT MSYECPLDE 180
GVEPDDVDCW CNTTSTWVVY GTCHHKKGEA RRSRAVTL PSHSTRKLQTR SQTWLESREY 240
TKHLIRVENW IFRNPGFALA AAAIAWLLGS STSQKVIYLV MILLIAPAYS IRCIGVSNRD 300
FVEGMSGGTW VDVVLEHGGC VTVMAQDKPT VDIELVTTTV SNMAEVRSYC YEASISDMAS 360
DSRCPTQGEA YLDKQSDTY VCKRTLVD RG WNGCGLEFGK GSLVTCAKFA CSKMTGKSI 420
QPENLEYRIM LSVHGSQHS MIVNDTGHE T DENRAKVEIT PNSPRAEATL GPGSLGLDC 480
EPRTGLDFSD LYYLTMNNKH WLVKKEWFHD IPLPWHAGAD TGTPHWNNKE ALVEFKDAHA 540
KRQTVVVLGS QEGAVHTALA GALEAEMDGA KGRLLSGHLK CRLKMDKRLR KGVSYSLCTA 600
AFTFTKIPAE TLHGTVTVEV QYAGTDGPK VPAQMAVDMQ TLTVPVGLIT ANPVITESTE 660
NSKMMLELDP PFGDSYIVIG VGEKKITHHW HRSGSTIGKA FEATVRGAKR MAVLGD TAWD 720
FGSVGGALNS LGKGIHQIFG AAFKSLF GGM SWFSQILIGT LLMWLGLNTK NGSISLMCLA 780
LGGVLI FLST AVSAD 795

SEQ ID NO: 10     moltype = AA length = 791
FEATURE          Location/Qualifiers
source           1..791
                 mol_type = protein
                 organism = Zika virus

SEQ ID NO: 10
MKNPKKEIRR IRIVNMLKRG VARVNPLGGL KRLPAGLLG HGPIRMVLAI LAFLRFTAIAK 60
PSLGLINRWG SVGKKEAMEI IKKFKDLAA MLRIINARKE KRRRGADTSI GIIGLLTTA 120
MAAEITRRGS AYYMYLDRSD AGKAISFAT LGVKNCHVQI MDLGHMCDAT MSYECPLDE 180
GVEPDDVDCW CNTTSTWVVY GTCHHKKGEA RRSRAVTL PSHSTRKLQTR SQTWLESREY 240
TKHLIKVENW IFRNPGFALV AVAIAWLLGS STSQKVIYLV MILLIAPAYS IRCIGVSNRD 300
FVEGMSGGTW VDVVLEHGGC VTVMAQDKPT VDIELVTTTV SNMAEVRSYC YEASISDMAS 360
DSRCPTQGEA YLDKQSDTY VCKRTLVD RG WNGCGLEFGK GSLVTCAKFT CSKMTGKSI 420
QPENLEYRIM LSVHGSQHS MIGYETDEDR AKVEVTPNSP RAEATLGGFG SLGLDCEPRT 480
GLDFSDLYYL TMNNKHWLVH KEWFHDIPLP WHAGADTGT P HWNNKEALVE FKDAHAKRQT 540
VVVLGSQEGA VHTALAGALE AEMDGA KGR L FSGHLKCR LK MDKLR LKGV S YSLCTAAFTF 600
TKVPAETLHG TVTVEVQYAG TDGPKLIPVQ MAVDMQTLTP VGR LITANPV ITESTENSKM 660
MLELDP PPGD SYIVIGVGD K ITHHWHRSG STIGKA FEAT VRGAKR MAVL GD TAWDFGSV 720
GGVFN SLGKG IHQIFGA AFK SLFGGMSWFS QTLIGTL LVW LGLNTKNGSI SLTCLALGGV 780

```

-continued

MIFLSTAVSA D 791

SEQ ID NO: 11 moltype = AA length = 795
 FEATURE Location/Qualifiers
 source 1..795
 mol_type = protein
 organism = Zika virus

SEQ ID NO: 11

MKNPKEEIRR IRIVNMLKRG VARVSPFGGL KRLPAGLLLG HGPIRMVLAI LAFLRFTAIAK 60
 PSLGLINRWG SVGKKEAMEI IKKFKKDLAA MLRIINARKE KRRGDTSTV GIVGLLLTTA 120
 MAVEVTRRGS AYYMYLDRSD AGEAISFPTT LGMNKCYIQI MDLGHMCDAT MSYECPLDE 180
 GVEPDDVDCW CNTTSTWVVY GTCHHKKGEA RRSRAVTLP SHSTRKLQTR SQTWLESREY 240
 TKHLIRVENW IFRNPGFALA AAAIAWLLGS STSQKVIYLV MILLIAPAYS IRCIGVSNRD 300
 FVEGMSGGTW VDVVLEHGGC VTVMAQDKPA VDIELVTTTV SNMAEVRSYC YEASISDMAS 360
 DSRCPTQGEA YLDKQSDTQY VCKRTLVDRLG WNGCGLEFGK GSLVTCAKFA CSKMTGKSI 420
 QPENLEYRIM LSVHGSQHSG MIVNDTGHET DENRAKVEIT PNSPRAEATL GPGFSLGLDC 480
 EPRTGLDFSD LYYLTMNNKH WLVHKEWFHD IPLPWHAGAD TGTPHWNNKE ALVEFKDAHA 540
 KRQTVVVLGS QEGAVHTALA GALEAEMDGA KGRLLSSGHLK CRLKMDKRLR KGVSYSLCTA 600
 AFTFTKIPAE TLHGTVTVEV QYAGTDGPCK VPAQMAVDMQ TLTPVGRILIT ANPVITESTE 660
 NSKMMLELDP PFGDSYIVIG VGEKKITHHW HRSGSTIGKA FEATVRGAKR MAVLGDATWD 720
 FGSVGGALNS LGKGIHQIFG AAFKSLFGGM SWFSQILIGT LLVWLGLNTK NGSISLTCCLA 780
 LGGVLIFLST AVSAD 795

SEQ ID NO: 12 moltype = AA length = 795
 FEATURE Location/Qualifiers
 source 1..795
 mol_type = protein
 organism = Zika virus

SEQ ID NO: 12

MKNPKKSGG FRIVNMLKRG VARVSPFGGL KRLPAGLLLG HGPIRMVLAI LAFLRFTAIAK 60
 PSLGLINRWG SVGKKEAMEI IKKFKKDLAA MLRIINARKE KRRGADTSV GIVGLLLTTA 120
 MAAEVTRRGS AYYMYLDRND AGEAISFPTT LGMNKCYIQI MDLGHMCDAT MSYECPLDE 180
 GVEPDDVDCW CNTTSTWVVY GTCHHKKGEA RRSRAVTLP SHSTRKLQTR SQTWLESREY 240
 TKHLIRVENW IFRNPGFALA AAAIAWLLGS STSQKVIYLV MILLIAPAYS IRCIGVSNRD 300
 FVEGMSGGTW VDVVLEHGGC VTVMAQDKPT VDIELVTTTV SNMAEVRSYC YEASISDMAS 360
 DSRCPTQGEA YLDKQSDTQY VCKRTLVDRLG WNGCGLEFGK GSLVTCAKFA CSKMTGKSI 420
 QPENLEYRIM LSVHGSQHSG MIVNDTGHET DENRAKVEIT PNSPRAEATL GPGFSLGLDC 480
 EPRTGLDFSD LYYLTMNNKH WLVHKEWFHD IPLPWHAGAD TGTPHWNNKE ALVEFKDAHA 540
 KRQTVVVLGS QEGAVHTALA GALEAEMDGA KGRLLSSGHLK CRLKMDKRLR KGVSYSLCTA 600
 AFTFTKIPAE TLHGTVTVEV QYAGTDGPCK VPAQMAVDMQ TLTPVGRILIT ANPVITESTE 660
 NSKMMLELDP PFGDSYIVIG VGEKKITHHW HRSGSTIGKA FEATVRGAKR MAVLGDATWD 720
 FGSVGGALNS LGKGIHQIFG AAFKSLFGGM SWFSQILIGT LLMWLGLNTK NGSISLMCLA 780
 LGGVLIFLST AVSAD 795

SEQ ID NO: 13 moltype = AA length = 795
 FEATURE Location/Qualifiers
 source 1..795
 mol_type = protein
 organism = Zika virus

SEQ ID NO: 13

MKNPKKSGG FRIVNMLKRG VARVSPFGGL KRLPAGLLLG HGPIRMVLAI LAFLRFTAIAK 60
 PSLGLINRWG SVGKKEAMEI IKKFKKDLAA MLRIINARKE KRRGADTSV GIVGLLLTTA 120
 MAAEVTRRGS AYYMYLDRND AGEAISFPTT LGMNKCYIQI MDLGHMCDAT MSYECPLDE 180
 GVEPDDVDCW CNTTSTWVVY GTCHHKKGEA RRSRAVTLP SHSTRKLQTR SQTWLESREY 240
 TKHLIRVENW IFRNPGFALA AAAIAWLLGS STSQKVIYLV MILLIAPAYS IRCIGVSNRD 300
 FVEGMSGGTW VDVVLEHGGC VTVMAQDKPT VDIELVTTTV SNMAEVRSYC YEASISDMAS 360
 DSRCPTQGEA YLDKQSDTQY VCKRTLVDRLG WNGCGLEFGK GSLVTCAKFA CSKMTGKSI 420
 QPENLEYRIM LSVHGSQHSG MIVNDTGHET DENRAKVEIT PNSPRAEATL GPGFSLGLDC 480
 EPRTGLDFSD LYYLTMNNKH WLVHKEWFHD IPLPWHAGAD TGTPHWNNKE ALVEFKDAHA 540
 KRQTVVVLGS QEGAVHTALA GALEAEMDGA KGRLLSSGHLK CRLKMDKRLR KGVSYSLCTA 600
 AFTFTKIPAE TLHGTVTVEV QYAGTDGPCK VPAQMAVDMQ TLTPVGRILIT ANPVITESTE 660
 NSKMMLELDP PFGDSYIVIG VGEKKITHHW HRSGSTIGKA FEATVRGAKR MAVLGDATWD 720
 FGSVGGALNS LGKGIHQIFG AAFKSLFGGM SWFSQILIGT LLMWLGLNTK NGSISLMCLA 780
 LGGVLIFLST AVSAD 795

SEQ ID NO: 14 moltype = AA length = 795
 FEATURE Location/Qualifiers
 source 1..795
 mol_type = protein
 organism = Zika virus

SEQ ID NO: 14

MKNPKKSGG FRIVNMLKRG VARVSPFGGL KRLPAGLLLG HGPIRMVLAI LAFLRFTAIAK 60
 PSLGLINRWG SVGKKEAMEI IKKFKKDLAA MLRIINARKE KRRGADTSV GIVGLLLTTA 120
 MAAEVTRRGS AYYMYLDRND AGEAISFPTT LGMNKCYIQI MDLGHMCDAT MSYECPLDE 180

-continued

```

GVPEPDDVDCW CNTTSTWVVY GTCHHKKGEA RRSRAVTL P SHSTRKLQTR SQTWLESREY 240
TKHLIRVENW IFRNPGFALA AAAIAWLLGS STSQKVIYLV MILLIAPAYS IRCIGVSNRD 300
FVEGMSGGTW VDVVLEHGGC VTVMAQDKPT VDIELVTTTV SNMAEVRSYC YEASISDMAS 360
DSRCPTQGEA YLDKQSDTQY VCKRTLVDNRG WNGCGLEFGK GSLVTCAKFA CSKKMTGKSI 420
QPENLEYRIM LSVHGSQHS G MIVNDTGHE T DENRAKVEIT PNSPRAEATL GGFGLSLGLDC 480
EPRTGLDFSD LYYLTMNNKH WLVHKEWFHD IPLPWHAGAD TGTPHWNNKE ALVEFKDAHA 540
KRQTVVVLGS QEGAVHTALA GALEAEMDGA KGRLLSSGHLK CRLKMDKRLR KGVSYSLCTA 600
AFTFTKIPAE TLHGTVTVEV QYAGTDGPCK VPAQMAVDMQ TLTPVGR LIT ANPVITESTE 660
NSKMMLELDP PFGDSYIVIG VGEKKITHHW HRSGSTIGKA FEATVRGAKR MAVLGD TAWD 720
FGSVGGALNS LGKGIHQIFG AAFKSLFGGM SWFSQILIGT LLMWLGLN TK NGSISLMCLA 780
LGGVLIFLST AVSAD 795

```

SEQ ID NO: 15 moltype = AA length = 795

FEATURE Location/Qualifiers

source 1..795

mol_type = protein

organism = Zika virus

SEQ ID NO: 15

```

MKNPKKKSGG FRIVNMLKRG VARVSPFGGL KRLPAGLLLG HGPIRMVLAI LAF LRFTA I K 60
PSLGLINRWG SVGKKEAMEI IKKFKKDLAA MLRIINARKE KRRRGADTSV GIVGLLLTTA 120
MAAEVTRRGS AYYMYLDRND AGEAISFPPT LGMNKCYIQI MDLGHMCDAT MSYECPLMDE 180
GVPEPDDVDCW CNTTSTWVVY GTCHHKKGEA RRSRAVTL P SHSTRKLQTR SQTWLESREY 240
TKHLIRVENW IFRNPGFALA AAAIAWLLGS STSQKVIYLV MILLIAPAYS IRCIGVSNRD 300
FVEGMSGGTW VDVVLEHGGC VTVMAQDKPT VDIELVTTTV SNMAEVRSYC YEASISDMAS 360
DSRCPTQGEA YLDKQSDTQY VCKRTLVDNRG WNGCGLEFGK GSLVTCAKFA CSKKMTGKSI 420
QPENLEYRIM LSVHGSQHS G MIVNDTGHE T DENRAKVEIT PNSPRAEATL GGFGLSLGLDC 480
EPRTGLDFSD LYYLTMNNKH WLVHKEWFHD IPLPWHAGAD TGTPHWNNKE ALVEFKDAHA 540
KRQTVVVLGS QEGAVHTALA GALEAEMDGA KGRLLSSGHLK CRLKMDKRLR KGVSYSLCTA 600
AFTFTKIPAE TLHGTVTVEV QYAGTDGPCK VPAQMAVDMQ TLTPVGR LIT ANPVITESTE 660
NSKMMLELDP PFGDSYIVIG VGEKKITHHW HRSGSTIGKA FEATVRGAKR MAVLGD TAWD 720
FGSVGGALNS LGKGIHQIFG AAFKSLFGGM SWFSQILIGT LLMWLGLN TK NGSISLMCLA 780
LGGVLIFLST AVSAD 795

```

SEQ ID NO: 16 moltype = AA length = 795

FEATURE Location/Qualifiers

source 1..795

mol_type = protein

organism = Zika virus

SEQ ID NO: 16

```

MKNPKKKSGG FRIVNMLKRG VARVSPFGGL KRLPAGLLLG HGPIRMVLAI LAF LRFTA I K 60
PSLGLINRWG SVGKKEAMEI IKKFKKDLAA MLRIINARKE KRRRGADTSV GIVGLLLTTA 120
MAAEVTRRGS AYYMYLDRND AGEAISFPPT LGMNKCYIQI MDLGHMCDAT MSYECPLMDE 180
GVPEPDDVDCW CNTTSTWVVY GTCHHKKGEA RRSRAVTL P SHSTRKLQTR SQTWLESREY 240
TKHLIRVENW IFRNPGFALA AAAIAWLLGS STSQKVIYLV MILLIAPAYS IRCIGVSNRD 300
FVEGMSGGTW VDVVLEHGGC VTVMAQDKPT VDIELVTTTV SNMAEVRSYC YEASISDMAS 360
DSRCPTQGEA YLDKQSDTQY VCKRTLVDNRG WNGCGLEFGK GSLVTCAKFA CSKKMTGKSI 420
QPENLEYRIM LSVHGSQHS G MIVNDTGHE T DENRAKVEIT PNSPRAEATL GGFGLSLGLDC 480
EPRTGLDFSD LYYLTMNNKH WLVHKEWFHD IPLPWHAGAD TGTPHWNNKE ALVEFKDAHA 540
KRQTVVVLGS QEGAVHTALA GALEAEMDGA KGRLLSSGHLK CRLKMDKRLR KGVSYSLCTA 600
AFTFTKIPAE TLHGTVTVEV QYAGTDGPCK VPAQMAVDMQ TLTPVGR LIT ANPVITESTE 660
NSKMMLELDP PFGDSYIVIG VGEKKITHHW HRSGSTIGKA FEATVRGAKR MAVLGD TAWD 720
FGSVGGALNS LGKGIHQIFG AAFKSLFGGM SWFSQILIGT LLMWLGLN TK NGSISLMCLA 780
LGGVLIFLST AVSAD 795

```

SEQ ID NO: 17 moltype = DNA length = 9999

FEATURE Location/Qualifiers

misc_feature 1..9999

note = SAM Vector

misc_feature 7562..7563

misc_feature 7562..7563

note = Insert starts after nucleotide 7562

source 1..9999

mol_type = other DNA

organism = synthetic construct

SEQ ID NO: 17

```

ataggcggcg catgagagaa gccagacca attacctacc caaaatggag aaagttcacg 60
ttgacatcga ggaagacagc ccattcctca gagctttgca gcgagcttc cgcagtttg 120
aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcate 180
tggcttcaaa actgatcgaa acggaggtgg acccatccga cagatcctt gacattggaa 240
gtgcgcccgc cccgagaagt tattctaagc acaagtatca ttgtatctgt ccgatgagat 300
gtgcggaaga tccggacaga ttgtataagt atgcaactaa gctgaagaaa aactgtaagg 360
aaataactga taaggaattg gacaagaaaa tgaaggagct gcgcccgctc atgagcgacc 420
ctgacctgga aactgagact atgtgcctcc acgacgacga gtcgtgtcgc tacgaagggc 480

```

-continued

aagtcgctgt	ttaccaggat	gtatacgcgg	ttgacggacc	gacaagtctc	tatcaccaag	540
ccaataaggg	agtttagatc	gcctactgga	taggctttga	caccaccctt	tttatgttta	600
agaacttggc	tggagcatal	ccatcatact	ctaccaactg	ggccgacgaa	accgtgttaa	660
cggtcgttaa	cataggccta	tgcagctctg	acgttatgga	gcggtcacgt	agagggatgt	720
ccattctctag	aaagaagtat	ttgaaacctat	ccaacaatgt	tctattctct	gttggctcga	780
ccatctacca	cgagaagagg	gacttactga	ggagctggca	cctgccgtct	gtatttctct	840
tacgtggcaa	gcaaaattac	acatgtcgg	gtgagactat	agttagtgtc	gacgggtacg	900
tcgttaaaag	aatagctatc	agtccaggcc	tgtatgggaa	gccttcaggc	tatgtctcta	960
cgatgcaccg	cgagggatcc	ttgtgctgca	aagtgacaga	cacattgaac	ggggagaggg	1020
tctcttttcc	cgtgtgcacg	tatgtgccag	ctacattgtg	tgaccaaatg	actggcatac	1080
tggcaacaga	tgtcagtgcg	gacgacgccc	aaaaactgct	ggttgggctc	aaccagcgta	1140
tagtctgcaa	gggtcgcacc	cagagaaca	ccaatccat	gaaaaattac	cttttgcctg	1200
tagtggccca	cggcatttgc	aggtgggcaa	aggaatata	ggaagatcaa	gaagatgaaa	1260
ggccactagg	actacgagat	agacagttag	tcatgggggtg	ttgttgggct	tttagaaggg	1320
acaagataac	atctatttat	aagcgcctcg	ataccacaac	catcatcaaa	gtgaaccagc	1380
atctccactc	attcgtgctg	cccaggatag	gcagtaacac	attggagatc	gggctgagaa	1440
caagaatcag	gaaagtgtta	gaggagcaca	aggagccctc	acctctcatt	accgcccagg	1500
acgtacaaga	agctaagtgc	gcagccgatg	aggctaagga	ggtgcgtgaa	gccgaggagt	1560
tgcgcgcagc	tctaccacct	ttggcagctg	atggtgagga	gccactctcg	gaagccgatg	1620
tcgacttgat	gttacaagag	gctggggccg	gctcagtgga	gacacctcgt	ggcttgataa	1680
aggttaccag	ctacgattgg	gaggacaaga	tcggctctta	cgtctgctct	tctccgcagg	1740
ctgtactcaa	gagtgaaaa	ttatcttgca	tccacctctc	cgtgaacaa	gtcatagtga	1800
taacacactc	tggccgaaaa	ggcgcttatg	ccgtggaacc	ataccatggt	aaagtgtgg	1860
tgccagaggg	acatgcaata	ccogtccagg	actttcaagc	tctgagtgaa	agtgccacca	1920
ttgtgtacaa	cgaacgttag	ttcgtaaaa	ggtacctgca	ccatattgcc	acacatggag	1980
gagcgtgaa	cactgatgaa	gaatattaca	aaactgtcaa	gccagccgag	cacgacggcg	2040
aatacctgta	cgacatcgac	aggaacacgt	gcgtcaagaa	agaactatgc	actgggctag	2100
ggctcacagg	cgagctgggt	gatcctccct	tccatgaatt	cgctacgag	agtctgagaa	2160
cacgaccagc	cgtcccttac	caagtaccaa	ccataggggt	gtatggcgtg	ccaggatcag	2220
gcaagtctgg	catcattaaa	agcgcagtca	ccaaaaaaga	tctagtgggtg	agcgcacaaga	2280
aagaaaactg	tgcagaaatt	ataagggcag	tcaagaaaa	gaaagggctg	gacgtcaatg	2340
ccagaactgt	ggaactcagt	ctcttgaatg	gatgcaaa	ccccgtagag	accctgtata	2400
ttgacgaaag	ttttgcttgt	catgcaggta	ctctcagagc	gctcatagcc	attataagac	2460
ctaaaaaggc	agtctctg	gggatccca	aacagtgcgg	tttttttaac	atgatgtgcc	2520
tgaagtgca	ttttaaccac	gagatttgca	cacaagtctt	ccacaaaagc	atctctcgcc	2580
gttgcactaa	atctgtgact	tggtctgctg	caaccttgtt	ttacgacaaa	aaaatgagaa	2640
cgacgaatcc	gaaagagact	aaagtgtgta	ttgacactac	cggcagatcc	aaacctaaagc	2700
aggacgatct	cattctcact	tgtttcagag	ggtgggtgaa	gcagttgcaa	atagattaca	2760
aagcacaaga	aaatgatgac	gcagctgcct	ctcaagggct	gaccctgaaa	ggtgtgtatg	2820
ccgttcggtg	caaggtgaat	gaaaaactc	tgtacgcacc	cacctcagaa	catgtgaacg	2880
tcctactgac	ccgcacggag	gaccgcacg	tgtgaaaaac	actagccggc	gacccatgga	2940
taaaaaact	gactgccaag	tacctggga	atctactg	cacgatagag	gagtggcaag	3000
cagagcatga	tgccatcatg	aggcacatct	tggagagacc	ggaccctacc	gacgtcttcc	3060
agaataaggc	aaacgtgtgt	tggcccaagg	ctttagtgcc	ggtgctgaag	accgctggca	3120
tagacatgac	cactgaaaca	tggaaactg	tggattattt	tgaaacggac	aaagctcact	3180
cagcagagat	agttatgaa	caactatg	tgaggttctt	tggactcag	ctggactccg	3240
gtctatctt	tgcaccact	gttcogttat	ccataggaa	taactcactg	gataactccc	3300
cgctgcctaa	catgtacggg	ctgaataaag	aagtggctcg	tcagctctct	cgcaggtacc	3360
cacaactgcc	tcgggcagtt	gccactggaa	gagctctatg	catgaacact	ggtacactgc	3420
gcaattatga	tccgcgcata	aacctagtac	ctgtaaacag	aagactgcct	catgctttag	3480
tcctccacca	taatgaacac	ccacagagtg	acttttcttc	atctcgtcag	aaattgaagg	3540
gcgaaactgt	cctgggtggc	ggggaaaagt	tgtccgtccc	aggcaaaatg	gttgactggt	3600
tgtcagaccg	gcctgaggct	accttcagag	ctcggctgga	tttaggcac	ccagggtgatg	3660
tgcccaaata	tgacataata	ttgtttaatg	tgaggacccc	atataaatac	catcactatc	3720
agcagtgatg	agaccatg	attaagctta	gcattgtgac	caagaaagct	tgtctgcac	3780
tgaatcccgg	cggaaacctg	gtcagcatag	gttatgggta	cgtgacagc	ggcagcgaaa	3840
gcatcattgg	tgtctatagc	cggcagttca	agttttcccg	ggatgcaaa	cogaaatcct	3900
cacttgaaga	gacggaagtt	ctgtttgtat	tcattgggta	cgatcgcaag	gcccgctacg	3960
acaactctta	caagctttca	tcaaccttga	ccaacattta	tacaggttcc	agactccacg	4020
aagccggatg	tgcaccctca	tatcatgtg	tgcaggggga	tattgccaag	gccaccgaa	4080
gagtgattat	aaatgctgct	aacagcaaa	gacaacctgg	cggaggggtg	tgcggagcgc	4140
tgtataagaa	attcccgtaa	agcttcgat	tacagccgat	cgaagttaga	aaagcgcgac	4200
tggtaaaagg	tgcagctaaa	catatcattc	atgccgtagg	accaaaactc	aaaaagttt	4260
cggaggttga	aggtgacaaa	catctggcag	aggcttatga	gtccatcgct	aagattgtca	4320
acgataacaa	ttacaagtca	gtagcgattc	cactgtgtgc	caccggcatc	ttttccggga	4380
acaaagatcg	actaacccaa	tcattgaacc	atctgtgac	agctttagac	accactgatg	4440
cagatgtagc	catatactgc	agggacaaga	aatgggaaat	gactctcaag	gaagcagtg	4500
ctaggagaga	cgcagtgag	gagatagca	tatccgacga	ctcttcagtg	acagaaactg	4560
atgcagagct	ggtgaggggt	catccgaaga	gttctttggc	tggaaagga	ggctacagca	4620
caagcgatgg	caaaaacttc	tcataatttg	aaggaccaa	gtttcaccag	gcggccaagg	4680

-continued

atatagcaga	aattaatgcc	atgtggcccg	ttgcaacgga	ggccaatgag	caggtatgca	4740
tgtatatacct	cggagaaagc	atgagcagta	ttaggtcgaa	atgccccgctc	gaagagtccg	4800
aagcctccac	accacctagc	acgctgcctt	gcttgtgcat	ccatgccatg	actccagaaa	4860
gagtacagcg	cctaaaagcc	tcacgtccag	aacaaattac	tgtgtgctca	tcctttccat	4920
tgccgaagta	tagaataact	ttgctgtcag	agatccaatg	ctcccagcct	atattgttct	4980
caccgaaagt	gcctgcgtat	atctcatccaa	ggaagtatct	cgtggaaaca	ccaccggtag	5040
acgagactcc	ggagccatcg	gcagagaacc	aatccacaga	ggggacacct	gaacaaccac	5100
cacttataac	cgaggatgag	accaggacta	gaacgcctga	gcgatcatc	atcgaagagg	5160
aagaagagga	tagcataagt	ttgctgtcag	atggcccagc	ccaccaggtg	ctgcaagtctg	5220
aggcagacat	tcacgggccc	ccctctgtat	ctagctcatc	ctggccatt	cctcatgcat	5280
ccgactttga	tgtggacagt	ttatccatac	ttgacaccct	ggagggagct	agcgtgacca	5340
gctgggcaac	gtcagccagc	actaactctt	acttcgcaa	gagtatggag	tttctggcgc	5400
gaccggtgca	ataccactcg	acagtattca	ggaaccctcc	acatcccgcct	cgcgcacaa	5460
gaacaccgtc	acttgcaacc	agcagggcct	gctcgagaac	cagcctagtt	tcaccccccgc	5520
caggcgtgaa	tagggtgatc	actagagagg	agctcgaggc	gcttaccocg	tcacgcactc	5580
ctagcaggtc	ggtctcgaga	accagcctgg	tctccaacc	gccagggcga	aataggggtga	5640
ttacaagaga	ggagtctgag	ccgtctgtag	cacaacaaca	atgacggttt	gatgcccgtg	5700
catacatctt	ttctctccgac	accggtcaag	ggcatttaca	acaaaaatca	gtaaggcaaa	5760
cggtgctatc	cgaagtgggtg	ttggagagga	cgaattgga	gatttcgtat	gccccgcgcc	5820
tcgaccaaga	aaaagaagaa	ttactacgca	agaaattaca	gttaaatccc	acactgcta	5880
acagaagcag	ataccactcc	aggaaggtgg	agaacatgaa	agccataaca	gctagacgta	5940
ttctgcaagg	cctagggcat	tatttgaagg	cagaagaaa	agtggagtgc	taccgaacc	6000
tgcactcctgt	tcctttgtat	tcactatagtg	tgaaccgtgc	cttttcaagc	cccaaggtctg	6060
cagtggaaagc	ctgtaaccgc	atgttgaag	agaactttcc	gactgtggct	tcttactgta	6120
ttattccaga	gtacgatgcc	tatttggaca	tggttgacgg	agcttcatgc	tgcttagaca	6180
ctgccagttt	ttgccctgca	aagctgcgca	gctttccaaa	gaaacactcc	tatttggaac	6240
ccacaatac	atcggcagtg	ccttcagcga	tcagaaacac	gctccagaac	gtcctggcag	6300
ctgccacaaa	aagaaattgc	aatgtcacgc	aatgagaga	attgcccgta	ttggattcgg	6360
cgccctttaa	tgtggaatgc	ttcaagaaat	atgctgtgaa	taatgaatat	tgggaaacgt	6420
ttaaagaaaa	ccccatcagg	cttactgaag	aaaacgtggt	aaattacatt	accaaattaa	6480
aaggaccaaa	agctgctgct	ctttttgcca	agacacataa	tttgaatatg	ttgcaggaca	6540
taccaatgga	caggtttgta	atggacttaa	agagagacgt	gaaagtgact	ccaggaacaa	6600
aacatactga	agaacgcgcc	aaggtcacgg	tgatccaggc	tgccgatccg	ctagcaacag	6660
cgtatctgtg	cggaatccac	cgagagctgg	ttaggagatt	aaatgcccgc	ctgcttccga	6720
acattcatac	actgtttgat	atgtcggctg	aagactttga	cgctattata	gccgagcact	6780
tccagcctgg	ggattgtgct	ctggaactgc	acatcgcctc	gtttgataaa	agtgaggacg	6840
acgccatggc	cttgaccggt	ttaatgattc	tggaaagact	aggtgtggac	gcagagctgt	6900
tgacgctgat	tgaggcggct	ttcggcgaaa	tttcatcaat	acatttgccc	actaaaaacta	6960
aatttaaatt	cggagccatg	atgaaatctg	gaatgttcc	cacactgttt	gtgaacacag	7020
tcattaacat	tgtaatcgca	agcagagtgt	tgagagaacg	gctaaccgga	tcaccatgtg	7080
cagcattcat	tggagatgac	aatatcgtga	aaggagtcaa	atcggacaaa	ttaatggcag	7140
acaggtgcgc	cacctggttg	aatatggaag	tcaagattat	agatgctgtg	gtgggcgaga	7200
aagcgcctta	ttctgtgga	gggtttattt	tgtgtgactc	cgtgaccggc	acagcgtgcc	7260
gtgtggcaga	ccccctaaa	agcttggcaa	acctctggca	gcagacgatg	gcagacgatg	7320
aacatgatga	tgacaggaga	agggcattgc	atgaagagtc	aacacgctgg	aacgagatgg	7380
gtattctttc	agagctgtgc	aaggcagtag	aatcaaggtg	tgaaacctga	ggaacttcca	7440
tcatagttat	ggccatgact	actctagcta	gcagtgttaa	atcattcagc	tacctgagag	7500
gggccctat	aaactctctac	ggctaaccctg	aatggactac	gacatagtct	agtcgcccaa	7560
gtgataaggc	gcccaccacc	agcggcggca	tacagcagca	attggcaagc	tgcttacata	7620
gaactcgcgg	cgattggcat	gccccttaa	aatttttatt	ttatttttct	tttcttttcc	7680
gaatcggatt	ttgtttttaa	tatttcaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	7740
aaaaaagaag	agcgtttaa	caagtgtat	ctggcctcat	gggccttcc	ttcactgcc	7800
gctttccagt	cgggaaacct	gtcgtgccag	ctgcattaac	atggtcatag	ctgtttccct	7860
gcgtattggg	cgctctccgc	ttctctgctc	actgactcgc	tgogctcgtg	cgttccggta	7920
aagcctgggg	tgccataatga	gcaaaaaggc	agcaaaaaggc	caggaaccgt	aaaaaggccg	7980
cgttgtcggc	gttttcccat	aggtctccgc	cccctgacga	gcatacaaaa	aatcgcagct	8040
caagtccag	gtggcgaaac	ccgacaggac	tataaagata	ccaggcgttt	ccccctggaa	8100
gctccctcgt	gctctctctc	gttccgaccc	tgccgcttac	cggtaccctg	tcgccctttc	8160
tcccttccgg	aagcgtggcg	ctttctcata	gctcacgctg	taggtatctc	agttcgggtg	8220
aggtcgtctg	ctccaagctg	ggctgtgtgc	acgaaccccc	cgltcagccc	gaccctgccc	8280
ccttatccgg	taactatogt	cttgagtcca	accggtaag	acacgactta	tcgccactgg	8340
cagcagccac	tggtaaacag	attagcagag	cgaggtatgt	agggcgtgct	acagagtctc	8400
tgaagtgggt	gcctaaactc	ggctacacta	gaagaacagt	atlttggtatc	tcgctctctg	8460
tgaagccagt	taccttcgga	aaaaaggtg	gtagctcttg	atccggcaaa	caaacaccgc	8520
ctggtagcgg	tggttttttt	gtttgcaagc	agcagattac	gcccagaaaa	aaaggatctc	8580
aagaagatcc	tttgatcttt	tctacggggt	ctgacgctca	gtggaaccga	aaactcacgtt	8640
aagggatttt	ggctatgaat	acacgggtgc	tgactgcgtt	agcaatttaa	ctgtgataaa	8700
ctaccgcatt	aatctctatc	gatgataagc	tgtcaaacat	gagaattctt	agaaaaactc	8760
atcgagcatc	aaatgaaact	gcaatttatt	catatcagga	ttatcaatc	catatttttg	8820
aaaaagccgt	ttctgtaatg	aaggagaaaa	ctcaccgagg	cagttccata	ggatggcaag	8880

-continued

```

atcctgggat cggctctgga ttccgactcg tccaacatca atacaaccta ttaatttccc 8940
ctcgtcaaaa ataaggttat caagtggaaa atcaccatga gtgacgactg aatccggtga 9000
gaatggcaaa agcttatgca tttctttcca gacttggtca acaggccagc cattaccgctc 9060
gtcatcaaaa tcactcgcat caaccaaacg gttattcatt cgtgattgcg cctgagcgag 9120
acgaaatcag ccatcgctgt taaaaggaca attacaaaaca ggaatcgaat gcaaccggcg 9180
caggaacact gccagcgcat caacaatatt ttcacctgaa tcaggatatt cttctaatac 9240
ctggaatgct gttttcccg ggaatcgact ggtgagtaac catgcatcat caggagtacg 9300
gataaaatgc ttgatggctg gaagaggcat aaattccgct agccagttta gtctgaccat 9360
ctcatctgta acatcattgg caacgctacc tttgccatgt ttcagaaaca actctggcgc 9420
atcgggcttc ccatacaatc gatagattgt cgcacctgat tgcccagatc tatcgcgagc 9480
ccatttatac ccataataat cagcatccat gttggaattt aatcgccgcc togagcaaga 9540
cgtttcccg tgaatatggc tcataaaccc ccttgattta ctgtttatgt aagcagacag 9600
ttttattggt catgagcggg tacaattttg aatgtattta gaaaaataa caaatagggg 9660
ttccgcgcac atttcccgga aaagtgccac ctaaattgta agcgttaata tttgtttaa 9720
attcgcgtta aattttgtt aaatcagctc atttttaac caataggccg aaatcggcaa 9780
aatcccttat aaatcaaaag aatagaccga gatagggttg agtggccgct acagggcgct 9840
cccattcgcc attcagctgt gcacaactgt gggaaaggcg tttcgggtcg ggctcttcg 9900
ctattacgcc agctggcgaa agggggatgt gctgcaaggc gattaagtgg ggtaacgcca 9960
gggttttccc agtcacacgc gtaatacgac tcactatag 9999
SEQ ID NO: 18          moltype = DNA length = 2091
FEATURE
misc_feature          1..2091
                        note = recombinant Zika virus antigen construct
source                1..2091
                        mol_type = other DNA
                        organism = synthetic construct

SEQ ID NO: 18
atgggcaagc ggtccgocgg ctctatcatg tggetggcct ctctggccgt ggtcatcgca 60
tgccgagagc cagcgagaggt caccaggaga ggcagcgctc actatatgta cctggacaga 120
aatgatgcgc gcgaggccat cagctttccc accacactgg gcatgaacaa gtgttacatc 180
cagatcatgg acctgggcca catgtgcatg gccaccatgt cctatgagtg tccaatgctg 240
gacgagggcg tggagcccca cgatgtgatg tgctgggtga ataccacatc cacatgggtg 300
gtgtacggca cctgccacca caagaaggga gaggcaaggc gctctcggag agcagtgaca 360
ctgccttccc actctaccgg gaagctgcag acaagatctc agacctggct ggagagccgg 420
gagtatacaa agcacctgat ccgggtggag aactggatct ttagaaatcc aggattcgca 480
ctggcagcag cagcaatcgc atggctgctg ggcagctcca cctcccagaa agtgatctac 540
ctggctcatg tctctgctat cgccccctgc tattccatca ggtgcatcgg cgtgtctaata 600
cgcgacttgc tggagggcat gtctggcggc acctgggtgg atgtggtgct ggagcacggc 660
ggctgcgtga cagtgatggc ccaggacaag ccaacogtgg acatcgagct ggtgaccaca 720
accgtgagca acatggccga ggtgcggctc tactgctatg aggccagcat ctccgacatg 780
gcctctgata gcagatgtcc caccagggc gaggcctacc tggacaagca gtctgataca 840
cagtacgtgt gcaagaggac cctggtggac aggggatggg gaaatggatg tggcctgttt 900
ggcaagggca gcctgggtgac atgcgccaaag ttcgcctgtt ctaagaagat gaccggcaag 960
agcatccagc cagagaacct ggagtaccgg atcatgctga gcgtgcaagg cagccagcac 1020
tccggcatga tctgtaacga cacaggccac gagacagatg agaatagggc caaggtggag 1080
atcacaccta acagcccacg cccgagggcc acctggggag gatttgctc cctgggctg 1140
gactgcgagc ctagaacagg cctggacttc tccgatctgt actatctgac catgaacaat 1200
aagcaactggc tggtgacaaa ggagtggttt cacgacatcc cactgccatg gcacgcagga 1260
gcagatacag gaaccccaac ctggaacaat aaggaggccc tgggtggagt caaggatgcc 1320
cacgccaaga ggcagacagt ggtggtgctg ggcagccagg agggagcagt gcacaccgcc 1380
ctggcaggcg ccctggaggc cgagatggac ggagcaaaag gcgcctgtc tagcggccac 1440
ctgaaagtgcc ggctgaagat ggataagctg agactgaagg gcgtgtccta ctctctgtgc 1500
acagccgctc tcaccttcac caagatccct gccagacac tgcacggcac agtgaccgtg 1560
gaggtgcagt atgccgcac agacggcccc tgtaaggtgc ctgcccagat gccctgggat 1620
atgcagacac tgaccctgt gggcaggctg atcaccgcca atccagtgat cacagagtcc 1680
accgaaaact ctaagatgat gctggagctg gacccccctt ttggcgatag ctatctgtg 1740
atcggcgtgg gcgagaagaa gatcacacac cactggcacc gcagcggctc cacaatcggc 1800
aaggcctttg agccaccctg gaggggagca aagaggatgg ccgtgctggg cgacaccgca 1860
tgggatttgc gctccgtggg aggcgcctct aactctctgt gcaagggcat ccaccagatc 1920
ttcggcgcgc cctttaagtc cctgttcggc ggcctgtctt ggtttagcca gatcctgatc 1980
ggcacactgc tgatgtggct gggcctgaac accaagaatg gctctatcag cctgatgtgc 2040
ctggccctgg gaggcgtgct gatcttctct agcaccgccc tgtccgctg a 2091
SEQ ID NO: 19          moltype = AA length = 696
FEATURE
REGION              1..696
                        note = recombinant Zika virus antigen construct
source              1..696
                        mol_type = protein
                        organism = synthetic construct

SEQ ID NO: 19

```

-continued

MGKRSAGSIM	WLASLAVVIA	CAGAAEVTRR	GSAYMYLDR	NDAGEAISEP	TTLGMNKCYI	60
QIMDLGHMCD	ATMSYECPLM	DEGVEPDDVD	CWCNTTSTWV	VYGTCHHKKG	EARRSRRAVT	120
LPSHSTRKLQ	TRSQTWLESR	EYTKHLIRVE	NWIFRNPGFA	LAAAIAWLL	GSSTSQKVIY	180
LVMILLIAPA	YSIRCIGVSN	RDFVEGMSGG	TWVDVVLEHG	GCVTVMAQDK	PTVDIELVTT	240
TVSNMAEVRS	YCYEASISDM	ASDSRCPTQG	EAYLDKQSDT	QYVCKRTLVD	RGWNGCGCLF	300
GKGSIVTCAK	FACSKKMTGK	SIQPENLEYR	IMLSVHGSQH	SGMIVNDTGH	ETDENRAKVE	360
ITPNSPRAEA	TLGGFGSLGL	DCEPRTGLDF	SDLYYLTMMN	KHWLVHKEWF	HDIPLPWHAG	420
ADTGTTPHWN	KEALVEFKDA	HAKRQTVVVL	GSQEGAVHTA	LAGALEAEMD	GAKGRLSSGH	480
LKCRLLKMDKL	RLKGVSYSLC	TAAFTFTKIP	AETLHGTVTV	EVQYAGTDGP	CKVPAQMAVD	540
MQTLTPVGR	ITANPVITES	TENSKMMLEL	DPPFGDSYIV	IGVGEKKITH	HHHRSGSTIG	600
KAFEATVRGA	KRMAVLGDTA	WDFGSGGAL	NSLGKGIHQI	FGAAFKSLFG	GMSWFSQILI	660
GTLLMWLGLN	TKNGSISLMC	LALGGVLIFL	STAVSA			696

SEQ ID NO: 20 moltype = AA length = 92
 FEATURE Location/Qualifiers
 source 1..92
 mol_type = protein
 organism = Zika virus

AEVTRRSAY	YMLDRNDAG	EASIFPTTLG	MNKCYIQIMD	LGHMCDATMS	YECPLDEGV	60
EPDDVDCWCN	TTSTWVYGT	CHHKGEARR	SR			92

SEQ ID NO: 21 moltype = AA length = 60
 FEATURE Location/Qualifiers
 source 1..60
 mol_type = protein
 organism = Zika virus

RAVTLPSSHST	RKLQTRSQTW	LESREYTKHL	IRVENWIFRN	PGFALAAAAI	AWLLGSSTSQ	60
-------------	------------	------------	------------	------------	------------	----

SEQ ID NO: 22 moltype = AA length = 520
 FEATURE Location/Qualifiers
 source 1..520
 mol_type = protein
 organism = Zika virus

KVIYLVMLLL	IAPAYSIRCI	GVSNRDFVEG	MSGGTWVDVV	LEHGGCVTMV	AQDKPTVDIE	60
LVTTVSNMA	EVRSYCYEAS	ISDMASDSRC	PTQGEAYLDK	QSDTQYVCKR	TLVDRGWGNG	120
CGLFGKGSIV	TCAKFACSKK	MTGKSIQPEN	LEYRIMLSVH	GSQHSGMIVN	DTGHETDENR	180
AKVEITPNSP	RAEATLGGFG	SLGLDCEPRT	GLDFSDLYYL	TMNNKHVLVH	KEWFHDIPLP	240
WHAGADTGTP	HWNKEALVE	FKDAHAKRQT	VVVLGSQEGA	VHTALAGALE	AEMDGAKGRL	300
SSGHLKCRLL	MDKRLRLKGV	YSLCTAAFTF	TKIPAE TLHG	TVTVEVQYAG	TDGPKVPAQ	360
MAVDMQTLTP	VGRILITANPV	ITESTENSKM	MLELDPFPGF	SYIVIGVGEK	KITHHWHRS	420
STIGKAFEAT	VRGAKRMAVL	GTAWDFGVS	GGALNSLGKG	IHQIFGAAFK	SLFGGMSWFS	480
QILIGTLLMW	LGLNTRKNGSI	SLMCLALGGV	LIFLSTAVSA			520

SEQ ID NO: 23 moltype = DNA length = 2091
 FEATURE Location/Qualifiers
 misc_feature 1..2091
 note = recombinant Zika virus antigen construct
 source 1..2091
 mol_type = other DNA
 organism = synthetic construct

atgggcaagc	ggtccgcccg	ctctatcatg	tggctggcct	ctctggccgt	ggtcatcgca	60
tgcgcaggag	cagcggaggt	caccaggaga	gqcagcgcct	actatatgta	cctggacaga	120
aatgatgccg	gcgaggccat	cagccttccc	accacactgg	gcatgaaca	gtgttacatc	180
cagatcatgg	acctgggcca	catgtcgat	gccaccatgt	cctatgagtg	tccaatgctg	240
gacgagggcg	tggagcccga	cgatgtggat	tgctggtgta	ataccacatc	cacatgggtg	300
gtgtaccgca	cctgccacca	caagaagggg	gaggcaaggg	gctctcggag	agcagtgaca	360
ctgccttccc	actctaccgg	gaagctgcag	acaagatctc	agacctggct	ggagagccgg	420
gagtatacaa	agcacctgat	ccgggtggag	aactggatct	ttagaaatcc	aggattcgca	480
ctggcagcag	cagcaatcgc	atggctgctg	ggcagctcca	cctcccagaa	agtgatctac	540
ctggtcatga	cctgccacca	cgcccctgcc	tattccatca	ggtgcatcgg	cgtgtcta	600
cgcgacttcg	tggagggcat	gtctggcggc	acctgggtgg	atgtggtgct	ggagcacggc	660
ggctgcgtga	cagtgatggc	ccaggacaag	ccaaccgtgg	acatcgagct	ggtgaccaca	720
accgtgagca	acatggccga	ggtgcggctc	tactgctatg	aggccagcat	ctccgacatg	780
gcctctgata	gcagatgtcc	caccagggc	gaggcctacc	tggacaagca	gtctgatata	840
cagtacgtgt	gcaagaggac	cctggtggac	aggggatggg	gaaatggatg	tggcctgttt	900
ggcaagggca	gcctggtgac	atgcgccaag	ttcgcctgtt	ctaagaagat	gaccggcaag	960

-continued

```

agcatccagc cagagaacct ggagtaccgg atcatgctga gcgtgcacgg cagccagcac 1020
tccggcatga tegtgaacga cacaggccac gagacagatg agaatagggc caaggtggag 1080
atcacaccta acagcccacg ccccagggcc accctgggag gatttgctc cctgggcctg 1140
gactgcgagc ctagaacagc cctggacttc tccgatctgt actatctgac catgaacaat 1200
aagcactggc tggtgacaa ggagtggttt cagacatcc cactgccatg gcacgcagga 1260
gcagatacag gaaccccaca ctggaacaat aaggaggccc tgggtggagt caaggtgac 1320
cacgccaaga ggcagacagt ggtggtgctg ggcagccagg agggagcagt gcacaccgcc 1380
ctggcaggcg ccctggaggc cgagatggac ggagcaaaag gcgcctgtc tagcggccac 1440
ctgaagtgcc ggctgaagat ggataagctg agactgaagg gcgtgtccta ctctctgtgc 1500
acagccgctc tcaccttcac caagatccct gccgagacac tgcacggcac agtgaccgtg 1560
gaggtgcagt atgccggcac agacggcccc tgtaaggtgc ctgcccagat ggcctggat 1620
atgcagacac tgaccctgt gggcaggctg atcaccgcca atccagtgat cacagagtcc 1680
accgagaact ctaagatgat gctggagctg gacccccctt ttggcgatag ctatctgtg 1740
atcgccgtgg gcgagaagaa gatcacacac cactggcacc gcagcggctc caccctggg 1800
aaggccttta gcaccaccct gaaggagca cagaggctgg ccgcccctgg gcacaccgca 1860
tgggatttcg gctccatcgg aggcgtgttc aactctatcg gcaaggccgt gcaccaggtg 1920
tccgcgcgcg ccttccggac ccttccggac ggcctgtctt ggatcaccca ggcctgatg 1980
ggcgccctgc tgctgtggat gggcgtgac gcccgggacc ggtctatcgc cctggccttc 2040
ctggccaccg gaggcgtgct ggtgttctg gccaccaacg tgcacgcctg a 2091

```

```

SEQ ID NO: 24      moltype = AA length = 696
FEATURE          Location/Qualifiers
REGION          1..696
source          note = recombinant Zika virus antigen construct
                1..696
                mol_type = protein
                organism = synthetic construct

```

```

SEQ ID NO: 24
MGKRSAGSIM WLASLAVVIA CAGAAEVTRR GSAYMYLDR NDAGEAISFP TTLGMNKCYI 60
QIMDLGHMCD ATMSYECPLM DEGVEPDDVD CWCNTTSTWV VYGTCHHKKG EARRSRRAVT 120
LPSHSTRKLQ TRSQTWLESR EYTKHLIRVE NWIFRNPFGA LAAAAIAWLL GSSTSQKVIY 180
LVMILLIAPA YSIRCIGVSN RDFVEGMSGG TWVDVLEHG GCVTVMAQDK PTVDIELVTT 240
TVSNMAEVRS YCYEASISDM ASDSRCPTQG EAYLDKQSDT QYVCKRTLVD RGWNGCGLF 300
GKGSLVTCAK FACSKKMTGK SIQPENLEYR IMLSVHGSQH SGMIVNDTGH ETDENRAKVE 360
ITPNSPRAEA TLGGFGSLGL DCEPRTGLDF SDLYLTMNN KHHLVHKEWF HDIPLPHWAG 420
ADTGTPHWNN KEALVEFKDA HAKRQTVVVL GSQEGAVHTA LAGALEAEMD GARGLSSGH 480
LKCRKMKDKL RLKGVSYSLC TAAFTFTKIP AETLHGTVTV EVQYAGTDGP CKVPAQMAVD 540
MQTLTPVGR LITANPVITES TENSMMLEL DPPFGDSYIV IGVGKETHI HWHRSGSTLG 600
KAFSTTLKGA QRLAALGDTA WDFSGIGGVF NSIGKAVHQV FGGAFRTLFG GMSWITQGLM 660
GALLLWGMVN ARDRSIALAF LATGGVLVFL ATNVHA 696

```

```

SEQ ID NO: 25      moltype = AA length = 92
FEATURE          Location/Qualifiers
source          1..92
                mol_type = protein
                organism = Zika virus

```

```

SEQ ID NO: 25
AEVTRRSAY YMYLDRNDAG EAISFPTTLG MNKCYIQIMD LGHMCDATMS YECPLDEGV 60
EPDDVDCWCN TTSTWVYGT CHHKKGARR SR 92

```

```

SEQ ID NO: 26      moltype = AA length = 60
FEATURE          Location/Qualifiers
source          1..60
                mol_type = protein
                organism = Zika virus

```

```

SEQ ID NO: 26
RAVTLPSHST RKLQTRSQTW LESREYTKHL IRVENWIFRN PGFALAAAAI AWLLGSSTSQ 60

```

```

SEQ ID NO: 27      moltype = AA length = 520
FEATURE          Location/Qualifiers
REGION          1..520
source          note = hybrid Zika-JEV E protein
                1..520
                mol_type = protein
                organism = synthetic construct

```

```

SEQ ID NO: 27
KVIYLVMIILL IAPAYSIRCI GVSNRDFVEG MSGGTWVDVV LEHGGCVTVM AQDKPTVDIE 60
LVTTTVSNMA EVRSYCYEAS ISDMASDSRC PTQGEAYLDK QSDTYVCKR TLVDRGWGNG 120
CGLFGKGS LVTCAKFACSKK MTGKSIQPEN LEYRIMLSVH GSQHSGMIVN DTGHETDENR 180
AKVEITPNSP RAEATLGGFG SLGLDCEPRT GLDFSDLYYL TMNKHVLVH KEWFHDIPLP 240

```

-continued

WHAGADTGT	HWNNKEALVE	FKDAHAKRQT	VVVLGSQEGA	VHTALAGALE	AEMDGAKGRL	300
SSGHLKCRK	MDKLRKLGVS	YSLCTAAFTF	TKIPAETLHG	TVTVEVQYAG	TDGPCKVPAQ	360
MAVDMQTLTP	VGRLITANPV	ITESTENSKM	MLELDPFPGD	SYIVIGVGEK	KITHHWHRS	420
STLGKAFSTT	LKGAQRALAL	GDTAWDFGSI	GGVFNSIGKA	VHQVFGGAFR	TLFGGMSWIT	480
QGLMGALLLW	MGVNARDRSI	ALAFLATGGV	LVFLATNVHA			520

SEQ ID NO: 28 moltype = DNA length = 2082
 FEATURE Location/Qualifiers
 misc_feature 1..2082
 note = recombinant Zika virus antigen construct
 source 1..2082
 mol_type = other DNA
 organism = synthetic construct

SEQ ID NO: 28

atgggcaagc	ggtccgcg	ctctatcatg	tggctggcct	ctctggccgt	ggatcatgca	60
tgcgcaggag	caaccaggag	aggcagcgcc	tactatatgt	acctggacag	aaatgatgcc	120
ggcgaggcca	tcagctttcc	caccacactg	ggcatgaaca	agtgttacat	ccagatcatg	180
gacctgggcc	acatgtgcga	tgccaccatg	tcctatgagt	gtccaatgct	ggacgagggc	240
gtggagcccg	acgatgtgga	ttgctgggtg	aataccacat	ccacatgggt	ggtgtacggc	300
acctgccacc	acaagaagg	agaggcaagg	cgctctcgga	gagcagtgc	actgccttcc	360
cactctaccc	ggaagctgca	gacaagatct	cagacctggc	tggagagccg	ggagtataca	420
aagcacctga	tccgggtgga	gaactggatc	tttagaaatc	caggattcgc	actggcagca	480
gcagcaatcg	catggctgct	ggcgagctcc	acctcccaga	aagtgatcta	cctggctcatg	540
atcctgctga	tgcgccctgc	ctattccatc	aggtgcatcg	gcgtgtctaa	tcgcgacttc	600
gtggagggca	ccctgggtgga	cacctgggtg	gatgtggtgc	tggagcagcg	cggtgcgtg	660
acagtgatgg	cccaggacaa	gccaaccgtg	gacatcgagc	tggtgaccac	aaccgtgagc	720
aacatggccg	aggtgctggtc	ctactgctat	gaggccagca	tctccgacat	ggcctctgat	780
agcagatgtc	ccacccagg	cgaggcctac	ctggacaagc	agtctgatac	acagtacgtg	840
tgcaagagga	ccctgggtgga	caggggatgg	ggaaatggat	gtggcctggt	tgcaagggc	900
agcctggtga	catgcccaca	gttcgctgtg	tctaagaaga	tgaccggcaa	gagcatccag	960
ccagagaacc	tggagtaccg	gatcatgctg	agcgtgcacg	gcagccagca	ctccggcatg	1020
atcgtgaaag	acacaggcca	cgagacagat	gagaatagg	ccaaggtgga	gatcacacct	1080
aacagcccac	gcccagagc	caccctggga	ggatttgctc	ccctggccct	ggactgcgag	1140
cctagaacag	gcctggactt	ctccgatctg	tactatctga	ccatgaacaa	taagcactgg	1200
ctggtgcaca	aggagtgggt	tcacgacatc	ccactgcca	ggcagcagc	agcagataca	1260
ggaaccccac	actggaacaa	taaggaggcc	ctggtggagt	tcaaggatgc	ccacgccaag	1320
agggagacag	tggtgggtgct	ggcgagccag	gagggagcag	tgcacaccgc	cctggcagggc	1380
gccctggagg	ccgagatgga	cggagcaaa	ggccgctgtg	ctagcggcca	cctgaaagtgc	1440
cggtggaaga	tggataagct	gagactgaag	ggcgtgtcct	actctctgtg	cacagccgcc	1500
ttcaccttca	ccaagatccc	tgccagagca	ctgcacggca	cagtgaccgt	ggaggtgcag	1560
tatgcccggca	cagacggccc	ctgtaagggt	cctgcccaga	tggccgtgga	tatgcagaca	1620
ctgaccccctg	tgggcaggct	gatcaccgcc	aatccagtga	tcacagagtc	caccgagaac	1680
tctaagatga	tgctggagct	ggacccccct	tttggcgata	gctatatctg	gatcggcgctg	1740
ggcgagaaga	agatcacaca	ccactggcag	cgcagcggct	ccacaatcgg	caaggccctt	1800
gagccaccgc	tgaggggagc	aaagaggatg	gccgtgctgg	gcgacaccgc	atgggatttc	1860
ggctccgtgg	gagggcgcct	gaactctctg	ggcaagggca	tccaccagat	cttcggcgcc	1920
gcctttaagt	ccctgttcgg	cggcatgtct	tggtttagcc	agatcctgat	cggcacactg	1980
ctgatgtggc	tgggcctgaa	caccaagaat	ggctctatca	gcctgatgtg	cctggccctg	2040
ggaggcgtgc	tgatcttctc	gagcaccgcc	gtgtccgctc	ga		2082

SEQ ID NO: 29 moltype = AA length = 693
 FEATURE Location/Qualifiers
 REGION 1..693
 note = recombinant Zika virus antigen construct
 source 1..693
 mol_type = protein
 organism = synthetic construct

SEQ ID NO: 29

MGKRSAGSIM	WLASLAVVIA	CAGATRRGSA	YYMYLDRNDA	GEAISFPPTL	GMNKCIIQIM	60
DLGHMCDATM	SYECPMLDEG	VEPDDVDCWC	NTTSTWVYVG	TCHHKKGEAR	RSRRAVTLPS	120
HSTRKLQTRS	QTWLESREYT	KHLIRVENWI	FRNPGFALAA	AAIAWLLGSS	TSQKVIYLV	180
ILLIAPAYSI	RCIGVSNRDF	VEGMSGGTWW	DVLEHGGCV	TVMAQDKPTV	DIELVTTTVS	240
NMAEVRSYCY	EASISDMASD	SRCPQTGEAY	LDKQSDTQYV	CKRTLVDLRGW	GNGCGLFGKG	300
SLVTCAKFAC	SKMTGKSIQ	PENLEYRIML	SVHGSQHSGM	IVNDTGHETD	ENRAKVEITP	360
NSPRAEATLG	GFGSLGLDCE	PRTGLDFSDL	YYLTMNKNHW	LVHKEWFHDI	PLPWHAGADT	420
GTPHWNNKEA	LVEFKDAHAK	RQTVVVLGSQ	EGAVHTALAG	ALEAEMDGAK	GRLSSGHLKC	480
RLKMDKLRK	GVSYSLCTAA	FTTKIPAET	LHGTVTVEVQ	YAGTDGPCKV	PAQMAVDMQT	540
LTPVGRRLITA	NPVITESTEN	SKMMELEDDP	FGDSYIVIGV	GEKKITHHHH	RSGSTIGKAF	600

-continued

EATVRGAKRM AVLGDTAWDF GSVGGLNSL GKGIHQIFGA AFKSLFGGMS WFSQILIGTL 660
 LMWLGINTKN GSISLMCLAL GGVLIPLSTA VSA 693

SEQ ID NO: 30 moltype = AA length = 89
 FEATURE Location/Qualifiers
 source 1..89
 mol_type = protein
 organism = Zika virus

SEQ ID NO: 30 TRRGSAYMY LDRNDAGEAI SFPTTLGMNK CYIQIMDLGH MCDATMSYEC PMLDEGVEPD 60
 DVDCWCNTTS TWVYGTCHH KKGEARRSR 89

SEQ ID NO: 31 moltype = AA length = 60
 FEATURE Location/Qualifiers
 source 1..60
 mol_type = protein
 organism = Zika virus

SEQ ID NO: 31 RAVTLPSHST RKLQTRSQTW LESREYTKHL IRVENWIFRN PGFALAAAAI AWLLGSSTSQ 60

SEQ ID NO: 32 moltype = AA length = 520
 FEATURE Location/Qualifiers
 source 1..520
 mol_type = protein
 organism = Zika virus

SEQ ID NO: 32 KVIYLVMIILL IAPAYSIRCI GVSNRDFVEG MSGGTWVDVV LEHGGCVTM AQDKPTVDIE 60
 LVTTTVSNMA EVRSYCYEAS ISDMASDRC PTQGEAYLDK QSDTYVYCKR TLVDRGWGNG 120
 CGLFGKGSILV TCAKFACSKK MTGKSIQPEN LEYRIMLSVH GSQHSGMIVN DTGHETDENR 180
 AKVEITPNSP RAEATLGGFG SLGLDCEPRT GLDFSDLYYL TMNNKHVLVH KEWFHDIPLP 240
 WHAGADTGP HWNNKEALVE FKDAHAKRQT VVVLGSQEGA VHTALAGALE AEMDGAKGRL 300
 SSGHLKCRK MDKLRKGVYS YSLCTAAFTF TKIPAEHLG TVTVEVQYAG TDGPCKVPAQ 360
 MAVDMQTLTP VGRILITANPV ITESTENSKM MLELDPPFGD SYIVIGVGEK KITHHWHRSR 420
 STIGKAFEAT VRGAKRMAVL GDTAWDFGSV GGALNSLKGK IHQIFGAAFK SLFGGMSWFS 480
 QILIGTLLMW LGLNTRKNGSI SLMCLALGGV LIFLSTAVSA 520

SEQ ID NO: 33 moltype = DNA length = 12090
 FEATURE Location/Qualifiers
 misc_feature 1..12090
 note = SAM vector backbone with Zika antigen insert
 source 1..12090
 mol_type = other DNA
 organism = synthetic construct

SEQ ID NO: 33 ataggcggcg catgagagaa gccagacca attacotacc caaaatggag aaagtccagc 60
 ttgacatcga ggaagacagc ccattcctca gagctttgca gcggagcttc ccgcagtttg 120
 aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcatc 180
 tggcttcaaa actgatacga acggagggtg acccatccga cacgatcctt gacattggaa 240
 gtgcgcccgc ccgcagaatg tattctaagc acaagtatca ttgtatctgt ccgatgagat 300
 gtgcggaaga tccggacaga ttgtataagt atgcaactaa gctgaagaaa aactgtaagg 360
 aaataactga taaggaattg gacaagaaaa tgaaggagct cgccgcccgc atgagcgacc 420
 ctgacctgga aactgagact atgtgcctcc acgacgacga gtctgtctgc tacgaagggc 480
 aagtcgctgt ttaccaggat gtatacggcg ttgacggacc gacaagtctc taccaccaag 540
 ccaataaggg agttagagtc gcctactgga taggctttga caccaccctt tttatgttta 600
 agaacttggc tggagcatat ccatacact ctaccaactg ggccgacgaa accgtgttaa 660
 cggctcgtaa catagccta tcagctctg acgttatgga gcggtcacgt agagggatgt 720
 ccattcttag aaagaagtat ttgaaacat ccaacaatgt tctattctct gttggctcga 780
 ccatctacca cgagaagagg gacttactga ggagctggca cctgccctct gtatttcaact 840
 tacgtggcaa gcaaaattac acatgtcggg gtgagactat agttagttgc gacgggtacg 900
 tcgttaaaag aactagcacc tgtatgggaa gccttcagggc tatgctgcta 960
 cgatgcaccg cgagggatc ttgtgctgca aagtgcaga cacattgaac ggggagaggg 1020
 tctcttttcc cgtgtgcacg tatgtgccag ctacattgtg tgaccaaatg actggcatac 1080
 tggcaacaga tgtcagtcg gacgacgcgc aaaaactgct ggttgggctc aaccagcgta 1140
 tagtcgtcaa catagcacc cagagaaaaa ccaataccat gaaaaattac cttttgcccg 1200
 tagtgcccca ggcatctgct aggtgggcaa aggaatataa ggaagatcaa gaagatgaaa 1260
 ggccactagg actacgagat agacagttag tcatggggtg ttgttgggct ttagaaggc 1320
 acaagataac atctatattt aagcggcccg ataccctaac catcatcaa gtgaacagcg 1380
 atttccactc attcgtcgtg ccaggatag gcagtaaacac attggagatc gggctgagaa 1440
 caagaatcag gaaaatgtta gaggagcaca aggagccgtc acctctcatt accgccgagg 1500
 acgtacaaga agctaagtgc gcagccgatg aggctaagga ggtgcgtgaa gccgaggagt 1560

-continued

tgcgcgagc	tctaccacct	ttggcagctg	atgttgagga	gcccactctg	gaagccgatg	1620
tgcacttgat	gttacaagag	gctggggccg	gctcagtgga	gacacctcgt	ggcttgataa	1680
aggttaccag	ctacgatggc	gaggacaaga	toggctctta	cgctgtgctt	tctccgcagg	1740
ctgtactcaa	gagtgaaaaa	ttatcttgca	tccacctctt	cgctgaacaa	gtcatagtga	1800
taacacactc	tggccgaaaa	ggcgcttatg	ccgtggaacc	ataccatggt	aaagttagtg	1860
tgccagaggg	acatgcaata	cccgctccagg	actttcaagc	tctgagtga	agtgccacca	1920
ttgtgtacaa	cgaacgtgag	ttcgtaaaca	ggtacctgca	ccatattgcc	acacatggag	1980
gagcgctgaa	cactgatgaa	gaatattaca	aaactgtcaa	gcccagcgag	cacgacggcg	2040
aataacctgta	cgacatcgac	aggaaacagt	cggtcaagaa	agaactagtc	actgggctag	2100
ggctcacagg	cgagctgggt	gatcctccct	tccatgaatt	cgctacagag	agtctgagaa	2160
cacgaccagc	cgctccttac	caagtaccaa	ccataggggt	gtatggcgtg	ccaggatcag	2220
gcaagtctgg	catcattaaa	agcgcagtc	caaaaaaga	tctagtgggt	agcgccaaga	2280
aagaaaaactg	tgtcaaacac	ataaggagcg	tcaagaaaat	gaaagggctg	gacgtcaatg	2340
ccagaactgt	ggactcagtg	ctcttgaatg	gatgcaacaa	ccccgtagag	accctgtata	2400
ttgacgaagc	ttttgcttgt	catgcaaggta	ctctcagagc	gctcatagcc	attataagac	2460
ctaaaaaggc	agtgtctctg	ggggatccca	aacagtgccg	tttttttaac	atgatgtgcc	2520
tgaagtgtca	ttttaaaccac	gagatttgca	cacaagtctt	ccacaaaagc	atctctcgcc	2580
gttgcaacta	atctgtgact	tggctcgtct	caacctgttt	ttacgacaaa	aaaaatgagaa	2640
cgacgaatcc	gaaagagact	aagatttgta	ttgacactac	cggcagtagc	aaacctaaagc	2700
aggacgatct	catctctcact	tgtttcagag	gggtgggtgaa	gcagttgcaa	atagattaca	2760
aaggcaacga	aataatgacg	cgagctgcct	ctcaagggct	gacccgtaaa	ggtgtgtatg	2820
ccgttcggta	caaggtgaat	gaaaaactc	tgtacgcacc	cacctcagaa	catgtgaacg	2880
tcctactgac	ccgcacggag	gaccgcatcg	tgtgaaaaac	actagccggc	gacccatgga	2940
taaaaaact	gactgccaag	taccctggga	atctcactgc	caagatagag	gagtggcaag	3000
cagagcatga	tgccatcactg	agccacatct	tggagagacc	ggacccctacc	gacgtcttcc	3060
agaataaggc	aaactgtgtg	tgggccaagg	ctttagtgcc	ggtgctgaag	accgctggca	3120
tagacatgac	cactgaacaa	tggaaactg	tggattatct	tgaaacggac	aaagctcact	3180
cagcagagat	agtattgca	caactatcg	tgaggtctct	tggactcgat	ctggactccc	3240
gtctatcttc	tgcaccactg	gttcogttat	ccattagtaa	taatcactgg	gataactccc	3300
cgctcgctaa	catgtacggg	ctgaataaag	aagtgtccg	tcagctctct	cgcaggtacc	3360
cacaactgcc	tccggcagtt	gccaactgaa	gagctctatg	catgaacact	ggtacactgc	3420
gcaattatga	tcccgccata	aacctagtag	ctgtaaacag	aagactgcct	catgctttag	3480
tcctccacca	taatgaacac	ccacagagtg	acttttcttc	attcgtcagc	aaattgaagg	3540
gcagaactgt	cctggtggtc	ggggaaaagt	tgtccgtccc	aggcaaaatg	ggtgactggt	3600
tgtcagaccg	gcctgagggc	acctcagag	ctcggctgga	tttaggcac	ccaggtgatg	3660
tgcccaata	tgacataatg	ttgttaatg	tgaggacccc	atataaatc	catcactatc	3720
agcagtgtga	agaccatgcc	atlaagctta	gcatgttgac	caagaaaagt	tgtctgcatc	3780
tgaatcccgg	cggaaacctgt	gtcagcatag	gttatgggta	cgctgacagg	gccagcgaaa	3840
gcatcattgg	tgtatagcg	cggcagttca	agttttcccg	ggtatgcaaa	ccgaaatcct	3900
caactgaaga	caacggaaag	ctgtttgtat	tcattgggta	cgatcgcaag	gcccgtaccg	3960
acaatcctta	caagccttca	tcaaccttga	ccaacattta	tacaggttcc	agactccacg	4020
aagccggatg	tgcacctca	tatcatgtgg	tgcaggggga	tattgccacg	gccaccgaa	4080
gagtgattat	aaatgctggt	aacagcaaa	gacaacctgg	cggaggggtg	tgcggagcgc	4140
tgtataagaa	attcccgctaa	agcttcgatt	tacagccgat	cgaagttaga	aaagccgac	4200
tggctcaaagg	tgcagctaaa	catatcattc	atgccgtagg	acaaaacttc	aaacaaagttt	4260
cggaggttga	aggtgacaaa	cagttggcag	aggcttatga	gtccatcgct	aagattgtca	4320
acgataacaa	ttacaagtca	gtagcgattc	cactgttctc	caccggcatc	ttttccggga	4380
acaaagatcg	actaacccca	tcattgaacc	atttgctgac	agcttttagac	accatgatg	4440
cagatgtagc	catatactgc	agggacaaga	aatgggaaat	gactctcaag	gaagcagtg	4500
ctaggagaga	agcagtgagg	gagatagca	tatccgacga	ctcttcagtg	acagaacctg	4560
atgcagagct	ggtgaggggt	catccgaaga	gttctttggc	tggaaagga	ggctacagca	4620
caagcgatgg	caaaactttc	tcataatttg	aagggaccaa	gtttcaccag	goggccaagg	4680
atatagcaga	aatlaatgcc	atgtggccc	ttgcaacgga	ggccaatgag	caggtatgca	4740
tgtatatcct	cggagaaagc	atgagcagta	ttaggtcgaa	atgccccgct	gaagagtcgg	4800
aagcctccac	accacctagc	acgctgcctt	gcttgtgcat	ccatgccatg	actccagaaa	4860
gagtacagcg	ctctaaaagc	tcacgtccag	aacaatttac	tgtgtgctca	tcctttccat	4920
tgccgaagta	tagaatcact	ggtgtgcaga	agatccaatg	ctcccagcct	atattgttct	4980
caccgaaagt	gcctgogtat	atcctcccaa	ggaagtatct	cggtgaaaca	ccaccggtag	5040
acgagactcc	ggagccatcg	gcagagaacc	aatccacaga	ggggacacct	gaacaaccac	5100
cacttataac	cagagatgag	accaggaacta	gaacgcctga	gccgatcctc	atcgaagagg	5160
aagaagagga	tagcataagt	ttgctgtcag	atggcccagc	ccaccaggtg	ctgcaagtcg	5220
aggcagacat	tcacggggcg	ccctctgtat	ctagctcctc	ctggtccatt	cctcatgcat	5280
ccgactttga	tgtggacagt	ttatccatac	ttgacacctc	ggagggagct	agcgtgacca	5340
gccccgcaac	ctcagccag	acttaactctt	acttcgcaaa	gagtatggag	tttctggcgc	5400
gaccgggtgcc	tgcgctcoga	acagtatcca	ggaacctctc	acatcccgtc	ccgcccacaa	5460
gaacaccgtc	acttgcaacc	agcagggcct	gctcagaaac	cagcctagtt	tcacccccgc	5520
cagggcgtgaa	ttgggtgagc	actagagagg	agctcagggc	gcttaccctg	tcacgcactc	5580
ctagcaggtc	gctctcagag	actagcctgg	tctccaacc	gccagggcga	aatagggtga	5640
ttacaagaga	ggagtttgag	gcgttcgtag	cacaacaaca	atgacgggtt	gatgccccgt	5700
catacatctt	ttctctcgac	accggtcaag	ggcatttaca	acaaaaatca	gtaaggcaaa	5760

-continued

cgggtgctatc	cgaagtgggtg	ttggagagga	cogaattgga	gatttcgtat	gccccgcgc	5820
tcgaccaaga	aaaagaagaa	ttactacgca	agaaattaca	gttaaatccc	acacctgcta	5880
acagaagcag	ataccagtcc	aggaaggtgg	agaacatgaa	agccataaca	gctagacgta	5940
ttctgcaagg	ccttagggcat	ttatggaagg	cagaaggaaa	agtggagtgc	taccgaacce	6000
tgcatcctgt	tctcttggat	tcatctagtg	tgaaccgtgc	cttttcaagc	cccaaggtcg	6060
cagtggaaagc	ctgtaacgcc	atgttgaaa	agaactttcc	gactgtggct	tcttactgta	6120
ttattccaga	gtacgatgcc	tatttggaca	tggttgacgg	agcttcatgc	tgcttagaca	6180
ctgccagttt	ttgccctgca	aagctgcgca	gctttccaaa	gaaacactcc	tatttggaac	6240
ccacaatac	atcggcagtg	ccttcagcga	tccagaacac	gctccagaac	gtcctggcag	6300
ctgccacaaa	aagaaattgc	aatgtcacgc	aaatgagaga	attgcccgta	ttggattcgg	6360
cggcctttaa	tgtggaatgc	ttcaagaaat	atgctgttaa	taatgaatat	tgggaaacct	6420
ttaaagaaaa	ccccatcagg	cttactgaag	aaaactgggt	aaattacatt	accaaattaa	6480
aaggaccaaa	actgttggat	cttttggcga	agacacataa	tttgaatatg	ttgcaggaca	6540
taccaatgga	caggtttgta	atggacttaa	agagagacgt	gaaagtgact	ccaggaacaa	6600
aacatactga	agaacggccc	aaggtacagg	tgatccaggc	tgccgatccg	ctagcaacag	6660
cgtatctgtg	cggaaatccac	cgagagctgg	ttaggagatt	aaatgctggc	ctgcttccga	6720
acattcaatac	actgttggat	cttctggcgtg	aagactttga	cgtattata	gccgagcact	6780
tccagcctgg	ggattgtggt	ctggaactg	acatcgcgtc	gtttgataaa	agtgaggacg	6840
acgcatggc	tctgaccgcg	ttaatgattc	tggaaagactt	aggtgtggac	gcagagctgt	6900
tgacgtgat	tgaggcggct	ttcggcgaaa	tttcatcaat	acatttgccc	actaaaacta	6960
aatttaaaatt	cggagccatg	atgaaatctg	gaatgttcc	cacactgttt	gtgaaccag	7020
tcattaacat	tgtaatcgca	agcagagtgt	tgagagaacg	gctaaccgga	tcaccatgtg	7080
cagcattcoat	tggagatgac	aatatcgtga	aaggagtcaa	atcggacaaa	ttaatggcag	7140
acaggtgcgc	cacctgggtg	aatatggaag	tcaagattat	agatgctgtg	gtgggcgaga	7200
aagcgcctta	tttctgtgga	gggtttattt	tgtgtgactc	cgtgaccggc	acagcgtgcc	7260
gtgtggcaga	ccccctaaaa	aggctgttta	agcttggcaa	acctctggca	gcagacgatg	7320
aacatgatga	tgacaggaga	agggcattgc	atgaagagtc	aacacgctgg	aaccgagtgg	7380
gtattctttc	agagctgtgc	aaggcagtag	aatcaaggta	tgaaacgcta	ggaacttcca	7440
tcatagttat	ggccatgact	actctagcta	gcagtgttaa	atcattcagc	tacctgagag	7500
gggcccctat	aactctctac	ggctaaoctg	aatggactac	gacatagtct	agtcgcgcaa	7560
gatgggcaag	cggtcocggc	gctctatcat	gtggctggcc	tctctggccg	tggtcatcgc	7620
atgcgcagga	gcagcggagg	tcaccaggag	aggcagcggc	tactatatgt	acctggacag	7680
aaatgatgcc	ggcagggcca	tcagctttcc	caccacactg	ggcatgaaca	agtgttacct	7740
ccagatcatg	gacctggggc	acatgtgcga	tgccaccatg	tccatagagt	gtccaatgct	7800
ggacgagggc	gtggagcccg	acgatgtgga	ttgctgggtg	aataccacat	ccacatgggt	7860
ggtgtacggc	acctgccacc	caaagaaggg	agaggcaagg	cgtctcggga	gagcagtgc	7920
actgccttcc	cactctacc	ggaagctgca	gacaagatct	cagacctggc	tgagagccg	7980
ggagtataca	aagcacctga	tcoggtgga	gaactggatc	tttagaaatc	caggattcgc	8040
actggcagca	gcagcaatcg	catggctgct	gggcagctcc	acctcccaga	aagtgatcta	8100
cctggtcatg	atcctgctga	tcgcccctgc	ctattccatc	aggtgcatcg	gcgtgtctaa	8160
tcgcgacttc	gtggagggca	tgtctggcgg	cacctgggtg	gatgtgggtc	tgagacacgg	8220
cggctgogtg	acagtgatgg	ccaggacaaa	gccaacctg	gacatcgagc	tggtgaccac	8280
aacctgtagc	aacatggccc	aggtgcggtc	ctactgctat	gaggccagca	tctccgacat	8340
ggcctctgat	agcagatgac	ccaccaggg	cgaggcctac	ctggacaagc	agtgatgatac	8400
acagtagctg	tgcaagagga	ccctgggtga	caggggatgg	ggaatggat	gtggcctggt	8460
tggaagggc	agcctgtgga	catgcgccaa	gttcgcctgt	tctaagaaga	tgaccggcaa	8520
gagcatccag	ccagagaacc	tggagtaccg	gatcatgctg	agcgtgcacg	gcagccagca	8580
ctccggcatg	atcgtgaacg	acacaggcca	cgagacagat	gagaataggg	ccaaggtgga	8640
gatcacacct	aacagcccac	gcgcgaggc	cacctggga	ggatttggtc	ccctgggctc	8700
ggactgcgag	cctagaacag	gctcggactt	ctccgatctg	tactatctga	ccatgaacaa	8760
taagcactgg	ctggtgcaca	aggagtgggt	tcacgacatc	ccactgceat	ggcacgcagg	8820
agcagataca	ggaaccccac	actggaacaa	taaggaggcc	ctggtggagt	tcaaggatgc	8880
ccacgcccaag	aggcagacag	tgggtgtgct	gggcagccag	gagggagcag	tgcaaccgc	8940
cctggcagggc	gcccctggagg	ccgagatgga	cggagcaaa	ggccgcctgt	ctagcggcca	9000
cctgaagtgc	cggctgaaga	tggataagct	gagactgaag	ggcgtgtcct	actctctgtg	9060
cacagccgcc	ttcaccttca	ccaagatccc	tgccgagaca	ctgcaccggca	cagtgtaccgt	9120
ggaggtgcag	tatgccggca	cagacggccc	ctgtaagggtg	cctgcccaga	tgccctgga	9180
tatgcagaca	ctgaccctcg	tggcaggct	gatcaccgcc	aatccagtga	tcacagagtc	9240
caccgagaac	tctaagatga	tgtcggagct	ggacccccct	tttggcgata	gctatatcgt	9300
gatcggogtg	ggcggaaga	agatcacaca	ccactggcac	cgcagcggct	ccacaatcgg	9360
caaggccttt	gaggccaccg	tgaggggagc	aaagaggatg	gcctgtctgg	gogacaccgc	9420
atgggatttc	ggctccgtgg	gaggccctc	gaactctctg	ggcaaggcca	tcaccagat	9480
cttcggcgcc	gctttaaagt	ccctgttcgg	cggcatgtct	tggtttagcc	agatcctgat	9540
cggcacactg	ctgatgtggc	tgggcctgaa	caccaagaat	ggctctatca	gctctatgtg	9600
cctggccctg	ggaggcgtgc	tgatcttctc	gagcaccgcc	gtgtccgcct	gatgataagg	9660
cgcgccacc	cagcggccgc	atcacgcagc	aattggcaag	ctgcttcat	agaactcgcg	9720
gcgattggca	tgccgcctta	aaatttttat	tttatttttc	ttttcttttc	cgaatcggat	9780
tttgttttta	atattttcaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	9840
gagcgtttaa	acacgtgata	tctggcctca	tgggccttcc	tttactgccc	cgttttccag	9900
tcgggaaacc	tgtcgtgcca	gctgcattaa	catggtcata	gctgttctct	tgctatttgg	9960

-continued

gcgctctccg	cttctctgct	cactgactcg	ctgctctcgg	tcgttcgggt	aaagcctggg	10020
gtgcctaagt	agcaaaaggc	cagcaaaagg	ccaggaaccg	taaaaaggcc	gcgttgctgg	10080
cgtttttcca	taggctccgc	ccccctgacg	agcatcacia	aaatcgacgc	tcaagtccga	10140
ggtggcgaaa	cccagacagga	ctataaagat	accaggcggt	tccccctgga	agctccctcg	10200
tgcgctctcc	tggtccgacc	ctgcccctta	ccggatacct	gtccgccttt	ctcccttcgg	10260
gaagcgtggc	gctttctcat	agctcacgct	gtaggtatct	cagttcgggtg	taggtcgttc	10320
gctccaagct	gggctgtgtg	caogaacccc	ccgttcagcc	cgaccgctgc	gccttatccg	10380
gtaactatcg	tcttgagctc	aaccoggtaa	gacacgactt	atcgccactg	gcagcagcca	10440
ctggtaacag	gattagcaga	gcgaggtatg	taggcgggtc	tacagagttc	ttgaagtggg	10500
ggcctaacta	cggtacact	agaagaacag	tatttggtat	ctgctctctg	ctgaagccag	10560
ttaccttcgg	aaaagagtt	ggtagctctt	gatccggcaa	acaaccacc	gctggtagcg	10620
gtggtttttt	tgtttgcaag	cagcagatta	cgccgagaaa	aaaaggatct	caagaagatc	10680
ctttgatcct	ttctacgggg	ctgcagcctc	agtggaacga	aaactcacgt	taagggattt	10740
tggtcatgaa	tacacggctc	ctgactgcgt	tagcaattta	actgtgataa	actaccgcat	10800
taaagcttat	cgatgataag	ctgtcaaaac	tgagaattct	tagaaaaact	catcgagcat	10860
caaatgaaac	tgcaatttat	tcatatcagg	attatcaata	ccatattttt	gaaaaagccg	10920
tttctgtaat	ttctacgggg	actcaccgag	gcagttccat	aggatggcaa	gatcctggta	10980
tcggtctcgg	attccgactc	gtccaacatc	aatacaacct	attaatttcc	cctcgtcaaa	11040
aataaggtta	tcaagtgaga	aatcaccatg	agtgcgact	gaatccgggtg	agaatggcaa	11100
aagcttatgc	atctctttcc	agacttgctc	aacaggccag	ccattacgct	cgatcatcaa	11160
atcactcgca	tcaaccaaac	cgttattcat	tcgtgattgc	gcctgagcga	gacgaaatac	11220
gcgatcgctg	ttaaaaggac	aattacaaac	aggaatcgaa	tgcaaccggc	gcaggaacac	11280
tgccagcgca	tcaacaatat	tttccactga	atcaggatat	tcttctaata	cctggaatgc	11340
tgttttcccg	gggatcgcag	tggtgagtaa	ccatgcatca	tcaggagtac	ggataaaatg	11400
cttgatggtc	ggaagagcca	taaatccgt	cagccagttt	agtctgacca	tctcatctgt	11460
aacatcattg	gcaacgctac	ctttgccatg	ttcagaaac	aactctggcg	catcgggctt	11520
cccatacaat	cgatagattg	tcgcacctga	ttgcccgaca	ttatcgcgag	cccatttata	11580
cccataataa	tcagcatcca	tggtggaatt	taatcgccgc	ctcgagcaag	acgtttcccg	11640
ttgaatatgg	ctcataaac	cccttgattt	actgtttatg	taagcagaca	gttttatgtt	11700
tcatgagcgg	atacatatct	gaatgtatct	agaaaaataa	acaaataggg	gttcgcgcga	11760
catttccccc	aaaagtgcga	cctaaattgt	aagcgttaat	attttgttaa	aatcgcggtt	11820
aaatttttgt	taaatcagct	cattttttaa	ccaataggcc	gaaatcggca	aaatccctta	11880
taaatcaaaa	gaatagaccg	agataggggt	gagtgccgcg	tacagggcgc	tcccattcgc	11940
cattcaggct	gcgcaactgt	tggaagggc	gtttcgggtc	gggcctcttc	gctattacgc	12000
cagctggcga	aaggggatg	tgctgcaagg	cgattaagtt	gggtaacgcc	agggttttcc	12060
cagtcacacg	cgtaatacga	ctcactatag				12090

SEQ ID NO: 34 moltype = DNA length = 12090
 FEATURE Location/Qualifiers
 misc_feature 1..12090
 note = SAM vector backbone with Zika antigen insert
 source 1..12090
 mol_type = other DNA
 organism = synthetic construct

ataggcggcg	catgagagaa	gcccagacca	attacctacc	caaaatggag	aaagttcacg	60
ttgacatcga	ggaagacagc	ccattcctca	gagctttgca	gcggagcttc	ccgcagtttg	120
aggtagaagc	caagcaggtc	actgataaag	accatgctaa	tgccagagcg	ttttcgcatc	180
tggettcaaa	actgatcgaa	acggagggtg	accatccga	cacgatcctt	gacattggaa	240
gtgcgcccgc	ccgcagaatg	tattctaagc	acaagtatca	ttgtatctgt	ccgatgagat	300
gtgcggaaga	tccggacaga	ttgtataaag	atgcaactaa	gctgaagaaa	aactgtaagg	360
aaataactga	taaggaattg	gacaagaaaa	tgaaggagct	cgccgcgctc	atgagcgacc	420
ctgacctgga	aaactgagact	atgtgcctcc	acgacgacga	gtcgtgtcgc	tacgaagggc	480
aagtcgctgt	ttaccaggat	gtatacggcg	ttgacggacc	gacaagtctc	tatcaccaag	540
ccaataaggg	agtttagagc	gctactggga	taggctttga	caccaccctt	tttatgttta	600
agaacttggc	tgagcatalc	ccatcatact	ctaccaactg	ggccgacgaa	accgtgttaa	660
cggtctgtaa	cataggccta	tcagactctg	acgttatgga	gcggtcacgt	agagggatgt	720
ccattcttag	aaagaagtat	ttgaaacat	ccaacaatgt	tctattctct	gttggctcga	780
ccatctacca	cgagaagagg	gacttactga	ggagctggca	cctgccgtct	gtatttcact	840
tacgtggcaa	gcaaaattac	acatgtcggg	gtgagaactat	agttagttgc	gacgggtacg	900
tcggtaaaag	aatagctatc	agtcacggcc	tgtatgggaa	gccttcaggc	tatgctgcta	960
cgatgcaccg	cgagggattc	ttgtgctgca	aagtgcagca	cacattgaac	ggggagaggg	1020
tctcttttcc	ctgtgtgcag	tatgtgccag	ctacattgtg	tgaccaaatg	actggcatac	1080
tggaacacga	gctgagtcgg	gacgacgcgc	aaaaactgct	ggttgggctc	aaccagcgta	1140
tagtctgcaa	cggtcgcacc	cagagaaaca	ccaataccat	gaaaaattac	cttttgcctg	1200
tagtggccca	ggcatttgct	aggtgggcaa	aggaatataa	ggaagatcaa	gaagatgaaa	1260
ggccactagg	actacagatg	agacagttag	tcatgggggtg	ttgttgggct	tttagaaggg	1320
acaagataac	atctatttat	aagcgcctgg	ataccctaac	catcatcaaa	gtgaaccagc	1380
atctccactc	atctgtgctg	cccaggatag	gcagtaacac	atggagatgc	gggctgagaa	1440
caagaatcag	gaaaaatgta	gaggagcaca	aggagccgtc	acctctcatt	accgcccagg	1500

-continued

acgtacaaga	agctaagtgc	gcagccgatg	aggctaagga	ggtgcgtgaa	gccgaggagt	1560
tgcgcgcagc	tctaccacct	ttggcagctg	atgttgagga	gccacctctg	gaagccgatg	1620
tgcacttgat	gttacaagag	gctggggccg	gctcagtgga	gacacctctg	ggcttgataa	1680
aggttaccag	ctacgatggc	gaggacaaga	toggetctta	cgctgtgctt	tctccgcagg	1740
ctgtactcaa	gactgtaaaa	ttatcttgca	tccaccctct	cgctgaacaa	gtcatagtga	1800
taacacactc	tggccgaaaa	gggcgttatg	cogtggaaac	ataccatggt	aaagtagtgg	1860
tgccagaggg	acatgcaata	cccgccagg	actttcaagc	tctgagttaa	agtgccacca	1920
ttgtgtacaa	cgaacgtgag	ttcgtaaaca	ggtacctgca	ccatattgcc	acacatggag	1980
gagcgtgaa	cactgatgaa	gaatattaca	aaactgtcaa	gccagcgag	cacgacggcg	2040
aatacctgta	cgacatcgac	aggaaacagt	gcgtcaagaa	agaactagtc	actgggctag	2100
ggctcacagg	cgagctggtg	gatcctccct	tccatgaatt	cgctacagag	agtctgagaa	2160
cacgaccagc	cgctccttac	caagtaccaa	ccataggggt	gtatggcgtg	ccaggatcag	2220
gcaagtctgg	gactgtctgaa	agcgcatgca	ccaaaaaaga	tctagtgtg	agcgccaaga	2280
aagaaaactg	tgcagaaatt	ataagggacg	tcaagaaaat	gaaagggctg	gacgtcaatg	2340
ccagaactgt	ggactcagtg	ctcttgaatg	gatgcaaaaa	ccccgtagag	accctgtata	2400
ttgacgaagc	ttttgcttgt	catgcaggta	ctctcagagc	gctcatagcc	attataagac	2460
ctaaaaaggg	agtgctctgc	ggggatccca	aacagtgcgg	tttttttaac	atgatgtgcc	2520
tgaagtgca	ttttaaccac	gagatttgca	cacaagtctt	ccacaaaagc	atctctcgcc	2580
gttgcaactaa	atctgtgact	tcggctcgtc	caacctgtgt	ttacgacaaa	aaaatgagaa	2640
cgacgaatcc	gaaagagact	aagattgtga	ttgacactac	cggcagtacc	aaacctaaagc	2700
aggacgactc	cattctcaact	gtttccagag	ggtgggtgaa	gcagttgcaa	atagattaca	2760
aaggcaacga	aataatgacg	gcagctgcct	ctcaagggct	gacctgtaa	ggtgtgtatg	2820
ccgttcggta	caaggtgaat	gaaaatcctc	tgtacgcacc	cacctcagaa	catgtgaacg	2880
tctactgac	ccgcacggag	gaccgcacog	tgtggaaaac	actagccggc	gacctatgga	2940
taaaaacact	gactgcccaag	tacctgggga	atctcactgc	cacgatagag	gagtgccaag	3000
cagagcatga	tgccatcatg	aggcacatct	tggagagacc	ggacctacc	gacgtcttcc	3060
agaataaggg	aaacgtgtgt	tgggccaagg	ctttagtgc	ggtgctgaag	accgctggca	3120
tagacatgac	caactgaacaa	tggaaactg	tggattattt	tgaaacggac	aaagctcact	3180
cagcagagat	agtattgaa	caactatgag	tgaggttctt	tggactcgat	ctggactccg	3240
gtctattttc	tgcacccact	gttccggtat	ccattaggaa	taatcactgg	gataactccc	3300
cgctgcctaa	catgtacggg	ctgaataaag	aagtggctcg	tcagctctct	cgcaggtacc	3360
cacaactgcc	tccggcagtt	gccactggaa	gagctctatg	catgaacact	ggtacactgc	3420
gcaattatga	tcgcgcgata	aaacctagtac	ctgtaaacag	aagactgcct	catgctttag	3480
tctccacca	taatgaacac	ccacagagtg	acttttcttc	atctcgtcagc	aaatggaag	3540
gcagaactgt	cctgggtgtc	ggggaaaagt	tgtccgtccc	aggcaaaatg	gttgactggt	3600
tgtcagaccg	ctcgtaggtc	accctcagag	ctcggctgga	tttaggcac	ccaggtgatg	3660
tgcccaaata	tgcataaata	tttgtaatg	tgaggacccc	atataaatac	catcactatc	3720
agcagtgta	agaccatgcc	attaagctta	gcattgtgac	caagaaagct	tgtctgcac	3780
tgaatcccgg	cggaaacctgt	gtcagcatag	gttatggtta	cgctgacagg	gccagcgaaa	3840
gcactattgg	tgctatagcg	cggcagttca	agttttcccg	ggtatgcaaa	ccgaaatcct	3900
cacttgaaga	gacggaaagt	ctgtttgtat	tcattgggta	cgatcgcaag	gcccgctacgc	3960
acaactctta	caagctttca	tcaaccttga	ccaacattta	tacaggttcc	agactccacg	4020
aagccggatg	tgcacctctc	tatcatgtgg	tgcgagggga	tattgccacg	gccaccgaa	4080
gagtgattat	aaatgctgct	aaacgcaag	gacaacctgg	cggaggggtg	tgcggagcgc	4140
tgtataagaa	attcccggaa	agcttcgatt	tacagccgat	cgaagttaga	aaagcgcgac	4200
tggtaaaagg	tgcagctaaa	catatcattc	atgccgtagg	accaaacttc	aacaaagtgt	4260
cggaggttga	aggtgacaaa	cagttggcag	aggcttatga	gtccatcgct	aagattgtca	4320
acgataacaa	ttacaagctc	gtagcgattc	cactgtttgc	caccggcac	ttttccggga	4380
acaaagatcg	actaacccaa	tcattgaacc	atgtgtgac	agctttagac	accactgatg	4440
cagatgtagc	catatactgc	agggacaaga	aatgggaaat	gactctcaag	gaagcagtg	4500
ctaggagaga	agcagtgagg	gagatagca	tatccagcga	ctcttcagtg	acagaacctg	4560
atgcagagct	ggtgagggtg	catccgaaga	gttctttggc	tggaaaggaag	ggctacagca	4620
caagcagtg	caaaaacttc	tcataatttg	aagggaacaa	gtttccaccg	gggccaagg	4680
atatagcaga	aattaatgcc	atgtggccc	ttgcaaccgga	ggccaatgag	caggtatgca	4740
tgtatatcct	cggagaaagc	atgagcagta	ttaggtcgaa	atgcccgcgc	gaagagtcgg	4800
aagcctccac	accacttagc	acgctgcctt	gcttgtgcat	ccatgccatg	actccagaaa	4860
gagtagacgg	cctaaaagcc	tcacgtccag	aacaaattac	tgtgtgctca	tcctttccat	4920
tgccgaagta	tagaatcaact	ggtgtgcaga	agatccaatg	ctcccagcct	atattgttct	4980
caccgaaagt	gcctgogtat	atcatccaa	ggaagtatct	cgtggaaaca	ccaccggtag	5040
acgagactcc	ggagccatcg	cgagagaacc	aatccacaga	ggggacacct	gaacaaccac	5100
cacttataac	cgaggatgag	accaggacta	gaacgcctga	gcgatcatc	atcgaagagg	5160
aagaagagga	tagcataagt	ttgctgtcag	atggcccagc	ccaccaggtg	ctgcaagtcg	5220
aggcagacat	tcacggggcc	ccctctgtat	ctagctcatc	ctggctcatt	cctcatgcat	5280
ccgactttga	tgtggcagct	ttatccatac	ttgacacctc	ggagggagct	agcgtgacca	5340
gctgggcaac	gtcagccgag	actaactctt	acttcgcaaa	gagtatggag	tttctggcgc	5400
gaccggtgcc	tgcgctcoga	acagatttca	ggaacctcc	acatcccgcct	ccgcgcacaa	5460
gaacaccgtc	acttgcacc	agcagggcct	gctcagaaac	cagcctagtt	tcacccccgc	5520
cagcgtgaa	tgtgtgatc	actagagagg	agctcagggc	gcttaccggc	tcacgcactc	5580
ctagcaggtc	ggtctcgaga	accagcctgg	tctccaacct	gccagcgcta	aataggggtga	5640
ttacaagaga	ggagtttgag	gcgttcgtag	cacaacaaca	atgacggttt	gatgctgggtg	5700

-continued

catacatctt	ttctctccgac	accggtcaag	ggcattttaca	acaaaaatca	gtaaggcaaa	5760
cggtgctatc	cgaagtgggtg	ttggagagga	cogaattgga	gatttcgtat	gccccgcgc	5820
tgcaccaaga	aaaagaagaa	ttactacgca	agaaattaca	gttaaattccc	acacctgcta	5880
acagaagcag	ataccagtc	aggaaggtgg	agaacatgaa	agccataaca	gctagacgta	5940
ttctgcaagg	cccaggcatt	tatttgaagg	cagaagggaaa	agtgaggtgc	taccgaaccc	6000
tgcctcctgt	tcctttgtat	tcactctagt	tgaaccgtgc	cttttcaagc	cccaaggtcg	6060
cagtggaagc	ctgtaacgcc	atgttgaaag	agaactttcc	gactgtggct	tcttactgta	6120
ttattccaga	gtacgatgcc	tatttggaca	tggttgacgg	agcttcatgc	tgcttagaca	6180
ctgccagttt	ttgccctgca	aagctgcgca	gctttccaaa	gaaacactcc	tatttggaac	6240
ccacaatacg	atcggcagtg	ccttcagcga	tccagaacac	gctccagaac	gtcctggcag	6300
ctgccacaaa	aagaaatg	aatgtcacgc	aatgagaga	attgcccgta	ttggattcgg	6360
cgcccttaa	tgtggaatgc	ttcaagaaat	atgcgtgtaa	taatgaatat	tgggaaactg	6420
ttaaagaaaa	cccactccag	cttactgaag	aaaacgtggt	aaattacatt	accaaataa	6480
aaggacaaa	agctgctgct	ctttttgcca	agacacataa	tttgaatatg	ttgcaggaca	6540
taccaatgga	caggtttgta	atggacttaa	agagagcgt	gaaagtgact	ccaggaacaa	6600
aacatactga	agaacggccc	aaggtacagg	tgatccaggc	tgccgatccg	ctagcaacag	6660
cgatctctgt	cggaaatccac	ccagagctgg	ttagagatt	aaatgcggtc	ctgcttccga	6720
acattcatac	actgtttgat	atgtcggctg	aagactttga	cgctattata	gccgagcact	6780
tccagcctgg	ggattgtggt	ctggaaactg	acatcgctc	gtttgataaa	agtgaggacg	6840
agccatggc	tctgaccggc	ttaatgattc	tggaaagact	aggtgtggac	gcagagctgt	6900
tcgagctgat	tgaggcgct	ttcggcgaaa	tttcatcaat	acattttgcc	actaaaacta	6960
aatttaaatt	cggagccatg	atgaaatctg	gaatgttctc	cacactgttt	gtgacacag	7020
tcattaacat	tgtaatcgca	agcagagtg	tgagagaacg	gctaaccgga	tcaccatgtg	7080
cagcattcat	tggagatgac	aatatcgtga	aaggagtcaa	atcggacaaa	ttaatggcag	7140
acaggtgcgc	cacctggttg	aatatggaag	tcaagattat	agatgctgtg	gtgggcgaga	7200
aagcgcctta	ttctctgga	gggtttattt	tgtgtgactc	cgtagccggc	acagcgtgcc	7260
gtgtggcaga	ccccctaaaa	aggctgttta	agcttggcaa	acctctggca	gcagacgatg	7320
aacatgatga	tgacagagga	agggcattgc	atgaagagtc	aacacogctgg	aaccgagtg	7380
gtattcttcc	agagctgtgc	aagggcagtag	aatcaaggtg	tgaaccgta	ggaacttcca	7440
tcatagttat	ggccatgact	actctagcta	gcagtgttaa	atcattcagc	tccttgagag	7500
gggccccat	aactctctac	ggctaacctg	aatggactac	gacatagtct	agtcccocaa	7560
gatgggcaag	cgttccggcc	gctctatcat	gtggctggcc	tctctggccg	tggctatcgc	7620
atgcgcagga	gcagcggagg	tcaccaggag	agggcagccc	tactatagt	acctggacag	7680
aatgatgccc	ggcagggcca	tcagcttccc	caccacactg	ggcatgaaca	agtgttacat	7740
ccagatcatg	gacctgggccc	acatgtgcga	tgccaccatg	tcctatgagt	gtccaatgct	7800
ggcaggggc	gtggagcccg	acgatgtgga	ttgctgggtg	aataccacat	ccacatgggt	7860
ggtgtacggc	acctgcccac	acaagaaggg	agaggcaagg	cgctctcgga	gagcagtgac	7920
actgccttcc	cactctaccc	ggaagctgca	gacaagatct	cagacctggc	tggagagccc	7980
ggagtataca	aagcacctga	tcgggtgga	gaactggatc	tttagaaatc	caggattcgc	8040
actggcagca	cgccaatcg	catggctgct	gggcagctcc	acctcccaga	aagtgatcta	8100
cctggtcatg	atcctgctga	tcgcccctgc	ctattccatc	aggtgcatcg	gcgtgtctaa	8160
tcgcaacttc	gtggagggca	tgtctggcgg	cacctgggtg	gatgtggtgc	tggagcacgg	8220
cggtctgctg	acagtgtatg	cccaggacaa	gccaacctg	gacatcgagc	tggtagccac	8280
aacctgtgagc	aacatggccg	ctactgctat	gaggccagca	tctccgacat	8340	
ggcctctgat	agcagatgct	ccaccagggg	cgaggcctac	ctggacaagc	agtctgatac	8400
acagtacgtg	tgaagagga	ccctggtgga	caggggatgg	ggaatggat	gtggcctggt	8460
tggcaagggc	agcctggtga	catgcgccaa	gttcgcctgt	tctaagaaga	tgaccggcaa	8520
gagcatccag	ccagagaacc	tgagtagacc	gatcatgctg	agcgtgcaag	gcagccagca	8580
ctccggcatg	atcgtgaacg	acacaggcca	cgagacagat	gagaataggg	ccaaggtgga	8640
gatcacacct	aacagcccac	gcgccgaggg	cacctgggga	ggatttggct	ccctgggcct	8700
ggactgcgag	cctagaacag	gcttggactt	ctccgatctg	tactatctga	ccatgaacaa	8760
taagcaactg	ctggtgcaca	aggagtgggt	tcacgacatc	ccactgccat	ggcacgcagg	8820
agcagataca	ggaaccccac	actggaacaa	taaggaggcc	ctggtggagt	tcaaggatgc	8880
ccacgccaa	aggcagacag	tgggtgtgct	gggcagccag	gagggagcag	tgcacaccgc	8940
cctggcaggg	gcctggggg	ccgagatgga	cggagcaaa	ggccgcctgt	ctagcggcca	9000
cctgaagtgc	cggctgaaga	tggaataagc	gagactgaa	ggcgtgtcct	actctctgtg	9060
cacagccgcc	ttcaccttca	ccaagatccc	tgccgagaca	ctgcacggca	cagtgaccgt	9120
ggaggtgca	tatgcccggca	cagacggccc	ctgtaaggtg	cctgccccaga	tggccgtgga	9180
tatgcagaca	ctgaccctgt	tgggcaggct	gatcaccgcc	aatccagtga	tcacagagtc	9240
caccgagaac	cttaagatga	tgctggagct	ggacccccct	tttggcgata	gctatatogt	9300
gatcggcgtg	ggcagagaaga	agatcacaca	ccactggcac	cgcagcggct	ccaccctggg	9360
caaggccttt	agcaccaccc	tgaaggggagc	acagaggctg	gcgccctgtg	ggcagaccgc	9420
atgggatctc	ggctccatcg	gaggcgtggt	caactctatc	ggcaaggccc	tgaccaggtg	9480
gttcggcggc	ccctttcgga	cgccatgtct	tggatcaccc	agggcctgat	9540	
gggcgccctg	ctgctgtgga	tgggctgtaa	cgcccgggac	cggtctatcg	ccctggcctt	9600
cctggccacc	ggaggcgtgc	tgtgttccct	ggccaccaac	gtgcacgcct	gatgataagg	9660
cgcccccacc	cagcggccgc	atacagcagc	aattggcaag	ctgcttacct	agaactcgcg	9720
gcgatttgca	tcgcccttta	aaaattttat	tttatttttc	ttttcttttc	cgaatcggat	9780
tttgttttta	atatttcaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	9840
gagcgtttaa	acacgtgata	tctggcctca	tgggccttcc	tttcaactgc	cgctttccag	9900

-continued

tccggaaaacc	tgtcgtgcc	gotgcattaa	catggtcata	gctgtttcct	tgcgtattgg	9960
gcgctctccg	cttctctcgt	cactgactcg	ctgcgctcgg	tcgttcgggt	aaagcctggg	10020
gtgcctaattg	agcaaaaggc	cagcaaaagg	ccaggaaccg	taaaaaggcc	gcgttgctgg	10080
cgTTTTTcca	tggctccgc	ccccctgacg	agcatcaca	aaatcgacgc	tcaagtcaga	10140
ggtggcgaaa	cccgacagga	ctataaagat	accaggcggt	tccccctgga	agctccctcg	10200
tgcgctctcc	tgttccgacc	ctgcccctta	cggataacct	gtcccgcctt	ctcccctcgg	10260
gaagcgtggc	gctttctcat	agctcacgct	gtaggatctc	cagttccggtg	taggtcgttc	10320
gctccaagct	gggctgtgtg	caogaacccc	cogttcagcc	cgaccgctgc	gccttatccg	10380
gtaactatcg	tcttgagctc	aacccggtaa	gacacgactt	atcgccactg	gcagcagcca	10440
ctggtaacag	gattagcaga	gcgaggatg	tagggcgtgc	tacagagttc	ttgaagtgg	10500
ggcctaacta	cggctacact	agaagaacag	tatttggtat	ctgcgctctg	ctgaagccag	10560
ttaccttcgg	aaaaagagtt	ggtagctctt	gatccggcaa	acaaaccacc	gctggtagcg	10620
gtggTTTTTt	tgtttgcaag	cagcagatta	cgcgcagaaa	aaaaggatct	caagaagatc	10680
ctttgatctt	ttctacgggg	tctgacgctc	agtggaacga	aaactcacgt	taagggattt	10740
tggcatgaa	tacacggtgc	ctgactgctg	tagcaattta	actgtgataa	actaccgcat	10800
taaagcttat	cgatgataag	ctgtcaaca	tgagaattct	tagaaaaact	catcgagcat	10860
caaatgaaac	tgcgaatttat	tcatatcagg	attatcaata	ccatattttt	gaaaaagccg	10920
tttctgtaat	gaaggagaaa	actcaccgag	gcagttccat	aggatggcaa	gatcctggta	10980
tccgctctcg	attccgactc	gtccaacatc	aatacaacct	attaatttcc	cctcgtcaaa	11040
aataaggtta	tcaagtgaga	aatcaccatg	agtgcagact	gaatccgggtg	agaatggcaa	11100
aagcttatgc	atttctttcc	agacttggtc	aacaggccag	ccattacgct	cgtcatcaaa	11160
atcactcgca	tcaaccaaac	cgttattcat	tcgtgattgc	gcctgagcga	gacgaaatac	11220
gcgatcgctg	ttaaaaggac	aattacaaac	aggaatcgaa	tgcaaccggc	gcaggaacac	11280
tgccagcgca	tcaacaatat	tttcacctga	atcaggatat	tcttctaata	cctggaatgc	11340
tgttttcccg	gggatcgtag	tggtgagtaa	ccatgcata	tcaggagtac	ggataaaatg	11400
cttgatggtc	ggaagaggca	taaattccgt	cagccagttt	agtctgacca	tctcatctgt	11460
aacatcattg	gcaacgctac	ctttgccatg	tttcagaaac	aactctggcg	catcgggctt	11520
cccatacaat	cgatagattg	tcgcacctga	ttgcccagca	ttatogcgag	cccatttata	11580
cccataataa	tcagcatcca	tgttggaatt	taatcgcggc	ctcgagcaag	acgtttcccg	11640
ttgaatatgg	ctcataaac	cccttgtatt	actgtttatg	taagcagaca	gttttattgt	11700
tcagtgcgag	atacatattt	gaatgtattt	agaaaaataa	acaaataggg	gttcccgca	11760
caatttcccg	aaaagtgcga	cctaaattgt	aagcgtaaat	atthttgtaa	aattcgcggt	11820
aaatttttgt	taaatcagct	catthtttaa	caaataggcc	gaaatcgcca	aaatccctta	11880
taaatcaaaa	gaatagaccg	agataggggt	gagtgccgcg	tacagggcgc	tcccattcgc	11940
cattcagctc	gcgcaactgt	tgggaaggcc	gtttcggctg	gggcctcttc	gctattacgc	12000
cagctggcga	aagggggatg	tgctgcaagg	cgattaagtt	gggtaaccgc	agggttttcc	12060
cagtcacacg	cgtaatacga	ctcaactatg				12090

SEQ ID NO: 35 moltype = DNA length = 12081
FEATURE Location/Qualifiers
misc_feature 1..12081
 note = SAM vector backbone with ZIKA antigen insert.
source 1..12081
 mol_type = other DNA
 organism = synthetic construct

SEQ ID NO: 35						
ataggcggcg	catgagagaa	gcccagacca	attacctacc	caaaatggag	aaagttcacg	60
ttgacatcga	ggaagacagc	ccattcctca	gagctttgca	gcggagcttc	cgcagtttg	120
aggtagaagc	caagcaggtc	actgataatg	accatgctaa	tgccagagcg	ttttcgcac	180
tggcttcaaa	actgatcgaa	acggagggtg	accatccga	cacgatcctt	gacattggaa	240
gtgcgcccg	ccgcagaatg	tattctaaag	acaagtatca	ttgtatctgt	ccgatgagat	300
gtcgggaaga	tccggacaga	ttgtataagt	atgcaactaa	gctgaagaaa	aactgtaagg	360
aaataactga	taaggaattg	gacaagaaaa	tgaaggagct	cgccgcgctg	atgagcgacc	420
ctgacctgga	aactgagact	atgtgcctcc	acgacgacga	gtogtgcgc	tacgaagggc	480
aagtcgctgt	ttaccaggat	gtatacggcg	ttgacggacc	gacaagtctc	tatcaccag	540
ccaataaggg	agttagagtc	gcctactgga	taggctttga	caccaccctt	tttatgttta	600
agaacttggc	tggagcatat	ccatcatact	ctaccaactg	ggccgacgaa	accgtgttaa	660
cggctcgtaa	cataggccta	tcagctctg	acgttatgga	gcggtcacgt	agagggatgt	720
ccattcttag	aaagaagtat	ttgaaacat	ccaacaatgt	tctattctct	gttggctcga	780
ccactcacca	acggaagagg	gacttactga	ggagctggca	cctgcccgtt	gtatttcact	840
tacgtggcaa	gcaaaattac	acatgtcgg	gtgagactat	agttagttgc	gacgggtacg	900
tcgTTAAAAG	aatagctatc	agtcacggcc	tgtatgggaa	gccttcagcg	tatgctgcta	960
cgatgcaccg	cgagggatc	ttgtgtgca	aagtgcagaa	cacattgaac	ggggagaggg	1020
tctcttttcc	agttgacag	tatgtgccag	ctacattgtg	tgaccaaatg	actggcctac	1080
tggcaacaga	tgtcagtgcc	gacgacgccc	aaaaactgct	ggttgggctc	aaccagcgt	1140
tagtcgtcaa	cggtcgaccc	cagagaaaca	ccaataccat	gaaaaattac	cttttgcctg	1200
tagtggccca	ggcatttctg	aggtgggcaa	aggaatataa	ggaagatcaa	gaagatgaaa	1260
ggccactagg	actacagtag	agacagttag	tcatgggggtg	ttgttgggct	tttagaagcc	1320
acaagataac	atctatttat	aagcggcccg	atacccaaac	catcatcaaa	gtgaacagcg	1380
atthccaactc	attcgtgctg	cccaggatag	gcagtaaacac	attggagatc	gggctgagaa	1440

-continued

caagaatcag	gaaaaatgta	gaggagcaca	aggagccgtc	acctctcatt	accgccgagg	1500
acgtacaaga	agctaagtgc	gcagccgatg	aggctaagga	ggtgcgtgaa	gccgaggagt	1560
tgccgcgagc	tctaccacct	ttggcagctg	atggtgagga	gcccactctg	gaagccgatg	1620
tcgacttgat	gttacaagag	gctggggccg	gctcagtgga	gacacctcgt	ggcttgataa	1680
aggttaccag	ctacgattgg	gaggacaaga	tcggctctta	cgctgtgctt	tctccgcagg	1740
ctgtactcaa	gagtgaaaaa	ttatcttgca	tcaccctctc	cgctgaacaa	gtcatagtga	1800
taacacactc	tgcccgaaaa	gggcgttatg	ccgtggaacc	ataccatggt	aaagtagtgg	1860
tgccagaggg	acatgcaata	cccgctccagg	actttcaagc	tctgagtgaa	agtgccacca	1920
ttgtgtacaa	cgaacgtgag	ttcgtaaaca	ggtacctgca	ccatattgcc	acacatggag	1980
gagcgcctga	cactgatgaa	gaatattaca	aaactgtcaa	gcccagcgag	cacgacggcg	2040
aatacctgta	cgacatcgac	aggaaaacgt	cgctcaagaa	agaactagtc	actgggctag	2100
ggctcacagg	cgagctgggt	gacccctcct	tccatgaatt	cgctacagag	agtctgagaa	2160
cacgaccagc	cgctcccttac	caagtaccaa	ccataggggt	gtatggcgtg	ccaggatcag	2220
gcaagtctgg	catcattaaa	agcgcagtca	ccaaaaaaga	tctagtgggt	agcgccaaga	2280
aagaaaaactg	tgagaaaatt	ataagggacg	tcaagaaaat	gaaagggctg	gacgtcaatg	2340
ccagaactgt	ggactcagtg	ctcttgaatg	gatgcaaaac	ccccgtagag	accctgtata	2400
ttgacgaaagc	ttttgcttgt	ctctcagagc	gctcagagtc	gctcatagcc	attataagac	2460
ctaaaaaggc	agtgtctctg	ggggatccca	aacagtgcgg	tttttttaac	atgatgtgcc	2520
tgaaaagtcca	ttttaaccac	gagatttgca	cacaagtctt	ccacaaaagc	atctctcgcc	2580
gttgcaactaa	atctgtgact	tcggctcgtc	caacctgttt	ttacgacaaa	aaaaatgagaa	2640
cgacgaatcc	cactgaagact	aaagattgta	ttgacactac	cggcagtagc	aaacctaaagc	2700
aggacgatct	cattctcact	tgtttcagag	ggtgggtgaa	gcagttgcaa	atagattaca	2760
aaggcaacga	aataatgacg	gcagctgcct	ctcaagggct	gaccctgaaa	ggtgtgtatg	2820
ccgttcggta	caaggtgaa	gaaaatcctc	tgtacgcacc	cacctcagaa	catgtgaacg	2880
tcctactgac	ccgcacggag	gaccgcctcg	tgtggaaaac	actagccggc	gacccatgga	2940
taaaaaactc	gactgccaa	taccctggga	atctcactgc	cacgatagag	gagtggcaag	3000
cagagcatga	tgccatcatg	aggcacatct	tgagagacc	ggaccctacc	gacgtcttcc	3060
agaataaggc	aaactgtgtg	tgggccaagg	ctttagtgcc	ggtgctgaag	accgctggca	3120
tagacatgac	cactgaacaa	tggaacactg	tggaattatt	tgaaacggac	aaagctcact	3180
cagcagagat	agtattgaac	caactatgct	tgaggtcttt	tggaactcgt	ctggactccg	3240
gtctatcttc	tgaccacct	gttccgttat	ccataggaaa	taactcactg	gataactccc	3300
cgctgcctaa	catgtacggg	ctgaataaag	aagtggctcg	tcagctctct	cgcaggtacc	3360
cacaactgcc	tcgggcagtt	gccaactgaa	gagctctatg	catgaaacct	ggtacactgc	3420
gcaattatga	tccgcgcata	aacctagtag	ctgtaaacag	aagactgcct	catgctttag	3480
tcctccacca	taataaacac	ccacagagtg	acttttcttc	atctcgtcag	aaattgaagg	3540
cgagaactgt	cctgggtggc	ggggaaaagt	tgtccgtccc	aggcaaaatg	ggtgactggt	3600
tgctcagaccg	ccctcagagc	acctcagag	ctcggctgga	tttaggcac	ccaggtgatg	3660
tgcccaaata	tgacataata	ttgtttaatg	tgaggacccc	atataaatac	catcactatc	3720
agcagtgatg	agaccatgcc	attaagctta	gcagtgtgac	caagaaaagc	tgtctgcate	3780
tgaaatcccgg	ggaaacctgt	ctcagcatag	gttatgggta	cgctgacagg	gccagcgaaa	3840
gcatcattgg	tgctatagcg	cggcagttca	agtttcccg	ggatgcaaaa	ccgaaatcct	3900
cacttgaaga	gacggaagtt	ctgtttgtat	tcattgggta	cgatcgcaag	gcccgtacgc	3960
acaatcctta	caagctttca	tcaaccttga	ccaacattta	tacaggttcc	agactccacg	4020
aagccggatg	tgaccctca	tatcatgtgg	tgccagggga	tattgccaag	gccaccgaa	4080
gagtgattat	aaatgctgct	aacagcaaa	gacaacctgg	cggaggggtg	tgccggagcg	4140
tgtataagaa	attcccggaa	agcttcgatt	tacagccgat	cgaagtagga	aaagcgcgac	4200
tggtcaaagg	tgacagtaaa	catatcattc	atgccgtagg	accaaaactc	aaaaaagttt	4260
cggaggttga	aggtgacaaa	cagttggcag	aggcttatga	gtccatcgct	aagattgtca	4320
acgataacaa	ttacaagtca	gtagcgattc	caactgtgtc	caccggcacc	ttttccggga	4380
acaaagatcg	actaacccaa	tcattgaacc	atctgtcgac	agctttagac	accactgatg	4440
cagatgtagc	catatactgc	agggacaaga	aatgggaaat	gactctcaag	gaagcagtg	4500
ctaggagaga	agcagtgagg	gagatatgca	tatccgacga	ctcttcagtg	acagaacctg	4560
atgcagagct	ggtgaggggt	catccgaaga	gttctttggc	tggaaggaa	ggctacagca	4620
caagcgatgg	caaaaactttc	tcataatttg	aagggaccaa	gtttcaccag	goggccaagg	4680
atatagcaga	aaatgaatgc	atgtggcccg	ttgcaacgga	ggccaatgag	caggtatgca	4740
tgtatatcct	cggagaaagc	atgacagta	ttaggtcgaa	atgccccgtc	gaagagtcgg	4800
aagcctccac	accacctagc	acgctgcctt	gcttgtgcat	ccatgccatg	actccagaaa	4860
gagtacagcg	cctaaaagcc	tcacgtccag	aacaaattac	tgtgtgctca	tcctttccat	4920
tgccgaagta	tgaatcact	ggtgtgcaga	agatccaatg	ctcccagcct	atattgttct	4980
caccgaaagt	gcttgogtat	attcatccaa	ggaagtatct	cgtggaaaaca	ccaccggtag	5040
acgagactcc	ggagccatcg	gcagagaacc	aatccacaga	ggggacacct	gaacaaccac	5100
cacttataac	cgaggatgag	accaggacta	gaacgcctga	gccgatcatc	atcgaagagg	5160
aagaagagga	tagcataaagt	ttcctgtcag	atggcccagc	cccaccagtg	ctgcaagtcg	5220
aggcagacat	tcacgggccc	ccctctgtat	ctagctcabc	ctggctcatt	cctcatgcat	5280
ccgactttga	tgtggacagt	ttatccatac	ttgacacctc	ggagggagct	agcgtgacca	5340
gcccgggcaac	gtcagccgag	actaacctct	acttcgcaaa	gagtatggag	tttctggcgc	5400
gaccgggtgcc	tcgctcctga	acagatttca	ggaacctccc	acatcccgtc	ccgcgcacaa	5460
gaacaccgtc	acttgcaacc	agcagggcct	gctcgagaac	cagcctagtt	tcacccccgc	5520
cagggcgtgaa	taggggtgatc	actagagagg	agctcagggc	gcttaccctg	tcacgcactc	5580
ctagcaggtc	ggtctcagaa	accagcctgg	tctccaacct	gccagggcga	aataggggtga	5640

-continued

ttacaagaga	ggagtttgag	gogttcgtag	cacaacaaca	atgaocggtt	gatgcgggtg	5700
catacatctt	ttctccgac	accggtcaag	ggcatttaca	acaaaaatca	gtaaggcaaa	5760
cggtgctatc	cgaagtggg	ttggagagga	cogaattgga	gatttcgfat	gccccgcgc	5820
tcgaccaaga	aaaagaaga	ttactacgca	agaaattaca	gttaaatccc	acacctgcta	5880
acagaagcag	ataccagtcc	aggaaggtgg	agaacatgaa	agccataaca	gctagacgta	5940
ttctgcaagg	cctagggcat	tatttgaagg	cagaaggaaa	agtggagtgc	taccgaacct	6000
tgatcctgt	tcctttgtat	tcactctagt	tgaaccgtgc	cttttcaagc	cccaaggctc	6060
cagtggaaag	ctgtaacgcc	atgttgaaag	agaactttcc	gactgtggct	tcttactgta	6120
ttattccaga	gtacgatgcc	tatttggaca	tggttgacgg	agcttcatgc	tgcttagaca	6180
ctgccagttt	ttgccctgca	aagctgcgca	gctttccaaa	gaaacactcc	tatttggaac	6240
ccacaatac	atcggcagtg	ccttcagcga	tccagaacac	gctccagaac	gtcctggcag	6300
ctgccacaaa	aagaaattgc	aatgtcacgc	aaatgagaga	attgcccgta	ttggattcgg	6360
cgccctttaa	tgtggaatgc	ttcaagaaat	atgocgtgaa	taatgaatat	tgggaaacgt	6420
ttaaagaaaa	ccccatcagg	cttactgaag	aaaacgtggt	aaattacatt	accaaattaa	6480
aaggaccaaa	agctgctgct	ctttttgca	agacacataa	tttgaatatg	ttcagggaca	6540
taccaatgga	caggtttgta	atggacttaa	agagagacgt	gaaagtgact	ccaggaacaa	6600
aacatactga	agaacgcgcc	aaggtacagg	tgatccagcc	tgccgatccg	ctagcaacag	6660
cgtatctgtg	cggaaatccac	cgagagctgg	ttaggagatt	aaatgctgct	ctgcttccga	6720
acattcatac	actgtttgat	atgtcggctg	aagactttga	cgctattata	gccgagcact	6780
tccagcctgg	ggattgtgtt	ctggaaactg	acatcgcgtc	gtttgataaa	agtgaggacg	6840
cgccatggc	tctgacgcgg	ttaatgattc	tggaaagact	aggtgtggac	gcagagctgt	6900
tgacgctgat	tgaggcggct	ttcggcgaaa	tttcatcaat	acatttgccc	actaaaacta	6960
aatttaaatt	cggagccatg	atgaaatctg	gaatgttcct	cacactgttt	gtgaaccacg	7020
tcattaacat	tgtaatcgca	agcagaggtg	tgagagaacg	gctaaccgga	tcaccatgtg	7080
cgcattcoat	tggagatgac	aatatcgtga	aaggagtcaa	atcgggacaa	ttaatggcag	7140
acaggtgcgc	cacctggttg	aatatggaag	tcaagattat	agatgctgtg	gtgggcgaga	7200
aagcgcctta	tttctgtgga	gggtttat	tgtgtgactc	cgtagccggc	acagcgtgcc	7260
gtgtggcaga	ccccataaaa	aggctgttta	agcttggcaa	acctctggca	gcagacgatg	7320
aacatgatga	tgcacagaga	agggcatctg	atgaaagatc	aacacgcctg	aaccgagtgg	7380
gtattctttc	agagctgtgc	aaggcagtag	aatcaaggta	tgaaaccgta	ggaacttcca	7440
tcatagttat	ggccatgact	actctagcta	gcagtgtaa	atcattcagc	tacctgagag	7500
gggcccctat	aactctgtac	ggctaaccctg	aatggactac	gacatagtct	agtcgcgcaa	7560
gatgggcaag	cgctccgcgc	gctctatcat	gtggctggcc	tctctggccg	tggtcatcgc	7620
atgcccagga	gcaaccagga	gaggcagcgc	ctactatatg	tacctggaca	gaaatgatgc	7680
cggcgagacc	atcagctttc	ccaccacact	gggcatgaac	aagtgttaca	tcagatcat	7740
ggacctgggc	cacatgtgtg	atgccaccat	gtcctatgag	tgtccaatgc	tggacgaggg	7800
cgtggagccc	cgatgtgtgg	attgctgggtg	taataccaca	tccacatggg	tggtgtacgg	7860
cacctgccac	cacaagaagg	gagaggcaag	gcgctctcgg	agagcagtga	cactgccttc	7920
ccactctacc	cggaaagctgc	agacaagatc	tcagacctgg	ctggagagcc	gggagataac	7980
aaagcacctg	atccgggtg	agaaactggat	ctttagaat	ccaggattcg	cactggcagc	8040
agcagcaatc	gcatggctgc	tgggcagctc	cacctccag	aaagtgatct	acctggtcat	8100
gatcctgctg	atcgcctcctg	cctattccat	caggtgcctc	ggcgtgtcta	atcgcgactt	8160
cgtggagggc	atgtctggcg	gcacctgggt	ggatgtgggtg	ctggagcagc	gcccgtcgt	8220
gacagtgatg	gcccaggaca	agccaacctg	ggacatcgag	ctggtgacca	caaccgtgag	8280
caacatggcc	gaggtgcggt	cctactgcta	tgaggccagc	atctccgaca	tggcctctga	8340
tagcagatgt	cccaccaggg	gcgaggccta	cctggacaag	cagtctgata	cacagtacgt	8400
gtgcaagagg	acctggtgtg	acaggggatg	gggaaatgga	tgtggcctgt	ttggcaaggg	8460
cagcctggtg	acatgcgccca	agttcgcctg	ttctaagaag	atgaccggca	agagcatcca	8520
gccagagaac	ctggagtacc	ggatcatgct	gagcgtgcac	ggcagccagc	actccggcat	8580
gatcgtgaa	gacacaggcc	acgagacaga	tgagaatagg	gccaaaggtg	agatcacacc	8640
taacagccca	cgcgccgagg	ccacctggg	aggatttggc	tccctgggcc	tggactgcga	8700
gcctagaaca	ggcctggact	tctccgatct	gtactatctg	accatgaaca	ataagcactg	8760
gctggtgac	aaggagtgg	ttcacgacat	cccactgcca	tggcacgcag	gagcagatac	8820
aggaacccca	cactggaaca	ataaggaggc	cctggtggag	ttcaaggatg	cccacgcca	8880
gaggcagaca	gtggtgggtg	tgggcagcca	ggagggagca	gtgcacaccg	ccctggcagg	8940
cgccctggag	cccagatgg	acggagcaaa	gggcccctg	tctagcggcc	acctgaaatg	9000
ccgctgaag	atggataagc	tgagactgaa	gggctgtcc	tactctctgt	gcacagccgc	9060
cttcaccttc	accaagatcc	ctgcccagac	actgcacggc	acagtgcacc	tggaggtgca	9120
gtatgccggc	acagacggcc	cctgtaaggt	gctgcccag	atggccgtg	atatgcagac	9180
actgaccctc	gtggcgagcc	caatccagtg	atcacagagt	ccaccagaaa		9240
ctctaagatg	atgctggagc	tggaccccc	ttttggcgat	agctataatg	tgatcggcgt	9300
gggcgagaag	aagatcacac	accaactggca	ccgcagcggc	tccacaatcg	gcaaggcctt	9360
tgaggccacc	gtgaggggag	caaagaggat	ggccgtgctg	ggcgacaccg	catgggattt	9420
cggtccgtg	gtggcgagcc	tgaactctct	gggcaagggc	atccaccaga	tcttcggcgc	9480
cgctttaa	tcctgtttc	gcggcatgtc	ttggtttagc	cagatcctga	tggcacact	9540
gctgatgtg	ctgggctctg	acaccaagaa	tggtctatc	agcctgatgt	gcttggccct	9600
gggagcgtg	ctgatcttcc	tgagcaccgc	cgtgtccgcc	tgatgataag	gcgcgccacc	9660
ccacggccg	cacagagctg	caattggcaa	gctgcttaca	tagaactcgc	ggcgattggc	9720
atgccgcctt	aaaattttta	ttttattttt	ctttctttt	ccgaaatcgga	ttttgttttt	9780
aatatttcaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	agagcgttta	9840

-continued

```

aacacgtgat atctggcctc atgggccttc ctttcaactgc ccgctttcca gtcgggaaac 9900
ctgtcgtgcc agctgcatta acatgggcat agctgtttcc ttgcgtattg ggcgctctcc 9960
gcttcctcgc tcaactgactc gctgogctcg gtctgtccgg taaagcctgg ggtgcctaata 10020
gagcaaaaagg ccagcaaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcggttttcc 10080
ataggctccg ccccccctgac gacatcaca aaaaatcgacg ctcaagttag aggtggcgaa 10140
acccgacagg actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc 10200
ctgttccgac cctgcccctt accggatacc tgtcccctt tctcccctcg ggaagcgtgg 10260
cgctttctca tagctcaagc tgtaggatc tcagttcgtt gtaggtcgtt cgtccaagc 10320
tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc gtaactatc 10380
gtcttgagtc caaccoggta agacacgact tatcgccact ggcagcagcc actggtaaca 10440
ggattagcag agcagagtat gtaggcgggt ctacagagtt cttgaagtgg tggcctaact 10500
acggctacac tagaagaaca gtatttggtt tctgcgctct gctgaagcca gttaccctcg 10560
gaaaagagtg ttgtagctct tgatccggca aacaaccac cgtggttagc ggtgggtttt 10620
ttgtttgcaa gcagcagatt acgcccagaa aaaaaggatc tcaagaagat cctttgatct 10680
tttctacggg gtctgagcct cagtggaaac aaaaactcac ttaagggatt ttggtcatga 10740
atacacggtg cctgactgag tttagcaatt aactgtgata aactaccgca ttaaagctta 10800
tcgatgataa aaatgactct tgatccggca tttagaaaaac tcatcgagca tcaaatgaaa 10860
ctgcaattta ttcataatcag gattatcaat accatatttt tgaaaaagcc gtttctgtaa 10920
tgaaggagaa aactcaccga gccagttcca taggatggca agatcctggt atcggctcgc 10980
gattccgact cgtccaacat caatacaacc tattaatttc ccctcgtcaa aaataaggtt 11040
atcaagttag aaatcaccat gagtgcgac tgaatccggt gagaatggca aaagcttatg 11100
catttcttcc cagactgttt caacaggcca gccattacgc tcgctatcaa aatcactcgc 11160
atcaacaaaa ccgttattca ttcgtgattg ccctgagcag agacgaaata cgcgatcgt 11220
gttaaaagga caattacaaa caggaatcga atgcaaccgg cgcaggaaca ctgccagcgc 11280
atcaacaata ttttcaacct aatcaggata ttcttctaat acctggaaatg ctgttttccc 11340
gggatcgcga gtggtgagta accatgcac atcaggagta cggataaaat gcttgatggt 11400
cgggaagaggc ataaatcccg tcagccagtt tagtctgacc atctcatctg taacatcatt 11460
ggcaacgcta cctttgccat gtttcagaaa caactctggc gcacogggct tccatataca 11520
tcgatagatt gtgcacactg attgcccagc attatcgaga gccatttat accatataa 11580
atcagcatcc atgttggat ttaatcggcg cctcgagcaa gacgtttccc gttgaaatg 11640
gctcataaca cccctgttat tactgtttat gtaagcagac agttttattg tcatgagcg 11700
gatacatatt tgaatgtatt taagaaaaa acaaatagg ggttccgccc acatttccc 11760
gaaaagtgcc acctaatttg taagcgttaa tttttgtta aaattccgct taaattttt 11820
ttaaatacgc tcatttttta accaataggc cgaatcggc aaaaatccct ataaatcaaa 11880
agaatagacc gagatagggg tgaatggcgg ctacagggcg ctcccattcg ccattcaggg 11940
tgcccaactg ttgggaaggc cgtttcgggt cgggcccctt cgtattacg ccagctggcg 12000
aaaggggatg gtgctgcaag gcgattaagt tgggtaacgc cagggtttcc ccagtcacac 12060
gcgtaatacg actcactata g 12081

```

```

SEQ ID NO: 36      moltype = RNA length = 12090
FEATURE           Location/Qualifiers
misc_feature      1..12090
                  note = SAM vector backbone with Zika antigen insert.
source           1..12090
                  mol_type = other RNA
                  organism = synthetic construct

```

```

SEQ ID NO: 36
ataggcggcg catgagagaa gccagacca attacctacc caaaatggag aaagttcacg 60
ttgacatcga ggaagacagc ccattcctca gagctttgca gcgagcttc ccgcagtttg 120
aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcatc 180
tggttcaaaa actgatcgaa acggagggtg acccatccga cacgatcctt gacattggaa 240
gtgcgcccgc ccgcagaatg tattctaagc acaagtatca ttgtatctgt ccgatgagat 300
gtgcggaaga tccggacaga ttgtataagt atgcaactaa gctgaagaaa aactgtaagg 360
aaataactga taaggaattg gacaagaaaa tgaaggagct cgcgcgctg atgagcgacc 420
ctgacctgga aactgagact atgtgcctcc acgacgagca gtctgtctgc tacgaagggc 480
aagtcgctgt ttaccaggat gtatacggcg ttgacggacc gacaagtctc taccaccaag 540
ccaataaggg agttagatc gctactgga taggctttga caccaccctt tttatgttta 600
agaacttggc tggagcatat ccatcactat ctaccaactg ggccagcaga accgtgttaa 660
cggtcgttaa cataggccta tgcagctctg acgttatgga gcggtcacgt agagggatgt 720
ccattcttag aaagaagtat ttgaaacctt ccaacaatgt tctattctct gttggctoga 780
ccatctacca cgagaagagg gacttactga ggagctggca cctgccgtct gtatttcaact 840
tacgtggcaa gcaaaattac acatgtcggg gtgagactat agttagtgc gacgggtacg 900
tcgttaaaag aatagctatc agtccaggcc tgtatgggaa gccttcagcc tatgctgcta 960
cgtgcaaccg ctagggatc ttgtctgca aagtgacaga cacattgaac ggggagaggg 1020
tctcttttcc cgtgtgcagc tatgtgccag ctacattgtg tgaccaaatg actggcatac 1080
tggcaacaga tgtcagtgcg gacgacggcg aaaaactgct ggttgggctc aaccagcgta 1140
tagtctgcaa ggtgcgacc agagagaaca ccaatccat gaaaaattac cttttgccc 1200
tagtgcccca cggatttgct aggtgggcaa aggaatataa ggaagatcaa gaagatgaaa 1260
ggccactagg actacagat agacagttag tcatgggggt ttgttgggct tttagaaggc 1320
acaagataac atctatttat aagcgcggc ataccctaac catcatcaaa gtgaacagcg 1380

```

-continued

atctccactc	attcgtgctg	cccagatag	gcagtaaac	attggagatc	ggcctgagaa	1440
caagaatcag	gaaaaatgta	gaggagcaca	aggagccgtc	acctctcatt	accgcccagg	1500
acgtacaaga	agctaagtgc	gcagccgatg	aggctaagga	ggctcgtgaa	gccgaggagt	1560
tgccgcgagc	tctaccacct	ttggcagctg	atgttgagga	gcccactctg	gaagccgatg	1620
tcgacttgat	gttacaagag	ctcggggccc	gctcagtgga	gacacctcgt	ggcttgataa	1680
agggtaccag	ctacgatggc	gaggacaaga	tcggctctta	cgctgtgctt	tctccgcagg	1740
ctgtactcaa	gagtgaaaaa	ttatcttgca	tccaccctct	cgctgaacaa	gtcatagtga	1800
taacacactc	tggccgaaaa	ggcggttatg	cogtgaacc	ataccatggt	aaagtagtgg	1860
tgccagaggg	acatgcaata	cccgccaggg	actttcaagc	tctgagtgaa	agtgccacca	1920
ttgtgtacaa	cgaacgtgag	ttcgtaaaca	ggtacctgca	ccatattgcc	acacatggag	1980
gagcgctgaa	cactgatgaa	gaatattaca	aaactgtcaa	gcccagcgag	cacgacggcg	2040
aatacctgta	cgacatcgac	aggaacacgt	cgctcaagaa	agaactagtc	actgggctag	2100
ggctcacagg	ggactcagtg	gctcctccct	tccatgaatt	cgccctacgag	agtctgagaa	2160
cacgaccagc	cgctccttac	caagtaccaa	ccataggggt	gtatggcgtg	ccaggatcag	2220
gcaagtctgg	catcattaaa	agcgcagtca	ccaaaaaaga	tctagtggtg	agcggccaaga	2280
aagaaaactg	tgcagaaatt	ataagggacg	tcaagaaaaa	gaaagggctg	gacgtcaatg	2340
ccagaactgt	gaactcagtg	ctcttgaatg	gatgcaaaaca	ccccgtagag	accctgtata	2400
ttgacgaagc	ttttgcttgt	catgcaggta	ctctcagagc	gctcatagcc	attataagac	2460
ctaaaaaggg	agtgtctctg	ggggatccca	aaactgtcgg	tttttttaac	atgatgtgcc	2520
tgaaagtgca	ttttaaccac	gagatttgca	cacaagtctt	ccacaaaagc	atctctcgcc	2580
gttgcaactaa	atctgtgact	tcggctgctc	caacctgtgt	ttacgacaaa	aaaatgagaa	2640
cgacgaatcc	gaaagagact	aagattgtga	ttgacactac	cggcagtacc	aaacctaaagc	2700
aggacgatct	cattctcact	tgtttcagag	ggtgggtgaa	gcagttgcaa	atagattaca	2760
aaggcaacga	aataatgacg	gcagctgcct	ctcaagggct	gacccgtaaa	ggtgtgtatg	2820
ccggttcgta	caaggtgaaat	gaaaatcctc	tgtacgcacc	cacctcagaa	catgtgaacg	2880
tcctactgac	ccgcacggag	gaccgcacog	tgtggaaaac	actagccggc	gacccatgga	2940
taaaaact	gactgccaag	taccctggga	atctcactgc	cacgatagag	gagtggcaag	3000
cagagcatga	ggccatcatg	aggcacatct	tggagagacc	ggaccctacc	gacgtcttcc	3060
agaataaggg	taacogtgtgt	tgggccaagg	cttttagtgc	ggtgtcgaag	accgctggca	3120
tagacatgac	cactgaacaa	tggaaactg	tggattattt	tgaaacggac	aaagctcact	3180
cagcagagat	agtattgaac	caactatcog	tgaggttctt	tggactcgat	ctggactccg	3240
gtctattttc	tgcaccact	gttcogttat	ccattagtaa	taactactgg	gataactccc	3300
cgctgcctaa	actgtacggg	ctgaataaag	aagtggctcg	tcagctctct	cgcaggtacc	3360
cacaactgcc	tcgggcagtt	gccactggaa	gagcttatga	catgaacact	ggtacactgc	3420
gcaattatga	tccgcgcata	aacctagtac	ctgtaaacag	aagactgcct	catgctttag	3480
tcctccacca	caatgaacac	ccacagagtg	acttttcttc	atctcgtcagc	aaattgaagg	3540
gcagaaactgt	tcctgggtgct	ggggaaaaag	tgtccgtccc	aggcaaaaag	ggtgactggt	3600
tgtcagaccg	gcctgaggct	accttcagag	ctcggctgga	tttaggcac	ccaggtgatg	3660
tgcccaaata	tgacataata	tttgtaaatg	tgaggacccc	atataaatac	catcactatc	3720
agcagtgatg	agccatgacc	attaagccta	gcagtgtgac	caagaaagct	tgtctgcatc	3780
tgaatcccgg	ggaaacctgt	gtcagcatag	gttatgggta	cgctgacagg	gccagcgaaa	3840
gcatcattgg	tgtctatagc	cggcagttca	agttttccc	ggtatgcaaa	ccgaaatcct	3900
cacttgaaga	gacggaagtt	ctgtttgtat	tcattgggta	cgatcgcag	gcccgtacgc	3960
acaatcctta	caagctttca	tcaaccttga	ccaacattta	tacaggttcc	agactccacg	4020
aagccggatg	tgcaccctca	tatcatgtgg	tgcgagggga	tattgcccag	gccaccgaa	4080
gagtgatatt	aaatgctgct	aaacagcaag	gacaacctgg	cgaggggggtg	tcgagagcgc	4140
tgtataagaa	attcccggaa	agcttcgatt	tacagccgat	cgaagttaga	aaagcgcgac	4200
tggtaaaagg	tcagactaaa	catatcattc	atgcccgtag	accaaacttc	aacaaagtgt	4260
cggaggttga	agggtgacaaa	cagttggcag	aggcttatga	gtccatcgct	aagattgtca	4320
acgataacaa	ttacaagtca	gtagegattc	cactgttgtc	caccggcacc	ttttccggga	4380
acaaaagatc	actaacccaa	tcattgaacc	atltgtgtac	agctttagac	accactgatg	4440
cagatgtagc	catatactgc	agggacaaga	aatgggaaat	gactctcaag	gaagcagtg	4500
ctaggagaga	agcagtgagg	gagataatga	tatccgacga	ctcttcagtg	acagaacctg	4560
atgcagagct	ggtgaggggtg	catccgaaga	gttctttggc	tggaaagga	ggctacagca	4620
caagcagatg	caaaaacttc	tcataatttg	aagggaccaa	gtttccaccg	gocggcaagg	4680
atatagcaga	aaataactgc	atgtgcccgc	ttgcaacgga	ggccaaatgag	caggtatgca	4740
tgtatctcct	cggagaaagc	atgagcagta	ttaggtcgaa	atgcccgcgc	gaagagtccg	4800
aagcctccac	accacctagc	acgctgcctt	gcttgtgcat	ccatgccatg	actccagaaa	4860
gagtacagcg	cctaaaagcc	tcacgtccag	aacaaattac	tgtgtgctca	tcctttccat	4920
tgccgaagta	tgacatcaact	gggtgtcaga	agatccaatg	ctcccagcct	atattgttct	4980
caccgaaagt	gcctgcgtat	atctatccaa	ggaagtatct	cggtgaaaca	ccaccggtag	5040
acgagactcc	ggagccatcg	gcagagaacc	aatccacaga	ggggacacct	gaacaaccac	5100
cacttataac	cgaggatgag	accaggacta	gaacgcctga	gcccgatcac	atcgaagagg	5160
aagaagagga	tagataactg	ttgtctcag	atggcccga	ccaccaggtg	ctgcaagtcc	5220
aggcagacat	tcacggggcc	ccctctgtat	ctagctcatc	ctggctcatt	cctcatgcat	5280
ccgactttga	tgtggacagt	ttatccatac	ttgacaccct	ggagggagct	agcgtgacca	5340
gccccgcaac	gtcagccgag	actaactctt	acttcgcaa	gagtatggag	tttctggcgc	5400
gaccggtgcc	tgcgctcoga	acagatttca	ggaacctcc	acatcccctc	cocgcacaaa	5460
gaacaccgctc	acttgcaacc	agcagggcct	gctcagaaac	cagcctagtt	tccaccccgc	5520
caggcgtgaa	tagggtgatc	actagagagg	agctcagggc	gcttaccctc	tcacgcactc	5580

-continued

ctagcaggtc	ggtctcagaga	accagcctgg	tctccaacco	gccaggcgta	aatagggtga	5640
ttacaagaga	ggagtttgag	gcgttcgtag	cacaacaaca	atgacgggtt	gatgcgggtg	5700
catacatctt	ttcctccgac	acoggtcaag	ggcatttaca	acaaaaatca	gtaaggcaaa	5760
cggtgctatc	cgaagtgggt	ttggagagga	cogaattgga	gatttcgtat	gccccgcgc	5820
tcgaccaaga	aaaagaagaa	ttactcgcga	agaaattaca	gttaaatccc	acacctgcta	5880
acagaagcag	ataccagttc	aggaaggtgg	agaacatgaa	agccataaca	gctagacgta	5940
ttctgcaagg	cctaggcctc	tatttgaagg	cagaaggaaa	agtggagtg	taccgaacct	6000
tgcatcctgt	tcctttgtat	tcactatag	tgaaccgtgc	cttttcaagc	cccaaggtcg	6060
cagtggaaag	ctgtaaacgc	aatgtgaaa	agaactttcc	gactgtggct	tcttactgta	6120
ttattccaga	gtacgatgcc	tatttggaca	tggttgacgg	agcttcatgc	tgcttagaca	6180
ctgccagttt	ttgccctgca	aagctgcgca	gctttccaaa	gaaacactcc	tatttggaac	6240
ccacaatacg	atcggcagtg	ccttcagcga	tccagaacac	gctccagaac	gtcctggcag	6300
ctgccacaaa	aagaaattgc	aatgtcacgc	aaatgagaga	attgcccgta	ttggattcgg	6360
cgccctttaa	tgtggaatgc	ttcaagaaat	atgctgtaa	taatgaatat	tggaacagt	6420
ttaaagaaaa	cccctacag	cttactgaag	aaaacgtggt	aaattacatt	accaaatata	6480
aaggacaaa	agctgctgct	ctttttgcca	agacacata	tttgaatatg	ttgcaggaca	6540
taccaatgga	caggtttgta	atggacttaa	agagagacgt	gaaagtga	ccaggaacaa	6600
aacatactga	agaacggccc	aaggtacagg	tgatccagc	tgccgatccg	ctagcaacag	6660
cgtatcctgt	cggaaatcac	cgagagctgg	ttaggagatt	aaatgcccgc	ctgcttccga	6720
acattcatac	actgtttgat	atgtcggctg	aagactttga	cgctattata	gccgagcact	6780
tccagcctgg	aggattgtgt	ctggaaactg	acatcgcgct	gtttgataaa	agtgaggacg	6840
acgccatggc	tctgaccgcg	ttaatgattc	tggaaagact	aggtgtggac	gcagagctgt	6900
tgacgctgat	tgaggcggct	ttcggcgaaa	tttcatcaat	acatttgccc	actaaaaacta	6960
aattttaaatt	cggagccatg	atgaaatctg	gaatgttctc	cacactgttt	gtgaacacag	7020
tcattaaacat	tgttaatgca	agcagagtg	tgagagaacg	gctaaccgga	tcaccatgtg	7080
cagcattcat	tggagatgac	aatatcgtga	aaggagtcaa	atcggacaaa	ttaatggcag	7140
acaggtgcgc	cacctggttg	aatatggaag	tcaagattat	agatgctgtg	gtggcgagaga	7200
aagcgcctta	tttctgtgga	gggtttattt	tgtgtgactc	cgtgaccggc	acagcgtgcc	7260
gtgtggcaga	ccccctaaaa	aggctgttta	agcttgccaa	acctctggca	gcagacgatg	7320
aacatgatga	tgacaggaga	agggcattgc	atgaagagtc	aacaogctgg	aaccgagttg	7380
gtattctctc	agagctgtgc	aagggcagtag	aatcaaggtg	tgaaacctga	ggaacttcca	7440
tcatagttat	ggcctatgca	actctagcta	gcagtgttaa	atcattcagc	tacctgagag	7500
gggccccctat	aactctctac	ggctaacctg	aatggactac	gacatagtct	agtcggccaa	7560
gatgggcaag	cggtccgccc	gctctatcat	gtggctggcc	tctctggccc	tggtcatcgc	7620
atgcccagga	gcagcggagg	tcaccaggag	agggcagccc	tactatagt	acctggacag	7680
aaatgatgcc	ggcggagcca	tcagctttcc	caccacactg	ggcatgaaca	agtgttacct	7740
ccagatcatg	gacctgggcc	acatgtgcga	tgccaccatg	tcctatgagt	gtccaatgct	7800
ggacgagggc	gtggagccc	acgatgtgga	ttgctggtgt	aataccacat	ccacatgggt	7860
ggtgtacggc	acctgcccac	acaagaaggg	agaggcaagg	cgctctcgga	gagcagtgac	7920
actgccttcc	cactctacc	ggaaagctgca	gacaagatct	cagacctggc	tggagagccc	7980
ggagtataca	aagcacctga	tcgggttga	gaactggatc	tttagaaatc	caggattcgc	8040
actggcagca	gcagcaatcg	catggctgct	gggcagctcc	acctcccaga	aagtgatcta	8100
cctggtcatg	atcctgctga	tgcccctgc	ctattccatc	aggtgcacg	gcgtgtctaa	8160
tcgagacttc	gtggaggcca	tctctggggc	cacctgggtg	gatgtggtgc	tggagcaccg	8220
cggtgctgtg	acagtgatgg	cccaggacaa	gccaaccgtg	gacatcgagc	tggtgaccac	8280
aaccgtgagc	aacatggccc	aggtgcggtc	ctactgctat	gaggccagca	tctccgacat	8340
ggcctctgat	agcagatgct	ccaccaggg	cgaggcctac	ctggacaagc	agtctgatac	8400
acagtacgtg	tgcagagaga	ccctgttga	caggggatgg	ggaaatggat	gtggcctggt	8460
tggcaagggc	agcctgttga	catgcccga	gttcgctgt	tctaagaaga	tgaccggcaa	8520
gagcatccag	ccagagaacc	tggagtaccg	gatcatgctg	agcgtgcaag	gcagccagca	8580
ctccggcatg	atcgtgaacc	acacaggcca	cgagacagat	gagaataggg	ccaaggtgga	8640
gatcacacct	aacagcccac	gcgcccaggg	cacctggga	ggatttggct	ccctgggcct	8700
ggactgagag	cctagaacag	gctggactt	ctccgatctg	tactatctga	ccatgaacaa	8760
taagcactgg	ctggtgcaca	aggagtgggt	tcacgacatc	ccactgcatc	ggcagcagc	8820
agcagataca	ggaaccccc	actggaacaa	taaggaggcc	ctggtggagt	tcaaggatgc	8880
ccacgccaag	aggcagacag	tgggtgtgct	gggcagcca	gagggagcag	tgacacccgc	8940
cctggcaggg	gcccctggagg	ccgagatgga	cgagcaaa	ggccgctgt	ctagcggcca	9000
cctgaagtgc	cggtcgaaga	tggataagct	gagactgaag	ggcgtgtcct	actctctgtg	9060
cacagccgcc	ttcaccttca	ccaagatccc	tgccagagaca	ctgcacggca	cagtgaccgt	9120
ggaggtgca	tatgcccagc	ctgtaaggtg	cctgcccaga	tgcccctgga	tgcccctgga	9180
tatgcagaca	ctgaccctg	tgggcaggct	gatcaccgcc	aatccagtga	tcacagagtc	9240
caccgagaac	tctaaagatg	tgctggagct	ggacccccct	tttggcgata	gtatatacgt	9300
gatcggcgtg	ggcagaaga	agatcacaca	ccactggcac	cgcagcggct	ccacaatcgg	9360
caaggccttt	gagcagcag	tagggggagc	aaagaggatg	gcccgtgctg	gagacaccgc	9420
atgggatttc	ggctccgtgg	gaggcgcct	gaactctctg	ggcaaggcca	tccaccagat	9480
cttcggcggc	gcctttaaagt	ccctgttcgg	cggcagctct	tggtttagcc	agatccctgat	9540
cggcacactg	ctgatgtggc	tgggctgaa	caccaagaat	ggctctatca	gcctgatgtg	9600
cctggccctg	tgatcttctc	gagcaccgcc	gtgtcccct	gatgataaag	gatgataaag	9660
cgcccccacc	cagcggccgc	atcacagcgc	aatggcaag	ctgcttacct	agaactcggc	9720
gcgattggca	tgccgcctta	aaatttttat	tttatttttc	ttttcttttc	cgaatcggat	9780

-continued

tttgTTTTA	atatttcaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	9840
gagcgTTTTA	acacgtgata	tctggcctca	tgggccttcc	tttcaactgc	cgctttccag	9900
tCGGGAAACC	tgtcgtGCCA	gctgcattaa	catggtcata	gctgtttcct	tcggtattgg	9960
gcgctctccg	cttctcgtct	cactgactcg	ctgcgctcgg	tcggtcgggt	aaagcctggg	10020
gtgcctaata	gacaaaagcc	agcaaaaagg	ccaggaaccg	taaaaaggcc	gcgttgctgg	10080
cgTTTTTCCA	taggctccgc	ccccctgacg	agcatcacia	aaatcgagcc	tcaagtcaga	10140
ggtggcGAAA	cccGACAGGA	ctataaagat	accagcgctt	tccccctgga	agctccctcg	10200
tgcgctctcc	tgttccgacc	ctgcgcctta	cggataacct	gtccgccttt	ctcccttcgg	10260
gaagcgtggc	gctttctcat	agctcacgct	gtaggtatct	cagttcggtg	taggtcgttc	10320
gctccaagct	gggctgtgtg	cacgaacccc	ccgttcagcc	cgaccgctgc	gccttatccg	10380
gtaactatcg	tcttgagtc	aacccggtaa	gacacgactt	atcgccactg	gcagcagcca	10440
ctggtaacag	gattagcaga	gcgaggtatg	taggcggtgc	tacagagttc	ttgaagtgg	10500
ggcctaacta	tcgaacagcc	agaagaacag	tatttggtat	ctgcgctctg	ctgaagccag	10560
ttaccttcgg	aaaaagagtt	ggtagctctt	gatccggcaa	acaaaccacc	gctggtagcg	10620
gtggtTTTTT	tgTTTGAAG	cagcagatta	cgcgagaaa	aaaaggatct	caagaagatc	10680
ctttgatctt	ttctacggg	tctgacgctc	agtggaaaca	aaactcacgt	taagggattt	10740
tggtcatgaa	gtccagctgc	ctgactgcgt	tagcaattta	actgtgataa	actaccgcat	10800
taaagcttat	cgatgataag	ctgtcaaca	tgagaattct	tagaaaaact	catcgagcat	10860
caaatgaaac	tgcaatttat	tcatatcagg	attatcaata	ccatattttt	gaaaaagccg	10920
tttctgtaat	gaaggagaaa	actcacccgag	gcagttccat	aggatggcaa	gatcctggta	10980
tcggctctcg	attccgactc	gtccaacatc	aatacaacct	attaatttcc	cctcgtcaaa	11040
aataaggtta	tcaagtgaga	aatcaccatg	agtgaagact	gaatccggtg	agaatggcaa	11100
aagcttatgc	atttctttcc	agacttggtc	aacaggccag	ccattacgct	cgtcacataa	11160
atcactcgca	tcaaccaaac	cgttattcat	tcgtgattgc	gcctgagcga	gacgaaatac	11220
gcgatcgcgt	gtaaaaggac	aattcaaac	aggaatcgaa	tgcaaccggc	gcaggaacac	11280
tgccagcgca	tcaacaatat	tttcacctga	atcaggatat	tcttctaata	cctggaatgc	11340
tgTTTTCCCG	gggatcgcag	tggtgagtaa	ccatgatca	tcaggagtac	ggataaaatg	11400
cttgatggtc	ggaagaggca	taaattccgt	cagccagttt	agtctgacca	tctcatctgt	11460
aacatcattg	gcaacgctac	ctttgccatg	tttcagaaac	aaactctggc	catcgggctt	11520
cccatacaat	cgatagattg	tcgcacctga	ttgcccgaca	ttatcgcgag	cccatttata	11580
cccataataa	tcagcatcca	tgTTTGAATT	taatcgcgcc	ctcagagca	acgTTTTCCCG	11640
ttgaatatgg	ctcaataaac	ccctgttatt	actgtttatg	taagcagaca	gTTTTATTGT	11700
tcatgagcgg	atacatattt	gaatgtattt	agaaaaataa	acaaataggg	gttccgcgca	11760
catTTCCCG	aaaagtGCCA	cctaaattgt	aagcgttaat	atTTTGTAA	aattcgcgctt	11820
aaattTTTGT	taaatcagct	catTTTTTAA	ccaataggcc	gaaatcggca	aaatccctta	11880
taaatcaaaa	gaatgacccg	agataggggt	gagTGGCCG	tacagggcgc	tccattcgc	11940
caatcaggct	gcgcaactgt	tggaagggc	gtttcgggtc	gggcctcttc	gctattacgc	12000
cagctggcga	aagggggatg	tgctgcaagg	cgattaagtt	gggtaacgcc	agggttttcc	12060
cagtcacacg	cgtaatacga	ctcaactatag				12090

```

SEQ ID NO: 37      moltype = RNA length = 12090
FEATURE           Location/Qualifiers
misc_feature      1..12090
                  note = SAM vector background with Zika antigen insert.
source           1..12090
                  mol_type = other RNA
                  organism = synthetic construct
    
```

ataggcggcg	catgagagaa	gccagacca	attacctacc	caaaatggag	aaagttcacg	60
ttgacatcga	ggaagacagc	ccattcctca	gagctttgca	gcggagcttc	ccgcagtttg	120
aggtagaagc	caagcaggtc	actgataatg	accatgctaa	tgccagagcg	ttttcgcate	180
tggcttcaaa	actgatcgaa	acggagggtg	acccatccga	caogatcctt	gacattggaa	240
gtgcgccccg	ccgcagaatg	tattctaagc	acaagtatca	ttgtatctgt	ccgatgagat	300
gtgcggaaga	tccggacaga	ttgtataagt	atgcaactaa	gctgaagaaa	aactgtaagg	360
aaataactga	taaggaattg	gacaagaaaa	tgaaggagct	cgccgcgctc	atgagcgacc	420
ctgacctgga	aaactgagact	atgtcctccc	acgacgacga	gtcgtgtcgc	tacgaagggc	480
aagtcgctgt	ttaccaggat	gtatacggg	ttgacggacc	gacaagtctc	tatcaccaag	540
ccaataaggg	agttagagtc	gcctactgga	taggctttga	caccaccctc	tttatgttta	600
agaacttggc	tggagcatal	ccatcatact	ctaccaactg	ggccgacgaa	accgtgttaa	660
cggtcgttaa	catagcccta	tcagctctcg	acgttatgga	gcggctcacgt	agagggatgt	720
ccattcttag	aaagaagtat	ttgaaacat	ccaacaatgt	tctattctct	gttggctcga	780
ccatctacca	cgagaagagg	gacttactga	ggagctggca	cctgccctct	gtatttcact	840
tacgtggcaa	gcaaaattac	acatgtcgg	gtgagactat	agttagttgc	gacgggtacg	900
tcgTTAAAG	aaatagctatc	agtcaggcc	tgtatgggaa	gccttcaggc	tatgctgcta	960
cgatgcaccg	cgagggatc	ttgtgctgca	aagtgcagca	cacattgaac	ggggagaggg	1020
tctcttttcc	cgTGTGACG	tatgtgccag	ctacattgtg	tgaccaaag	actggcatac	1080
tggcaacaga	tgTcagTgc	gacgacgcgc	aaaaactgct	ggttgggctc	aaccagcgta	1140
tagtcgtcaa	cggtcgcacc	caagaaaca	ccaataccat	gaaaaattac	cttttgcccc	1200
tagtgcccca	ggcatttct	aggtgggcaa	aggaatataa	ggaagatcaa	gaagatgaaa	1260
ggccactagg	actacgagat	agacagttag	tcatgggggtg	ttgttgggct	tttagaaggc	1320

-continued

acaagataac	atctatttat	aagcgcccg	ataccctaac	catcatcaaa	gtgaacagcg	1380
atctccactc	atctgtgctg	cccaggatag	gcagtaacac	attggagatc	gggctgagaa	1440
caagaatcag	gaaaatgtta	gaggagcaca	aggagccgctc	acctctcatt	accgccgag	1500
acgtacaaga	agctaagtgc	gcagccgatg	aggctaagga	gggtcgtgaa	gccgaggagt	1560
tgccgcgagc	tctaccacct	ttggcagctg	atggtgagga	gccactctcg	gaagccgatg	1620
tcgacttgat	gttacaagag	gctggggccg	gctcagtgga	gacacctcgt	ggcttgataa	1680
aggttaccag	ctacgatggc	gaggacaaga	tcggctctta	cgctgtgctt	tctccgcagg	1740
ctgtactcaa	gagtgaaaaa	ttatcttgca	tccacctctc	cgctgaacaa	gtcatagtga	1800
taacacactc	tggccgaaaa	gggcttatg	ccgtggaacc	ataccatggt	aaagtagtgg	1860
tgccagaggg	acatgcaata	cccgtccagg	actttcaagc	tctgagtga	agtgccacca	1920
ttgtgtacaa	cgaacgtgag	ttcgtaaaca	ggtacctgca	ccatattgcc	acacatggag	1980
gagcgtgaa	cactgatgaa	gaatattaca	aaactgtcaa	gccacgcgag	cacgacggcg	2040
aatacctcta	cgcacgaact	aggaaacagt	gcgtcaagaa	agaactagtc	actgggctag	2100
ggctcacagg	cgagctggg	gatcctccct	tccatgaatt	cgctacagag	agtctgagaa	2160
cacgaccagc	cgctccttac	caagtaccaa	ccataggggt	gtatggcgtg	ccaggatcag	2220
gcaagtctgg	catcattaaa	agcgcagtea	ccaaaaaaga	tctagtggg	agcgccaaga	2280
aagaaaaactg	tgccagaaat	ataagggagc	tcaagaaaat	gaaagggctg	gacgtcaatg	2340
ccagaactgt	ggactcagtg	ctcttgaatg	gatgcaaca	ccccgtagag	accctgtata	2400
ttgacgaagc	ttttgcttgc	catgcaagta	ctctcagagc	gctcatagcc	attataagac	2460
ctaaaaaggc	agtgcctcgt	ggggatccca	aacagtgccg	tttttttaac	atgatgtgcc	2520
tgaaaagtga	ttttaaccac	gagatttga	cacaagtctt	ccacaaaagc	atctctgcc	2580
gttgactaa	atctgtgact	tcggctcgtc	caacctgtt	ttacgacaaa	aaaaatgagaa	2640
cgacgaatcc	gaaagagact	aagatttga	ttgacactac	cggcagtagc	aaacctaaagc	2700
aggacgatct	catctcactc	tgcttcagag	ggggggtgaa	gcagttgcaa	atagattaca	2760
aaggcaacga	aataatgacg	cgagctgctc	ctcaagggct	gacccgtaaa	ggtgtgtatg	2820
ccgttcggta	caaggtgaat	gaaaaactc	tgtacgcacc	cacctcagaa	catgtgaacg	2880
tcctactgac	ccgcacggag	gaccgatcgt	tgtgaaaaac	actagccggc	gacccatgga	2940
taaaaaactc	gactgccaag	taccctggga	atctcactgc	caagatagag	gagtggcaag	3000
cagagcatga	tgcatacatg	aggcacatct	tggagagacc	ggaccctacc	gacgtcttcc	3060
agaataaggc	aaacgtgtgt	tgggccaagg	ctttagtgcc	gggtcgtgag	accgctggca	3120
tagacatgac	cactgaacaa	tggaaactc	tggattatct	tgaaacggac	aaagctcaact	3180
cagcagagat	agatagcaac	caactatgct	tgaggtctct	tggactcgat	ctggactccc	3240
gtctatcttc	gttaccactc	gttcogttat	ccattagtaa	taatcactgg	gataactccc	3300
cgctgcctaa	catgtacggg	ctgaataaag	aagtgttccg	tcagctctct	cgcaggtacc	3360
cacaactgcc	tcgggcagtt	gcaactggaa	gagctctatg	catgaacact	ggtacactgc	3420
gcaattatga	tcggcgata	aacctagtag	ctgtaaacag	aagactgctc	catgctttag	3480
tcctccacca	taatagaac	ccacagagtg	acttttcttc	atctgtcagc	aaattgaagg	3540
gcagaactgt	cctgggtggtc	ggggaaaagt	tgtccgtccc	aggcaaaatg	ggtgactggt	3600
tgtcagaccg	gcctgagggc	acctcagag	ctcggctgga	tttaggcac	ccaggtgatg	3660
tgcccaata	tgacataata	ttgttaatg	tgaggacccc	atataaatac	catcactatc	3720
agcagtgta	agaccatgct	attaagctta	gcattgtgac	caagaaaagt	tgtctgcac	3780
tgaatcccgg	cggaacctgt	gtcagcatag	gttatgggta	cgctgacag	gccagcgaaa	3840
gcacatctgg	tgctatagcg	cgccagttca	agttttcccg	ggatgcaaa	ccgaaatcct	3900
cacttgaaga	caaggaagtt	ctgtttgtat	tcattgggta	cgatcgcaag	gcccgtagcg	3960
acaactcctta	gacgctttca	tcaaccttga	ccaacattta	tacaggttcc	agactccacg	4020
aagccggatg	tgcacctca	tatcatgtgg	tgccagggga	tattgccacg	gccaccgaag	4080
gagtgattat	aaatgctgct	aacagcaaa	gacaacctgg	cgagggggtg	tgccggagcg	4140
tgtaataaga	atcccgga	agcttcgatt	tacagccgat	cgaagtagga	aaagccgac	4200
tggtcaaagg	tgcaactaaa	catatcattc	atgccgtagg	accaaaactc	aaacaaagt	4260
cgagggttga	agggtgacaaa	cagttggcag	aggcttatga	gtccatcgct	aagattgtca	4320
acgataacaa	ttacaagtca	gtagcgattc	cactgttctc	caccggcacc	ttttccggga	4380
acaaagatcg	actaacccaa	tcattgaacc	atctgtgac	agctttagac	accactgatg	4440
cagatgtagc	catatactgc	agggacaaga	aatgggaaat	gactctcaag	gaagcagtg	4500
ctaggagaga	agcagtgagg	gagatagca	tatccgacga	ctcttcagtg	acagaacctg	4560
atgcagagct	gggtgagggg	ctccogaaga	gttctttggc	tggaaagga	ggctacagca	4620
caagcgatgg	caaaactttc	tcataatttg	aagggaacaa	gtttcaccag	gcccgaagg	4680
atatagcaga	aatatagctc	atgtggcccg	ttgcaacgga	ggccaatgag	caggtatgca	4740
tgtatctcct	cgagaaagc	atgagcagta	ttaggtcgaa	atgccccgct	gaagagtcgg	4800
aagcctccac	accacctagc	acgctgctt	gcttgtgcat	ccatgccatg	actccagaaa	4860
gagtacagcg	ctcaaaagcc	tcagctccag	aacaataatc	tggtgtgctc	tcctttccat	4920
tgccgaagta	tagaatcact	gggtgtgcaga	agatccaatg	ctcccagcct	atattgttct	4980
caccgaaagt	gcctgcgtat	atccatccaa	ggaagtatct	cggtgaaaca	ccaccggtag	5040
acgagactcc	ggagccatcg	gcagagaacc	aatccacaga	ggggacacct	gaacaaccac	5100
cacttataac	cgaggatgag	accaggacta	gaacgcctga	gccgatcacc	atcgaaagag	5160
aagaagagga	tagcataagt	ttgctgtcag	atggcccagc	ccaccaggtg	ctgcaagtcg	5220
aggcagacat	tcacgggccc	ccctctgtat	ctagctcacc	ctggtccatt	cctcatgcat	5280
ccgacttga	tgtggacagt	ttatccatac	ttgacacctc	ggagggagct	agcgtgacca	5340
gcccggcaac	gtcagccgag	acttccgaaa	gagataggg	tttctggcgc		5400
gaccgggtgc	tgccgctcga	acagatttca	ggaacctcc	acatcccgtc	ccgcgcacaa	5460
gaacaccgctc	acttgcaacc	agcagggcct	gctcgagaac	cagcctagtt	tccaccgccg	5520

-continued

caggcgtgaa	taggggtgac	actagagagg	agctcgaggc	gcttaccocg	tcacgcactc	5580
ctagcaggtc	gggtctcgaga	accagcctgg	tctccaaccc	gccaggcgta	aataggggtg	5640
ttacaagaga	ggagtttgag	gcgttcgtag	cacaacaaca	atgaccggtt	gatgcccggg	5700
catacatctt	tctctccagc	accoggtcaag	ggcatttaca	acaaaaatca	gtaaggcaaa	5760
cggtgctatc	cgaagtggtg	ttggagagga	ccgaattgga	gatttcgfat	gccccgcgcc	5820
tcgaccaaga	aaaagaagaa	ttactacgca	agaaattaca	gttaaatccc	acacctgcta	5880
acagaagcag	ataccagtc	aggaaggtgg	agaacatgaa	agccataaca	gctagacgta	5940
ttctgcaagg	cctagggcat	tatttgaagg	cagaaggaaa	agtggagtg	taccgaacce	6000
tgcatcctgt	tcctttgtat	tcattctagt	tgaaccgtgc	cttttcaagc	cccaaggtcg	6060
cagtggaagc	ctgtaacgcc	atgttgaaag	agaactttcc	gactgtggct	tcttactgta	6120
ttattccaga	gtacgatgcc	tatttggaca	tggttgacgg	agcttcacgc	tgcttagaca	6180
ctgccagttt	ttgccctgca	aagctgcgca	gctttccaaa	gaaacactcc	tatttggaac	6240
ccacaatac	atcgtgcagt	cttctcagca	tccagaacac	gctccagaac	gtcctggcag	6300
ctgccacaaa	aagaattg	aatgtcacgc	aaatgagaga	attgcccgta	ttggattcgg	6360
cggcctttaa	tgtggaatgc	ttcaagaaat	atgctgtgaa	taatgaatat	tgggaaacgt	6420
ttaaagaaaa	ccccatcagg	cttactgaag	aaaacgtggt	aaattacatt	accaaattaa	6480
aaggaccaaa	agctgtgct	ctttttgca	agacacataa	tttgaatatg	ttgcaggaca	6540
taccaatgga	caggtttgta	atggacttaa	agagagacgt	gaaagtgact	ccaggaacaa	6600
aacatactga	agaacggccc	aaggtacagg	tgatccagcc	tgccgatccg	ctagcaacag	6660
cgtatctgtg	cggaaatccac	cgagagctgg	ttaggagatt	aaatgcccgc	ctgcttccga	6720
acattcaatc	actgtttgat	atgctcggct	aagactttga	cgctattata	gccgagcact	6780
tccagcctgg	ggattgtggt	ctggaactg	acatcgcgtc	gtttgataaa	agtgaggacg	6840
acgccatggc	tctgaccgcg	ttaatgattc	tggaaagact	aggtgtggac	gcagagctgt	6900
tgacgctgat	tgaggcggct	ttcggcgaaa	tttcatcaat	acatttgccc	actaaaacta	6960
aatttaaatt	cggagccatg	atgaaatctg	gaatgttcc	cacactgttt	gtgaaacacag	7020
tcattaacat	tgtaatcgca	agcagaggtg	tgagagaacg	gctaaccgga	tcaccatgtg	7080
cagcattcat	tggagatgac	aatatcgtga	aaggagtcaa	atcggacaaa	ttaatggcag	7140
acaggtgcgc	ccactgggtg	aatatggaag	tcaagattat	agatgctgtg	gtgggagaga	7200
aagcgcctta	tttctgtgga	gggtttattt	tgtgtgactc	cgtagccggc	acagcgtgcc	7260
gtgtggcaga	ccccctaaaa	aggctgttta	agcttggcaa	acctctggca	gcagacgatg	7320
aacatgatga	tgacaggaga	agggcattgc	atgaagagtc	aacacgcctg	aaccgagttg	7380
gtattctttc	agagctgtgc	aaggcagtag	aatcaaggta	tgaaacgcta	ggaacttcca	7440
tcatagttat	ggcctatgca	actctagcta	gcagtgtaaa	atcattcagc	tacctgagag	7500
gggcccctat	aactctctac	ggctaacctg	aatggactac	gacatagtct	agtccgcaa	7560
gatgggcaag	cggctccggc	gctctatcat	gtggctggcc	tctctggccg	tggtcatcgc	7620
atgcgcagga	ggcggggcca	tcaccaggag	aggcagcgcc	tactatatgt	acctggacag	7680
aaatgatgcc	ggcggaggcca	tcagctttcc	caccacactg	ggcatgaaca	agtgttacct	7740
ccagatcatg	gacctgggcc	acatgtgcga	tgccaccatg	tctatagagt	gtccaatgct	7800
ggacgagggc	gtggagcccg	acgatgtgga	ttgctgggtg	aataccacat	ccacatgggt	7860
ggtgtacggc	acctgccacc	acaagaaggg	agaggcaagg	cgctctcgga	gagcagtgac	7920
actgccttcc	cactctaccc	ggaagctgca	gacaagatct	cagacctggc	tgagagcccg	7980
ggagtataca	aagcacctga	tcgggtgga	gaactggatc	tttagaaatc	caggattcgc	8040
actggcagca	gcagcaatcg	catggctgct	gggcagctcc	acctcccaga	aagtgatcta	8100
cctggctcatg	atcctgtctga	tcgcccctgc	ctattccatc	aggtgcatcg	gcgtgtctaa	8160
tcgcaacttc	gtggagggca	tgtctggcgg	caactgggtg	gatgtgggtc	tgagacacgg	8220
cggtctcgtg	acagtgatgg	cccaggacaa	gccaaccctg	gacatcgagc	tggtgaccac	8280
aacctgtgagc	aacatggccc	aggtgcggtc	ctactgctat	gaggccagca	tctccgacat	8340
ggcctctgat	agcagatgtc	ccaccagggg	cgaggcctac	ctggacaagc	agtctgatac	8400
acagtaoctg	tgcaagagga	ccctgggtga	caggggatgg	ggaaatggat	gtggcctggt	8460
tggaagggc	agcctgtgga	catgcgccaa	gttcgcctgt	tctaagaaga	tgaccggcaa	8520
gagcatccag	ccagagaacc	tggagtaccg	gatcatgctg	agcgtgcacg	gcagccagca	8580
ctccggcatg	atcgtgtaac	acacaggcca	cgagacagat	gagaataggg	ccaaggtgga	8640
gatcacacct	aacagcccac	gcgcgagggc	cacctgggga	ggatttggtc	ccctgggctc	8700
ggactgogag	cctagaacag	gcctggactt	ctccgatctg	tactatctga	ccatgaacaa	8760
taagcactgg	ctggtgcaca	aggagtgggt	tcacgacatc	ccaactgccat	ggcacgcagg	8820
agcagataca	ggaaccccac	actggaacaa	taaggaggcc	ctggtggaat	tcaaggatgc	8880
ccacgcccaag	aggcagacag	tgggtggtgct	gggcagccag	gagggagcag	tgcaaccgcg	8940
cctggcaggg	gcccctggagg	ccgagatgga	cggagcaaa	ggccgcctgt	ctagcggcca	9000
cctgaagtgc	cggtggaaga	tggataagct	gagactgaag	ggcgtgtcct	actctctgtg	9060
cacagccgcc	ttcacttca	ccaagatccc	tgccgagaca	ctgcaccgca	cagtgaccgt	9120
ggaggtgcag	tatgcccggca	cagacggccc	ctgtaagggtg	cctgccccaga	tgcccggtgga	9180
tatgagaca	ctgaccctcg	tgggcaggct	gatcaccgcc	aatccagatg	tcacagagtc	9240
caccgagaac	tctaagatga	tgtctggagct	ggacccccct	tttggcgata	gctatatcgt	9300
gatcggcgtg	gctggaaga	agatcacaca	ccaactggcac	cgcagcggct	ccaccctggg	9360
caaggccttt	agcaccaccc	tgaagggagc	acagaggctg	gccgccctgg	gcgacaccgc	9420
atgggatttc	ggctccatcg	gagcgtgtgt	caactctatc	ggcaaggccg	tgaccaggtg	9480
gttcggcggc	gcctttcggga	ccctgttcgg	cggcatgtct	tggatcacc	agggcctgat	9540
gggcgccctg	ctcctgtgga	tggcgtgaa	cgcccgggac	cggtctatcg	ccctggcctt	9600
cctggccacc	ggaggcgtgc	tgggttcc	ggcccacac	gtgcacgcct	gatgataagg	9660
cgcccccacc	cagcggccgc	atcacagcag	aattggcaag	ctgcttacct	agaactcgcg	9720

-continued

```

cgatttgca tgcgcctta aaatTTTTat tttatTTTTc ttttTTTTc cgaatcggat 9780
ttgtTTTTa atatTTcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaagaa 9840
gagcgtTTaa acacgtgata tctggcctca tgggccttcc tttcactgcc cgctttccag 9900
tcgggaaacc tgtcgtgcca gctgcattaa catggtcata gctgtttcct tgcgtattgg 9960
gcgctctccg ctctctcgct cactgactcg ctgcgctcgg tcgttcgggt aaagcctggg 10020
gtgcctaata agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg 10080
cgTTTTtcca tagctccgc cccctgacg agcatcacia aaatcgacgc tcaagtCaga 10140
ggtggcGaaa cccgacagga ctataaagat accagcggtt tccccctgga agctccctcg 10200
tggctctccc tgttcggacc ctgcccgtta cgggatacct gtcgcctttt ctcctctcgg 10260
gaagcgtggc gctttctcat agctcacgct gtaggtatct cagttcggtg taggtcgttc 10320
gctccaagct gggctgtgtg cacgaacccc cgttcagcc cgaccgctgc gccttatccg 10380
gtaactatcg tcttgagtcg aaccgggtaa gacacgactt atcgccactg gcagcagcca 10440
ctggctaacg gattacgaga gcgaggtatg taggcgggtc tacagagttc ttgaagtgg 10500
ggcctaacta cggctacact agaagaacag tatttggtat ctgcgctctg ctgaagccag 10560
ttacctcggg aaaaagagtt ggtagctctt gatccggcaa acaaacccac gctggtagcg 10620
gtggTTTTt tgtttgcaag cagcagatta cgcgcagaaa aaaaggatct caagaagatc 10680
ctttgatctt ttctacgagg tctgacgctc agtggaacga aaactcacgt taagggattt 10740
tggcatgaa tacacgggtc ctgactgctg tagcaattta actgtgataa actaccgcat 10800
taaagcttat cgatgataag ctgtcaaaCa tgagaattct tagaaaaact catcgagcat 10860
caaatgaaac tgcaatttat tcatatcagg attatcaata ccatatTTTT gaaaaagccg 10920
ttctgtaaat gaaaggagaaa actcaccgag gcagttccat aggatggcaa gatcctggta 10980
tcggtctgog attccgactc gtccaacatc aatacaacct attaatTTcc cctcgtcaaa 11040
aataaggTTa tcaagtgaga aatcaccatg agtgacgact gaatccggtg agaatggcaa 11100
aagcttatgc atttctttcc agacttgTtc aacaggccag ccattacgct cgtcatcaaa 11160
atcactcgca tcaaccaaac cgttattcat tcgtgattgc gcctgagcga gacgaaatac 11220
gcgatcgctg ttaaaaggac aattacaac aggaatcgaa tgcaaccggc gcaggaacac 11280
tgccagcgca tcaacaatat tttcacctga atcaggatat tcttctaata cctggaatgc 11340
tgttttccog gggatcgcag ttgtgagtaa ccatgcatca tcaggagtac ggataaaatg 11400
cttgatggtc ggaagaggca taaattccgt cagccagttt agtctgacca tctcatctgt 11460
aacatcattg gcaacgctac ctttgccatg ttcagaaaac aactctggcg catcgggctt 11520
cccatacaat cgatagattg tcgcacctga ttgcccgaca ttatcgcgag cccatttata 11580
cccataaaa tccagcatcca tgttggatt taatcgcggc ctcgagcaag acgtttcccg 11640
ttgaatatgg ctcataaac cctctgtatt actgtttatg taagcagaca gttttattgt 11700
tcatgagcgg atacatattt gaatgtattt agaaaaataa acaaataggg gttccgcgca 11760
catttccccc aaaaagtcca cctaaattgt aagcgttaat attttgttaa aattcgcggt 11820
aaatTTTTgt taaatcagct catTTTTtaa ccaataggcc gaaatcggca aaatccctta 11880
taaatcaaaa aatagaccg agatagggtt gagtggccgc tacagggcgc tcccattcgc 11940
cattcaggct gcgcaactgt tgggaagggc gtttcggtgc gggcctcttc gctattacgc 12000
cagctggcga aaggggatg tgcTcaagg cgattaagtt gggtaaccgc agggTTTTcc 12060
cagtcacacg cgtAatacga ctcactatag 12090

```

```

SEQ ID NO: 38      moltype = RNA length = 12081
FEATURE           Location/Qualifiers
misc_feature      1..12081
                  note = SAM vector background with Zika antigen insert.
source           1..12081
                  mol_type = other RNA
                  organism = synthetic construct

```

```

SEQ ID NO: 38
ataggcggcg catgagagaa gcccagacca attacctacc caaaatggag aaagttcacg 60
ttgacatcga ggaagacagc ccattcctca gagctttgca gcggagcttc cgcagtttg 120
aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcac 180
tggttcaaa actgatcgaa acggagggtg acccatccga cacgatcctt gacattggaa 240
gtgcgcccg cgcgagaatg tattctaagc acaagtatca ttgtatctgt cogatgagat 300
gtgcggaaga tccggcagaca ttgtataagt atgcaactaa gctgaagaaa aactgtaagg 360
aaataactga taaggaattg gacaagaaaa tgaaggagct cgcgcgcgctc atgacgacc 420
ctgacctgga aactgagact atgtgcctcc acgacgacga gtcgtgtcgc tacgaagggc 480
aagtcgctgt ttaccaggat gtatacggcg ttgacggacc gacaagtctc taccaccaag 540
ccaataaggg agtttagagc gctactggga taggctttga caccaccctt tttatgttta 600
agaacttggc tggagcatat ccatcatact ctaccaactg ggccgagcaa accgtgttaa 660
cggtcgttaa cataggccta tgcagctctg acgttatgga gcggtcacgt agagggatgt 720
ccattcttag aaagaagtat ttgaaacat ccaacaatgt tctattctct gttggctcga 780
ccatctacca cgagaagagg gacttactga ggagctggca cctgccgctt gtatttca 840
tacgtggcaa gcaaaattac acatgtcggg gtgagactat agttagtTgc gacgggtacg 900
tcgttaaaag aatagctatc agtccaggcc tgtatgggaa gccttcaggc tatgctgcta 960
cgatgcaccg cgagggattc ttgtgctgca aagtgcagca cacattgaaC ggggagaggg 1020
tctcttttcc cgtgtgcacg tatgtgccag ctacattgtg tgaccaaatg actggcatac 1080
tggcaacaga tgtcagtgcg gacgacgcgc aaaaactgct ggttgggctc aaccagcgt 1140
tagtctgcaa cggtcgcacc cagagaacaa ccaatccat gaaaaattc cttttgcccg 1200
tagtggccca ggcatttTct aggtgggcaa aggaatataa ggaagatcaa gaagatgaaa 1260

```

-continued

ggccactagg	actacgagat	agacagttag	tcatgggggtg	ttgttgggct	tttagaaggc	1320
acaagataac	atctatztat	aagcgcccgg	ataccacaac	catcatcaaa	gtgaacagcg	1380
atctccactc	attcgtgctg	cccaggatag	gcagtaaacac	attggagatc	gggctgagaa	1440
caagaatcag	gaaaaatgta	gaggagcaca	aggagccgtc	acctctcatt	accgcccagg	1500
acgtacaaga	gagtaagtgc	gcagccgatg	aggctaagga	ggtgcgtgaa	gccgaggagt	1560
tgccgcgagc	tctaccacct	ttggcagctg	atggtgagga	gcccactctg	gaagccgatg	1620
tcgacttgat	gttacaagag	gctggggccg	gctcagtgga	gacacctcgt	ggcttgataa	1680
aggttaccag	ctacgatggc	gaggacaaga	toggctctta	cgctgtgctt	tctcccagg	1740
ctgtactcaa	gagtgaaaaa	ttatcttgca	tccaccctct	cgctgaacaa	gtcatagtga	1800
taacacactc	tggccgaaaa	gggcttatg	ccgtggaacc	ataccatggt	aaagtagtgg	1860
tgccagaggg	acatgcaata	cccgtccagg	actttcaagc	tctgagtcaa	agtgccacca	1920
ttgtgtacaa	cgaacgtgag	ttcgtaaaca	ggtacctgca	ccatattgcc	acacatggag	1980
gagcgtctaa	cactgataaa	gaatattaca	aaactgtcaa	gccagccgag	cacgacggcg	2040
aatacctgta	cgacatcgac	aggaaaacgt	gcgtcaagaa	agaactagtc	actgggctag	2100
ggctcacagg	cgagctggtg	gatcctccct	tccatgaatt	cgccctacag	agtctgagaa	2160
cacgaccagc	cgctccctac	caagtaccaa	ccataggggt	gtatggcgtg	ccaggatcag	2220
gcaagtctgg	cattctcaaa	agcccgatca	ccaaaaaaga	tctagtgtg	agcgcacaaga	2280
aagaaaactg	tcagaaaatt	ataagggacg	tcaagaaaat	gaaagggctg	gacgtcaatg	2340
ccagaactgt	ggactcagtg	ctcttgaatg	gatgcaacaa	ccccgtagag	accctgtata	2400
ttgacgaagc	ttttgcttgt	catgacggta	ctctcagagc	gctcatagcc	attataagac	2460
ctaaaaaggc	gactgccaag	ggggatccca	aacagtgcgg	tttttttaac	atgatgtgcc	2520
tgaaagtgca	ttttaaccac	gagatttgca	cacaagtctt	ccacaaaagc	atctctcgcc	2580
gttgcaactaa	atctgtgact	tcggctgctc	caacctgtgt	ttacgacaaa	aaaaatgagaa	2640
cgacgaatcc	gaaagagact	aagattgtga	ttgacactac	cggcagtacc	aaacctaaagc	2700
aggacgatct	gactctcact	gtttccagag	ggtgggtgaa	gcagttgcaa	atagattaca	2760
aaggcaacga	aataatgacg	gcagctgcct	ctcaagggct	gaccctgaaa	ggtgtgtatg	2820
ccgttcggta	caaggtgaat	gaaaatcctc	tgtacgcacc	cacctcagaa	catgtgaacg	2880
tctactgac	ccgcaaggag	caccgatcgt	tgtggaaaac	actagccggc	gacctatgga	2940
taaaaacact	gactgccaag	tacctgggga	atctcactgc	cacgatagag	gagtgccaag	3000
cagagcatga	tgccatcatg	aggcacatct	tggagagacc	ggacctacc	gacgtcttcc	3060
agaataaggc	aaacgtgtgt	tgggccaagg	ctttagtgc	ggtgctgaag	accgctggca	3120
tagacatgac	cactgaaaca	tgaaacactg	tggattattt	tgaaacggac	aaagctcact	3180
cagcagagat	agtattgaaac	caactatgct	tgaggttctt	tggactcgat	ctggactccg	3240
gtctattttc	tgacccactc	gttccgttat	ccattaggaa	taactactgg	gataactccc	3300
cgctgcctaa	catgtacggg	ctgaataaag	aagtgttccg	tcagctctct	cgcaggtacc	3360
cacaactgcc	tcgggcagtt	gccaactgga	gagctctatg	catgaacact	ggtacactgc	3420
gcaattatga	tccgcgcata	aaacctagta	ctgtaaacag	aagactgcct	catgctttag	3480
tctccacca	taatgaacac	ccacagagtg	acttttcttc	atctcgtcagc	aaattgaagg	3540
gcagaactgt	cctggtggtc	ggggaaaaag	tgtccgtccc	aggcaaaaatg	ggtgactggt	3600
tgtcagaccg	gcctgaggct	accttcagag	ctcggctgga	tttaggcac	ccagggtgatg	3660
tgcccaaata	tgacataata	tttgtaaatg	tgaggacccc	atataaatac	catcactatc	3720
agcagtgatg	agaccatgcc	attaagctta	gcattgtgac	caagaaaagct	tgtctgcatc	3780
tgaatcccgg	cggaaacctgt	gtcagcatag	gttatggtta	cgctgacagg	gccagcgaaa	3840
gcatacttgg	tgctatagcg	cggcagttca	agttttcccg	ggtatgcaaa	ccgaaatcct	3900
cacttgaaga	gacggaaagt	ctgtttgtat	tcattgggta	cgatcgaag	gcccgctacgc	3960
acaatcctta	caagctttca	tcaaccttga	ccaacattta	tacaggttcc	agactccacg	4020
aagccggatg	tgacccttca	tatcatgtgg	tgcgagggga	tattgccacg	gccaccgaa	4080
gagtgattat	aaatgctgct	aaacgcaaa	gacaacctgg	cggagggggtg	tgccgagcgc	4140
tgtataagaa	attcccggaa	agcttcgatt	tacagccgat	cgaagttaga	aaagcgcgac	4200
tggtaaaagg	tgacagtaaa	catatcattc	atgccgtagg	accaaacttc	aaacaaagt	4260
cggaggttga	aggtgacaaa	cagttggcag	aggcttatga	gtccatcgct	aagattgtca	4320
acgataacaa	ttacaagtca	gtagcgattc	cactgttgtc	caccggcatc	ttttccggga	4380
acaaagatcg	actaacccaa	tcattgaacc	atltgctgac	agctttagac	accactgatg	4440
cagatgtagc	catatactgc	agggacaaga	aatgggaaat	gactctcaag	gaagcagtg	4500
ctaggagaga	agcagtgagg	gagatagca	tatccagca	ctcttcagtg	acagaacctg	4560
atgcagagct	ggtgagggtg	ctccgaaga	gttctttggc	tggaaaggaag	ggctacagca	4620
caagcagatg	caaaaacttc	tcataattgg	aagggaccaa	gtttccaccg	goggccaagg	4680
atatagcaga	aattaatgcc	atgtggcccg	ttgcaaccgga	ggccaatgag	caggtatgca	4740
tgtatatcct	cggagaaagc	atgagcagta	ttaggtcgaa	atgccccgtc	gaagagtcgg	4800
aaacctccac	aaatgctgct	agctgcctt	gcttgtgcat	ccatgccaatg	actccagaaa	4860
gagtacagcg	cctaaaagcc	tcacgtccag	aacaaattac	tgtgtgctca	tcttttccat	4920
tgccgaagta	tagaatcaact	ggtgtgcaga	agatccaatg	ctcccagcct	atattgttct	4980
caccgaaagt	gcctgcgat	atctatccaa	ggaagtatct	cgtggaaaca	ccaccggtag	5040
acgagactcc	ggagccatcg	cgagagaacc	aatccacaga	ggggacacct	gaacaaccac	5100
cacttataac	cgaggatgag	accaggacta	gaacgcctga	gccgatcatc	atcgaagagg	5160
aagaagagga	tagcataagt	ttgctgtcag	atggcccagc	ccaccaggtg	ctgcaagtcc	5220
aggcagacat	tcacggggccg	ccctctgtat	ctagctcatc	ctggctcatt	cctcatgcat	5280
ccgacttga	tgtggacagt	ttatccatac	ttgacacct	ggagggagct	agcgtgacca	5340
gcggggcaac	gtcagccgag	actaactctt	acttcgcaaa	gagtatggag	tttctggcgc	5400
gaccggtgcc	tgccctcoga	acagatttca	ggaaccctcc	acatcccgtc	ccgcgcacaa	5460

-continued

gaacacogtc	acttgcaccc	agcagggcct	gctcogagaac	cagcctagtt	tccaccccg	5520
caggcgtgaa	taggggtgatc	actagagagg	agctcogagge	gcttaccocg	tcacgcactc	5580
ctagcaggtc	ggtctcogaga	accagcctgg	tctccaaccc	gccagggcgt	aataggggtg	5640
ttacaagaga	ggagtttgag	gcgttcogtag	cacaacaaca	atgacgggtt	gatgcgggtg	5700
catacatctt	ttcctccgac	accogtcaag	ggcatttaca	acaaaaatca	gtaaggcaaa	5760
cgggtgctatc	cgaagtggg	ttggagagga	cogaattgga	gatttcgtat	gccccgcg	5820
tcgaccaaga	aaaagaagaa	ttactacgca	agaaattaca	gttaaattcc	acacctgcta	5880
acagaagcag	ataccagtc	aggaaggtgg	agaacatgaa	agccataaca	gctagacgta	5940
ttctgcaagg	cctagggcat	aatttgaagg	cagaaggaaa	agtgaggtgc	taccgaaccc	6000
tgatcctgt	tcctttgtat	tcactatagtg	tgaaccgtgc	ctttcaagc	cccaaggtcg	6060
cagtggaagc	ctgtaacgcc	atggtgaaag	agaactttcc	gactgtggct	tcttactgta	6120
ttattccaga	gtacgatgcc	tatttggaca	tggttgacgg	agcttcatgc	tgcttagaca	6180
ctgcccagtt	ttccctcgac	aaagctgcga	gctttccaaa	gaaacactcc	tatttggaac	6240
ccacaatacg	atcggcagtg	ccttcagcga	tccagaacac	gctccagaac	gtcctggcag	6300
ctgcccacaaa	aagaaatg	aatgtcacgc	aaatgagaga	attgcccgta	ttggattcgg	6360
cgcccttaa	tgtggaatgc	ttcaagaaat	atgctgtgta	taatgaatat	tgggaaactg	6420
ttaaagaaaa	cccactcgac	cttactgaag	aaaaactggt	aaattacatt	accaaataa	6480
aaggacaaa	agctgctgct	ctttttgca	agacacataa	tttgaatatg	ttgcaggaca	6540
taccaatgga	caggtttgta	atggacttaa	agagagcgt	gaaagtgact	ccaggaacaa	6600
aacatactga	agaacggccc	aaggtacagg	tgatccagcg	tgccgatccg	ctagcaacag	6660
cgtatctgtg	cggaatccac	cgagagctgg	ttagagatt	aaatgcggtc	ctgcttccga	6720
acattcatic	actgtttgat	atgtcggctg	aagactttga	cgctattata	gccgagcact	6780
tccagcctgg	ggatttggtt	ctggaaactg	acatcgctc	gtttgataaa	agtgaggacg	6840
acgccatggc	tctgaccggc	ttaatgatc	tggaaagact	aggtgtggac	gcagagctgt	6900
tcgagctgat	tgaggcggct	ttcggcgaaa	tttcatcaat	acatttgccc	actaaaacta	6960
aatttaaatt	cggagccatg	atgaaatctg	gaatgttctc	cacactgttt	gtgaacacag	7020
tcattaacat	tgtaatcgca	agcagaggtg	tgagagaacg	gctaaccgga	tcaccatgtg	7080
cagcattcat	tggagatgac	aatatcgtga	aaggagtcaa	atcggacaaa	ttaatggcag	7140
acaggtgcgc	cacotggttg	aatatggaag	tcaagattat	agatgctgtg	gtggcgaga	7200
aagcgcctta	tttctgtgga	gggtttattt	tgtgtgactc	cgtgaccggc	acagcgtgcc	7260
gtgtggcaga	ccccttaaaa	aggctgttta	agcttggcaa	acctctggca	gcagacgatg	7320
aacatgatga	tgacagagga	agggcattgc	atgaagatgc	aacacgctgg	aaccgagttg	7380
gtattctttc	agagctgtgc	aatcaaggtg	aatcaaggtg	tgaaccgta	ggaacttcca	7440
tcatagtatt	ggccatgact	actctagcta	gcagtgttaa	atcattcagc	tcactgagag	7500
gggcccctat	aactctctac	ggctaacctg	aatggactac	gacatagtct	agtccgcca	7560
gatgggcaag	cggctccggc	gctctatcat	gtggctggcc	tctctggcgg	tggtcatcgc	7620
atgcgcagga	gcaaccagga	gagggcagcc	ctactataatg	tacctggaca	gaaatgatgc	7680
cggcagggcc	atcagcttcc	ccaccacact	gggcatgaac	agtggttaca	tccagatcat	7740
ggacctgggc	cacatgtg	atgccaccat	gtcctatgag	tgtccaatgc	tgacagaggg	7800
cgtggagccc	gacgatgtgg	atgtctgggt	taataccaca	tccacatggg	tggtgtacgg	7860
cactgcccac	cacaagaagg	gagaggcaag	gcgctctcgg	agagcagtg	caactgcctc	7920
ccactctacc	cggagctg	agacaagatc	tcagacctgg	ctggagagcc	gggagtatac	7980
aaagcacctg	atccgggtgg	agaactggat	ctttagaat	ccaggattcg	cactggcagc	8040
agcagcaatc	gcatggctgc	ttggcagctc	cacctcccag	aaagtgtct	acctggctcat	8100
gatcctgctg	atcggcccctg	cctattccat	caggtgcatc	ggcgtgtcta	atcgcgactt	8160
cgtggagggc	atgtctggcg	gcacctgggt	ggatgtggtg	ctggagcagc	gcggctgcgt	8220
gacagtgatg	gcccagagca	agccaaccgt	ggacatcgag	ctggtgacca	caaccgtgag	8280
caacatggcc	gaggtgcggt	cctactgcta	tgaggccagc	atctccgaca	tggcctctga	8340
tagcagatgt	cccaccagg	gcgaggccta	cctggacaag	cagctctgata	cacagtactg	8400
gtgcaagagg	accctggtgg	acaggggatg	gggaaatgga	tgtggcctgt	ttggcaaggg	8460
cagcctgggtg	acatgcgcca	agttccgctg	ttctaagaag	atgaccggca	agagcatcca	8520
gccagagaac	ctggagtacc	ggatcatgct	gagcgtgcac	ggcagccagc	actccggcat	8580
gatcgtgaac	gacacaggcc	acgagacaga	tgagaatagg	gccaaaggtg	agatcacacc	8640
taacagccca	cgcgcogagg	ccaccctggg	aggatttggc	tccctgggcc	tgactgcca	8700
gcctagaaca	ggcctggact	tctccgatct	gtactatctg	accatgaaca	ataagcactg	8760
gctggtgcac	aaggatgggt	ttcacgacat	cccactgcca	tggcacgcag	gagcagatac	8820
aggaacccca	cactggaaca	ataaggaggc	cctggtggag	ttcaaggatg	cccacgcca	8880
gagccagaca	gtggtgtg	tgggcagcca	ggaggagca	gtgcacaccg	ccctggcagg	8940
cgccctggag	gcccagatgg	acggagcaaa	gggcccctg	tctagcggcc	acctgaagtg	9000
ccggctgaag	atggataagc	tgagactgaa	gggctgtcc	tactctctgt	gcacagccgc	9060
cttcaccttc	accaagatcc	ctgcogagac	actgcacggc	acagtgaccg	tggagggtgca	9120
gtatgccggc	acagacggcc	cctgtaaggt	gcctgcccag	atggcccgtg	atatgcagac	9180
actgaccctc	gtgggcaggc	tgatcaccgc	caatccagtg	atcacagagt	ccaccgagaa	9240
ctctaagatg	atggatgagc	tgagaccccc	ttttggcgat	agctatatcg	tgactcggctg	9300
gggcgagaag	aagatcacac	accactggca	ccgcagcggc	tccacaatcg	gcaaggcctt	9360
tgaggccacc	gtgaggggag	caaagaggat	ggccgtgctg	ggcgacaccg	catgggattt	9420
cggctccgtg	ggaggcggcc	tgaactctct	gggcaagggc	atccaccaga	tcttcggcgc	9480
cgcttttaag	tcctgtttcg	cgggctgtgc	ttggtttagc	cagatccctga	tcggcacact	9540
gctgatgtgg	ctgggctg	acaccaagaa	tggtctctac	agcctgatgt	gcctggccct	9600
gggagggcgtg	ctgatcttcc	tgagcaccgc	cgtgtccg	tgatgataag	gcgcgccacc	9660

-continued

```

ccagcggcgc catacagcag caattggcaa gctgcttaca tagaactcgc ggcgattggc 9720
atgccgcctt aaaatTTTTt ttttattttt cttttctttt ccgaatcgga ttttgTTTTt 9780
aatatttcaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaga agagcgttta 9840
aacacgtgat atctggcctc atgggccttc ctttcaactgc ccgctttcca gtcgggaaac 9900
ctgtcgtgcc agctgcatta acatggtcac agctgtttcc ttgcgtattg ggcgctctcc 9960
gcttctctgc tcaactgactc gctgcgctcg gtcgttcggg taaagcctgg ggtgcctaat 10020
gagcaaaaagg ccagcaaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc 10080
ataggctccg cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa 10140
accgcagcag actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc 10200
ctgttccgac cctgcgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg 10260
cgctttctca tagctcagc tgtaggatc tcagttcggt gtaggtcgtt cgctccaagc 10320
tgggctgtgt ccacgaacce cccggtcagc ccgaccgctg cgccttacc ggtaactatc 10380
gtcttgagtc gacgcaagat agacacgact tatgccact ggcagcagcc actggtaaca 10440
ggattagcag agcagagtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact 10500
acggctacac tagaagaaca gtatttggta tctgcgctct gctgaagcca gttaccttcg 10560
gaaaaagagt tggtagctct tgatccggca acaaacacc cgcgtgtagc ggtggtttt 10620
ttgtttgcaa cagactgatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct 10680
tttctacggg gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggctatga 10740
atcacaggtg cctgactcgc tttagcaatt aactgtgata aactaccgca ttaaagctta 10800
tcgatgataa gctgtcaaac atgagaattc ttagaaaaac tcatcgagca tcaaatgaaa 10860
ctgcaattta ttcatatcag gattatcaat accatatttt tgaaaaagcc gtttctgtaa 10920
tgaaggagaa aactaccgga ggcagttcca taggatggca agatcctggt atcggctctgc 10980
gattccgact cgtccaacat caatacaacc tattaatttc ccctcgtcaa aaataaggtt 11040
atcaagttag aaatccacat gagtgaagc tgaatccggt gagaatggca aaagcttatg 11100
catttcttcc cagactgttt caacaggcca gccattacgc tgcctatcaa aatcaactgc 11160
atcaaccaaa ccgttattca ttctgtattg cgctgagcg agacgaaata cgcgatcgtc 11220
gttaaaagga caattacaaa caggaatcga atgcaaccgg cgcaggaaca ctgccagcgc 11280
atcaacaata ttttcacotg aatcaggata ttcttctaac acctggaatg ctgttttccc 11340
ggggatcgca gtggtagata accatgcac atcaggagta atcagaaat gcttgatggt 11400
cggaaagagg ataaattccg tcagccagtt tagtctgacc atctcatctg taacatcatt 11460
ggcaacgcta cctttgccat gtttcagaaa caactctggc gcctcgggct tcccatataa 11520
tcgatagatt gtcgcacctg atgcccagc attatcgcca gccatttat acccatataa 11580
atcagcatcc atgttgaat ttaatcgcg cctcgagcaa gacgtttccc gttgaatatg 11640
gctcataaca cccctgttat tactgtttat gtaagcagac agttttattg ttcgatgagc 11700
gatacatatt tgaatgtatt tagaaaaata acaaatagc ggttccgcgc acatttcccc 11760
gaaaagtgcc acctaaattg taagcgtaa tattttgta aaatcgcgt taaatttttg 11820
ttaaatacag tcatttttta aaccaatggc gaaaatcgcc aaaatccctt ataaatcaaa 11880
agaatagacc gagataggtg tagtgggcgc ctacagggcg ctcccattcg ccattcaggc 11940
tgcccaactg ttgggaaggc cgtttcggtg cgggcctctt cgcattacg ccagctggcg 12000
aaagggggat gtcgtgcaag cggattaagt tgggtaacgc cagggttttc ccagtcacac 12060
gcgtaatacg actcaactata g

```

```

SEQ ID NO: 39      moltype = RNA length = 2091
FEATURE           Location/Qualifiers
misc_feature      1..2091
                  note = recombinant Zika virus antigen construct
source            1..2091
                  mol_type = other RNA
                  organism = synthetic construct

```

```

SEQ ID NO: 39
atgggcaagc ggtccgcggc ctctatcatg tggctggcct ctctggcctt ggtcatcgca 60
tgccagagag cagcggaggt caccaggaga ggcagcgcct actatatgta cctggacaga 120
aatgatgccc ggcaggccat cagctttccc accacactgg gcatgaaca gtgttacatc 180
cagatcatgg acctgggcca catgtgcgat gccaccatgt cctatgagtg tccaatgctg 240
gacgagggcg tggagcccga cgatgtggat tgctggtgta ataccacatc cacatgggtg 300
gtgtacggca cctgcaccca caagaagggg gaggcaaggg cctctcggag agcagtgaca 360
ctgccttccc actctaccgg gaagctgcag acaagatctc agacctggct ggagagccgg 420
gagtatacaa agcacctgat ccgggtggag aactggatct ttagaaatcc aggattcgca 480
ctggcagcag cagcaatcgc atggctgctg ggcagctcca cctcccagaa agtgatctac 540
ctggtcatga tctgtgatc gcgccctgcc tattccatca ggtgcatcgg cgtgtctaat 600
cgcgacttgg tggagggcat gtctggcggc acctgggtgg atgtggtgct ggagcacggc 660
ggctgcgtga cagtgatggc ccaggacaag ccaaccgtgg acatcgagct ggtgaccaca 720
accgtgagca acatggccga ggtgcggctc tactgctatg aggccagcat ctccgacatg 780
gcctctgata tctgtgatc caccagggc gaggcctacc tggacaagca gtcgatata 840
cagtagctgt gcaagaggac cctggtggac aggggatggg gaaatggatg tggcctgttt 900
ggcaagggca gcctggtgac atgcccgaag ttgcctgtt ctaagaagat gaccggcaag 960
agcatccagc cagagaacct ggagtaccgg atcatgtgta gcgtgcacgg cagccagcac 1020
tccggcatga tctgtgaacga cacaggccc gagacagatg agaatagggc caaggtggag 1080
atcacacctc acagcccagc cgcggaggcc acctggggg gatttggtc cctgggcctg 1140
gactgcgagc ctagaacagc cctggacttc tccgatctgt actatctgac catgaacaat 1200

```

-continued

```

aagcactggc tggcgcaaca ggagtggttt cacgacatcc cactgccatg gcaocgagga 1260
gcagatacag gaaccccaca ctggaacaat aaggaggccc tgggtggagt caaggatgcc 1320
cacgccaaga ggcagacagt ggtggtgctg ggcagccagg agggagcagt gcacaccgcc 1380
ctggcaggcg ccctggaggc cgagatggac ggagcaaaag gccgcctgtc tagcggccac 1440
ctgaagtgcc ccctgaagat ggataagctg agactgaagg gcgtgtccta ctctctgtgc 1500
acagccgcct tcaccttcac caagatccct gccagacac tgcacggcac agtgaccgtg 1560
gaggtgcagt atgccggcac agacggcccc tgtaaggtgc ctgcccagat ggcctggat 1620
atgcagacac tgaccctgtg gggcaggctg atcaccgcca atccagtgat cacagagtcc 1680
accgagaact ctaagatgat gctggagctg gacccccctt ttggcgatag ctatatcgtg 1740
atcgccgtgg gcgagaagaa gatcacacac cactggcacc gcagcggctc cacaatcggc 1800
aaggcctttg aggccaccgt gaggggagca aagaggatgg ccgtgctggg cgacaccgca 1860
tgggatattc gctccgtggg aggcgcctcg aactctcttg gcaagggcat ccaccagatc 1920
ttcggcggcg cctttaagtc cctgttcggc ggcatgtctt ggttagcca gatcctgatc 1980
ggcacactgc tgatgtggct gggcctgaac accaagaatg gctctatcag cctgatgtgc 2040
ctggccctgg gagcgtgct gatcttctcg agcacggccg tgccgcctg a 2091

```

```

SEQ ID NO: 40      moltype = RNA length = 2091
FEATURE           Location/Qualifiers
misc_feature      1..2091
                  note = recombinant Zika virus antigen construct
source           1..2091
                  mol_type = other RNA
                  organism = synthetic construct

```

```

SEQ ID NO: 40
atgggcaagc ggtccgccgg ctctatcatg tggctggcct ctctggccgt ggtcatcgca 60
tgccgaggag cagcggaggt caccaggaga ggcagccct actatatgta cctggacaga 120
aatgatgccg gcgaggccat cagcttccc accacactgg gcatgaacaa gtgttacatc 180
cagatcatgg acctgggcca catgtgcgat gccaccatgt cctatgagtg tccaatgctg 240
gacgaggcgg tggagcccga cgatgtggat tgctgggtga ataccacatc cacatgggtg 300
gtgtacggca cctgccacca caagaaggga gaggcaaggc gctctcggag agcagtgaca 360
ctgccttccc actctaccgg gaagctgcag acaagatctc agacctggtc ggagagccgg 420
gagtatacaa agcacctgat ccgggtggag aactggatct ttagaaatcc aggattcgca 480
ctggcagcag cagcaatcgc atggctgctg ggcagctcca cctcccagaa agtgatctac 540
ctggtcatga tctgctgat cggcctgccc tattccatca ggtgcatcgg cgtgtctaat 600
cgcgacttcc tggagggcat gctcggcggc acctgggtgg atgtggtgct ggagcacggc 660
ggctgcgtga cagtgatggc ccaggacaag ccaaccgtgg acatcgagct ggtgaccaca 720
accgtgagca acatggccga ggtgcggctc tactgctatg aggccagcat ctccgacatg 780
gcctctgata gcagatgtcc cacccagggc gaggcctacc tggacaagca gtctgatata 840
cagtacgtgt gcaagaggac cctggtggac aggggatggg gaaatggatg tggcctgttt 900
ggcaaggcca ccctggtgac atggcccaag ttgcctgtt ctaagaagat gaccggcaag 960
agcatccagc gcagaaacct ggagtaccgg atcatgtcta gcgtgcacgg cagccagcac 1020
tccggcatga tctgtaacga cacaggccac gagacagatg agaatagggc caaggtggag 1080
atcacaccta acagcccacg cgcaggggcc acctggggag gatttggctc cctgggctctg 1140
gactgagcag ctagaacagg cctggaactc tccgatctgt actatctgac catgaacaat 1200
aagcactggc tggcgcaaca ggagtggttt cacgacatcc cactgccatg gcaocgagga 1260
gcagatacag gaaccccaca ctggaacaat aaggaggccc tgggtggagt caaggatgcc 1320
cacgccaaga ggcagacagt ggtggtgctg ggcagccagg agggagcagt gcacaccgcc 1380
ctggcaggcg ccctggaggc cgagatggac ggagcaaaag gccgcctgtc tagcggccac 1440
ctgaagtgcc ggctgaagat ggataagctg agactgaagg gcgtgtccta ctctctgtgc 1500
acagccgcct tcaccttcac caagatccct gccagacac tgcacggcac agtgaccgtg 1560
gaggtgcagt atgccggcac agacggcccc tgtaaggtgc ctgcccagat ggcctggat 1620
atgcagacac tgaccctgtg gggcaggctg atcaccgcca atccagtgat cacagagtcc 1680
accgagaact ctaagatgat gctggagctg gacccccctt ttggcgatag ctatatcgtg 1740
atcgccgtgg gcgagaagaa gatcacacac cactggcacc gcagcggctc caccctgggc 1800
aaggccttta gcaccaccct gaagggagca cagaggtggc ccgcccctgg cgacaccgca 1860
tgggatattc gctccatcgg aggcgtgttc aactctatcg gcaagggcct gcaccaggtg 1920
ttcggcggcg cctttcggac cctgttcggc ggcatgtctt ggatcaccca gggcctgatg 1980
ggcgccttgc tgctgtggat gggcgtgaac gcccgggacc ggtctatcgc cctggccttc 2040
ctggccaccg gagcgtgct ggtgttctcg gccaccaacg tgcaocgctg a 2091

```

```

SEQ ID NO: 41      moltype = RNA length = 2082
FEATURE           Location/Qualifiers
misc_feature      1..2082
                  note = recombinant Zika virus antigen construct
source           1..2082
                  mol_type = other RNA
                  organism = synthetic construct

```

```

SEQ ID NO: 41
atgggcaagc ggtccgccgg ctctatcatg tggctggcct ctctggccgt ggtcatcgca 60
tgccgaggag caaccaggag aggcagcggc tactatatgt acctggacag aatgatgcc 120

```

-continued

ggcggaggcca	tcagctttcc	caccacactg	ggcatgaaca	agtgttacat	ccagatcatg	180
gacctggggcc	acatgtgoga	tgccaccatg	tcctatgagt	gtccaatgct	ggacgagggc	240
gtggagcccg	acgatgtgga	ttgctgggtg	aataccacat	ccacatgggt	ggtgtacggc	300
acctgccacc	aaaagaagg	agaggaagg	cgctctcgga	gagcagtjac	actgccttcc	360
cactctaccc	ggaagctgca	gacaagatct	cagacctggc	tggagagccg	ggagtataca	420
aagcacctga	tccgggtgga	gaactggatc	tttagaaatc	caggattcgc	actggcagca	480
gcagcaatcg	catggctgct	ggcgagctcc	acctcccaga	aagtgatcta	cctgggtcatg	540
atcctgctga	tcgcccctgc	ctattccatc	aggtgcatcg	gcgtgtctaa	tcgcgacttc	600
gtggagggca	tgctcgggcg	cacctgggtg	gatgtgggtc	tggagcagcg	cgctgcgtg	660
acagtgatgg	cccaggacia	gccaaccgtg	gacatcgagc	tggtgaccac	aaccgtgagc	720
aacatggccg	aggctgcgtc	ctactgctat	gaggccagca	tctccgacat	ggcctctgat	780
agcagatgtc	ccaccaggg	cgaggcctac	ctggacaagc	agctctgatac	acagtacgtg	840
tgcaagagca	tcctgggga	caggggatgg	ggaaatggat	gtggcctggt	tgcaaggggc	900
agcctgggtg	catgcgcaa	gttcgctgt	tctaagaaga	tgaccggcaa	gagcatccag	960
ccagagaacc	tggagtaccg	gatcatgctg	agcgtgcacg	gcagccagca	ctccggcatg	1020
atcgtgaacg	acacagggca	cgagacagat	gagaataggg	ccaaggtgga	gatcacacct	1080
aacagcccac	gcgcccggc	gacctgggga	ggatttgct	ccctgggct	ggactgcgag	1140
cctagaacag	gcctggactt	ctccgatctg	tactatctga	ccatgaacia	taagcactgg	1200
ctggtgcaca	aggagtgggt	tcacgacatc	ccactgccat	ggcacgcagg	agcagatata	1260
ggaacccac	actggaacia	taaggaggcc	ctggtggagt	tcaaggatgc	ccacggcaag	1320
agggcagacg	tggtgggtgc	ggcgagccag	gagggagcag	tgcacaccgc	cctggcagggc	1380
gccctggagg	ccgagatgga	cggagcaaa	ggccgctgt	ctagcggcca	cctgaagtgc	1440
cggtggaaga	tggataagct	gagactgaag	ggcgtgtcct	actctctgtg	cacagccgcc	1500
ttcaccttca	ccaagatccc	tgccgagaca	ctgcaaggca	cagtgaccgt	ggaggtgcag	1560
tatgccggca	cagacggccc	ctgtaagggt	cctgcccaga	tggccgtgga	tatgcagaca	1620
ctgaccctg	tggcgaggct	gacacccgcc	aatccagtga	tcacagagtc	caccgagAAC	1680
tctaagatga	tgtctggagct	ggacccccct	tttggcgata	gctatatcgt	gatcggcgtg	1740
ggcgagaaga	agatcacaca	ccactggcac	cgcagcggct	ccacaatcgg	caaggccttt	1800
gaggccaccg	tgaggggagc	aaagaggatg	gccgtgctgg	gcgacaccgc	atgggatttc	1860
ggctccgtgg	gaggcgccct	gaactctctg	ggcaagggca	tccaaccagat	cttcggcgcc	1920
gcctttaagt	ccctgttcgg	cggcatgtct	tggtttagcc	agatcctgat	cggcacactg	1980
ctgatgtggc	tggcctgaa	caccaagaat	gctctatca	gctgatgtg	cctggccctg	2040
ggaggcgtgc	tgatcttct	gagcacccgc	gtgtccgct	ga		2082

We claim:

1. An RNA-based vaccine construct encoding a polypeptide comprising a Zika virus prME antigen or a variant thereof, wherein the construct encodes a JEV signal sequence or a variant thereof in place of the Zika virus prME signal sequence, and wherein said construct comprises a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence which is at least 95% identical to SEQ ID NO: 19.
2. A construct according to claim 1 wherein said JEV signal sequence or variant thereof is juxtaposed immediately next to and N-terminal of the Zika virus prME antigen or variant thereof.
3. A construct according to claim 1 wherein said construct comprises a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence which is at least 98% identical to SEQ ID NO: 19.
4. A composition comprising: an immunologically effective amount of one or more of the constructs of claim 1; and a pharmaceutically acceptable carrier.
5. The composition according to claim 4, wherein the composition comprises a non-viral delivery material.
6. The composition according to claim 5, wherein non-viral delivery material comprises a submicron cationic oil-in-water emulsion which comprises an oil core, a cationic lipid, and a surfactant.
7. The composition according to claim 4 wherein the composition further comprises one or more nucleic acid sequences which encode one or more additional antigens and/or the composition further comprises one or more additional antigens.

8. The composition according to claim 4, wherein the composition is pharmaceutically acceptable for administration to a subject in combination with a further composition which comprises a nucleic acid comprising a sequence which encodes an additional antigen; and/or the composition is pharmaceutically acceptable for administration to the subject in combination with a further composition which comprises an additional antigen.
9. The composition according to claim 4 wherein the composition comprises one or more adjuvants.
10. The construct of claim 1; which is suitable for use in therapy.
11. A method for inducing an immune response to a Zika virus infection in a subject which comprises administering the construct of claim 1 to a subject.
12. A construct according to claim 2, wherein said construct comprises a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence which is at least 98% identical to SEQ ID NO: 19.
13. A composition comprising: an immunologically effective amount of one or more of the constructs of claim 2; and a pharmaceutically acceptable carrier.
14. A composition comprising: an immunologically effective amount of one or more of the constructs of claim 3; and a pharmaceutically acceptable carrier.
15. The composition according to claim 4, wherein the composition comprises a non-viral delivery material.
16. The composition according to claim 5, wherein said non-viral delivery material comprises a submicron cationic

oil-in-water emulsion; a liposome; or a biodegradable polymeric microparticle delivery system.

17. The composition according to claim **15**, wherein said non-viral delivery material comprises a submicron cationic oil-in-water emulsion; a liposome; or a biodegradable polymeric microparticle delivery system.

18. The composition according to claim **15**, wherein said non-viral delivery material comprises a submicron cationic oil-in-water emulsion comprises an oil core, a cationic lipid, and a surfactant.

19. The composition of any one of claim **4** which is suitable for use in therapy.

20. A method for inducing an immune response to a Zika virus infection in a subject which comprises administering the composition of claim **4** to a subject.

* * * * *